

Feidhmeannacht na Seirbhíse Sláinte Seirbhís Aisíoca Príomhchúraim

Bealach amach 5 an M50 An Bóthar Thuaidh Fionnghlas Baile Átha Cliath 11

Guthán: (01) 864 7100 Facs: (01) 834 3589

Ríomhphost: pburke.office@hse.ie Láithreán Gréasáin: www.hse.ie

Health Service Executive Primary Care Reimbursement Service

Exit 5 M50 North Road Finglas Dublin 11

Ph: (01) 864 7100 Fax: (01) 834 3589

email: pburke.office@hse.ie Website: www.hse.ie



Primary Care Reimbursement Service

STATISTICAL ANALYSIS OF CLAIMS AND PAYMENTS 2010

Contents Summary of Statistical Analysis

Page		Page		Page	
4	Introduction	16	Payments to Dentists	24	Summary of Statistical Information – GMS Scheme
6	Community Based Services –	17	Volume of Claims by Dentists	25	Summary of Statistical Information – LTI/DP Schemes
	Payment Arrangements	18	Payments to Optometrists/Ophthalmologists	26	Fees and Allowances under Capitation Agreement
8	Summary Statement of Activity During the Year	19	Volume of Treatments by Optometrists/Ophthalmologists	27	Fees and Allowances under Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health (Amendment)
9	The Year 2010	20	Cost per Person		Act 1996 and Methadone Treatment Scheme
10	Number of Agreements	21	Major Therapeutic Classification of Drugs,	28	Scale of Fees Payable to Pharmacists
П	Persons Eligible for Services		Medicines and Appliances – GMS Scheme	29	Scale of Fees Payable to Dentists
12	Payments to Doctors	22	Major Therapeutic Classification of Drugs,	30	Scale of Fees Payable to Optometrists/Ophthalmologists
13	Volume of Claims by Doctors		Medicines and Appliances – DP Scheme		
14	Payments to Pharmacies	23	Major Therapeutic Classification of Drugs, Medicines and Appliances – LTI Scheme		
15	Volume of Claims by Pharmacies				

Contents Detailed Statistical Analysis

Page	Table		Page	Table		Page	Table	
33 34	1 1.1	Summary of Statistical Information GMS 2006-2010 Summary of Statistical Information LTI/DP 2006-2010	65	14	GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service	98	19.8	HTD:The Products of Highest Cost in the Order of their Total Ingredient Cost
35	2	Number of Agreements	66	15	GMS: Cost of Medicines by Gender within Age Groups	101	20	GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
36 37	3 4	GMS: Payments to Doctors GMS: Cost of Prescriptions	68	16	GMS: Number of Prescription Forms and Items	106	20.1	DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
38 39	5 6	GMS: Cost of Stock Order Forms DTS: Payments to Dentists	69 70	16.1 16.2	GMS: Number of Stock Order Forms and Items GMS: Payment to Pharmacists in Respect	Ш	20.2	LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
40	7	GMS: Payment per Person	71	16.3	of Prescriptions GMS: Number of Items on Prescription Forms	116	20.3	HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
41	8	GMS: Number of Doctors in Eligible Person Cost Categories	72 73	16.4 16.5	DP: Number of Items on Claim Forms LTI: Number of Items on Claim Forms	119	21	GMS: Average Payment to Doctors in Panel Ranges
42 43	9 9.1	GMS: Number of Eligible Persons GMS: Number of Eligible Persons by Gender	74	17	GMS: Number of Dispensing Doctors and Persons for whom they Dispense	120 121	21.1	GMS: Number of Doctors in Payment Ranges GMS: Number of Pharmacists in Dispensing
49	9.2	within Age Groups GMS: Percentage of Eligible Persons by Mileage	75	18	GMS: Advance Payments to Pharmacists	122	23	Fee Ranges DP: Number of Eligible Persons and Number
52	9.3	Allocation GPVC: Number of Eligible Persons	76	19	Notes on Some of the More Commonly Prescribed Products	123	23.1	and Cost of Pharmacists Claims DP: Number of Pharmacists in Dispensing Fee/
53	9.4	GPVC: Number of Eligible Persons by Gender	77	19.1	GMS:The Most Commonly Prescribed Products in the Order of their Prescribing Frequency			Mark-Up Ranges
55	10	within Age Groups GMS: Size of Panels of Doctors	80	19.2	GMS:The Products of Highest Cost in the Order of their Total Ingredient Cost	124		LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
56	П	GMS: Payments to Doctors in each Health Service Executive Area	83	19.3	DP:The Most Commonly Prescribed Products in the Order of their Prescribing Frequency		24.1	LTI: Number of Pharmacists in Dispensing Fee/ Mark-Up Ranges
57	12	GMS: Number of Special Type Consultations and Out-of-Hours Claims	86	19.4	DP:The Products of Highest Cost in the Order of their Total Ingredient Cost	126 127	25 26	EEA: Number and Cost of Pharmacists Claims DTS: Number of Treatments
58	12.1	GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims	89	19.5	LTI: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	128 129	26.I 27	DTS: Number of Dentists in Payment Ranges HSE-COS: Number of Treatments and Cost
59	13	GMS: Analysis of Special Items of Service	92	19.6	LTI:The Products of Highest Cost in the Order			of Claims
60	13.1	GMS: Analysis of Special Items of Service by Health Service Executive Area	95	19.7	of their Total Ingredient Cost HTD:The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	130	27. I 28	HSE-COS: Number of Optometrists/ Ophthalmologists in Payment Ranges GMS: Investment in General Practice Development

Introduction

The Primary Care Reimbursement Service (PCRS) supports the delivery of primary health care by providing reimbursement services to Primary Care Contractors (General Practitioners, Pharmacists, Dentists and Optometrists/Ophthalmologists), for the provision of health services to members of the public in their own community, and has executive responsibility for the Demand Led Schemes nationally.

The state funded Demand Led Schemes, which include the General Medical Services (GMS) (i.e. Medical Cards/GP Visit Cards), Drugs Payment, Long Term Illness, Dental Treatment Services, European Economic Area, High Tech Drugs, Primary Childhood Immunisation, Health (Amendment) Act 1996, Methadone Treatment and HSE Community Ophthalmic Services, account for approximately 20% of the HSE's overall budget.

In 2010 PCRS handled over 75 million claim/payment transactions in respect of services provided to over 3.42 million people in their community by Doctors, Pharmacists, Dentists and Opticians, with an associated expenditure of €2.529 billion.

While executive responsibility for the Demand Led Schemes nationally has transferred to PCRS, the transition and streamlining of the Schemes is continuing to take place over a phased period so that the project can be continuously monitored and evaluated, and if required modified to deliver optimal results, for both the patients and the HSE.

Recent Trends

The increased uptake of the Demand Led Schemes continues as the economic climate presents ongoing challenges for people and available services. While expenditure budgets continue to reduce, the number of people on the Live Register and the demand for services keep growing.

As of 31 December 2010, the total number of eligible Medical Card holders was 1,615,809, which is approximately 38.1% of the total population. In addition the total number of GP Visit Cards reached 117,423, approximately 2.77% of the population. An additional 156,347 eligible persons were granted Medical Cards or GP Visit cards in 2010, an increase of 9.9% over 2009.

A focus on delivering efficiencies aligned with reductions in the cost of some reimbursable items has resulted in a reduction in expenditure of approximately 4.28% in 2010 (€2.529 billion in 2010 compared with €2.642 billion in 2009).

Outlook

With increases in demand and reducing budgets the focus of attention will continue to be the delivery of further efficiencies and the streamlining and standardisation of services.

The specific Value for Money (VfM) projects underway to ensure sustained efficiencies have continued to move apace during 2010, with the major project to centralise the processing of all Medical Cards being one of the primary focuses in this area.

The Medical Card centralisation programme is being delivered on a phased basis, and has moved ahead throughout 2010 as planned. Significant progress has been made during the year on this national project in providing an improved service to the public at less cost to the State.

Approximately 39% of the Medical Card population is now managed by the central office, with over a quarter of a million Medical Card applications and reviews processed centrally to date. Additional customer focused initiatives introduced in 2010, as part of the centralisation project include the new online Medical Card application service, the new website – www.medicalcard.ie, the use of SMS messaging to provide updates to applicants, the roll out of the national database to all local offices to support local customer service programs, the new call triage telephone system, the introduction of weekly panel listing updates for GPs, and the introduction of a streamlined user friendly review process for people over 70 years of age.

The next phase of the programme is to go live and process all new applications in the Central Office from a given date following a consultative process with staff representatives and in line with the recent agreement on pay and reform in the public service. Taking cognisance of the fact that this is a critical change project there are many benefits accruing in the final phase, e.g. better customer service, full implementation on a given date providing more clarity to all concerned (Clients, TDs, Primary Care Contractors, HSE staff etc.), facilitating staff redeployment to key frontline services, and resulting in the provision of better Customer Relations Management Services to the client.

In addition to the changes introduced and the processing and making of payments on a national basis to General Practitioners, Pharmacists, Dentists and Optometrists/ Ophthalmologists, the PCRS continues to compile statistics and trend analyses which are provided to customers, the Government, stakeholders, members of the public and other areas within the HSE.

This progress could not be achieved without the hardworking staff at every level involved in the change projects, and in the continued delivery of day to day services while new initiatives are developed and introduced. I would like to thank everybody involved for their individual contribution and commitment, and their team effort, in the delivery of these vital support services throughout a year in which significant changes were taking place. I would also like to thank all of our customers, General Practitioners, Pharmacists, Dentists and Optometrists/Ophthalmologists for their co-operation throughout 2010.

I would also like to acknowledge the contribution of the Chief Executive Officer, the Directors and the support of the HSE Board throughout 2010.

Patrick Burke

Primary Care Reimbursement Service

Community Based Services - Payment Arrangements

Almost all payments for services provided in the community by General Practitioners, Community Pharmacies, Dentists and Optometrists/Ophthalmologists are made by the Primary Care Reimbursement Service. Payments in the Year 2010 were in excess of €2.529bn. Estimated payments by the Primary Care Reimbursement Service for 2011 are €2.311bn.

Claim data is processed and payments are made by the Primary Care Reimbursement Service under the following Schemes/Payment Arrangements –

General Medical Services (GMS)

Persons who are unable without undue hardship to arrange general practitioner medical and surgical services for themselves and their dependants. Since the 1st October 2010, a person who is supplied by a Community Pharmacy Contractor with a drug, medicine or medical or surgical appliance on the prescription of a Registered Medical Practitioner, Registered Dentist or Registered Nurse Prescriber is charged 50 cent per item subject to a limit of €10 per family per month and this charge is recouped from payment to the Pharmacist.

Drugs, medicines and appliances supplied under the Scheme are provided through Community Pharmacies. In most cases the Doctor gives a completed prescription form to a person, who takes it to any pharmacy that has an agreement with the Health Service Executive to dispense GMS prescription forms. In rural areas the Doctor may dispense for those persons who opt to have their medicines dispensed by him/her. All GMS claims are processed and paid by the Primary Care Reimbursement Service.

Drugs Payment Scheme (DPS)

Under the Drugs Payment Scheme persons who are ordinarily resident in the State and who do not have a current medical card can benefit – an individual or family has now to pay no more than €120 in a calendar month for approved drugs, medicines and appliances for themselves or their families. In order to benefit under this Scheme a person must register themselves and their dependants with their Local Health Office. Items currently reimbursable under the Drugs Payment Scheme are those listed on the HSE Website. Other items which were reimbursable under the DCS and Refund of Drugs Schemes continue, in certain circumstances, to be reimbursable under the Drugs Payment Scheme. DPS claims are processed and paid by the Primary Care Reimbursement Service.

Long Term Illness Scheme (LTI)

On approval by the Health Service Executive, persons who suffer from one or more of a schedule of illnesses are entitled to obtain, without charge, irrespective of income, necessary drugs/medicines and/or appliances under the LTI Scheme. All LTI claims are processed and paid by the Primary Care Reimbursement Service.

Dental Treatment Services Scheme (DTSS)

Under the Dental Treatment Services Scheme GMS eligible adults have access to a range of treatments and clinical procedures comprised of Routine Treatments and Full Upper and Lower Dentures. Routine Treatments are now available for all eligible persons. Dentists may also prescribe a range of medicines to eligible persons. All claims under the DTSS are processed and paid by the Primary Care Reimbursement Service.

European Economic Area (EEA)

Residents from one of the other states of the European Economic Area, with established eligibility, who require emergency general practitioner services while on a temporary visit to the State are entitled to receive from a General Practitioner a GMS prescription form for necessary medication and to have such medication dispensed in a Pharmacy that has entered into an agreement with the Health Service Executive within the State. EEA claims are paid by the Primary Care Reimbursement Service.

High Tech Drugs (HTD)

Arrangements are in place for the supply and dispensing of High Tech medicines through Community Pharmacies. Such medicines are generally only prescribed or initiated in hospital and would include items such as anti-rejection drugs for transplant patients or medicines used in conjunction with chemotherapy or growth hormones. The medicines are purchased by the Health Service Executive and supplied through Community Pharmacies for which Pharmacists are paid a patient care fee. The cost of the medicines and patient care fees are paid by the Primary Care Reimbursement Service.

Primary Childhood Immunisation Scheme

A National Primary Childhood Immunisation Scheme provides for immunisation of the total child population with the aim of eliminating, as far as possible, such conditions as Diphtheria, Polio, Measles, Mumps, Rubella and more recently Meningococcal C Meningitis. Payments to Doctors under this Scheme are made by the Primary Care Reimbursement Service.

Health (Amendment) Act 1996

Under the Health (Amendment) Act 1996 certain health services are made available without charge to persons who have contracted Hepatitis C directly or indirectly from the use of Human Immunoglobulin – Anti D or the receipt within the State of another blood product or blood transfusion. General Practitioner services, pharmaceutical services, dental services and optometric/ophthalmic services provided under the Act are paid for by the Primary Care Reimbursement Service.

Methadone Treatment Scheme

Methadone is prescribed and dispensed by Doctors and Pharmacists for approved clients under the Methadone Treatment Scheme – capitation fees payable to participating Doctors and Community Pharmacists and claims by pharmacies for the ingredient cost of the Methadone dispensed and the associated dispensing fees are processed and paid by the Primary Care Reimbursement Service.

Health Services Executive Community Ophthalmic Services Scheme (HSE-COS)

Under the Health Service Executive Community Ophthalmic Services Scheme, adult medical card holders and their dependants are entitled, free of charge, to eye examinations and necessary spectacles/appliances. Claims by Optometrists/Ophthalmologists are paid by the Primary Care Reimbursement Service. Claims for spectacles provided under the Children's Scheme are also paid by the Primary Care Reimbursement Service.

Immunisations for certain GMS Eligible Persons

Agreement was reached between the Department of Health & Children and the Irish Medical Organisation on fee rates to be applied to certain immunisations for GMS eligible persons. The immunisations encompassed by the agreement are:- Pneumococcal, Influenza, Hepatitis B and the combined Pneumococcal/Influenza. The Health Service Executive facilitated claiming for any of these immunisations by extending the range of codes for 'Special Items of Service'.

General Practitioner Visit Card (GPVC)

Certain people in Ireland who do not qualify for a medical card may apply to the Health Service Executive for a GP Visit Card. GP Visit Cards allow individuals and families who qualify, to visit their General Practitioner for free. All GP claims are processed and paid by the Primary Care Reimbursement Service.

Discretionary Hardship Arrangements

Medical Card patients, for whom Non GMS Reimbursable Items have been prescribed, may make application to the HSE Local Health Office (LHO) for approval to have such items dispensed by a Community Pharmacist. Previously, the LHO reimbursed Community Pharmacists directly in respect of such prescribed items. In July 2009 the payment function for these items transferred to the Primary Care Reimbursement Service.

Summary Statement of Activity During the Year

- Payments in the Year were in excess of €2,529.65m.
- Claim data is processed and payments are made by the PCRS under the following Schemes:
 - General Medical Services (GMS);
 - Drugs Payment (DP);
 - Long Term Illness (LTI);
 - Dental Treatment Services (DTS);
 - European Economic Area (EEA);
 - High Tech Drugs (HTD);
 - Primary Childhood Immunisation;
 - Health (Amendment) Act 1996;
 - Methadone Treatment;
 - Health Service Executive Community Ophthalmic Services (HSE-COS).
- At year end there were more than 3.42m persons registered as being eligible to benefit under the General Medical Services, Drugs Payment, Long Term Illness, Dental Treatment and Health Service Executive Community Ophthalmic Services Schemes.

- More than 93% of eligible GMS persons availed of GP, Pharmaceutical, Dental or Ophthalmic services provided by more than 6,567 Doctors, Pharmacists, Dentists and Optometrists/Ophthalmologists.
- More than 69m prescription items were paid for by the PCRS – an increase of over 1.4m items on 2009.
- Fees and allowances paid to Doctors totalled €493.83m.
- Payments to Pharmacies totalled €1,564.87m:
 - GMS €1,233.26m;
 - DP €173.44m;
 - LTI €126.92m;
 - EEA €1.74m;
 - Patient Care Fees under the HTD Scheme €15.48m;
 - The Health (Amendment) Act 1996, Methadone Treatment Scheme, DTS prescriptions and Pharmacy Training Grants €14.03m.

- Payments to Dentists under the DTS totalled €75.77m.
- Payments to Optometrists/Ophthalmologists under the HSE-COS totalled €26.89m.
- Payments to Wholesalers under the HTD Scheme totalled €345.76m.
- Administration costs in the accounting period of 2010 were €20.49m.
- Claims processed are in respect of services provided in the community and availed of by almost 64.35% of the population.

The Year 2010

	Total of Payments for the year €2,529.	.65m
Doctors	Fees Allowances	€348.I3m €145.70m
Pharmacists	Fees and Mark-Up Drugs and Medicines	€357.51m €1,191.88m
Dentists		€75.77m
Optometrists/	Ophthalmologists	€26.89m
	gs Scheme Payment to Wholesalers Fees paid to Pharmacists	€345.76m €15.48m
Investment in	General Practice Development	€2.04m
Administration	n	€20.49m

- Fees to Doctors include an amount of €9.05m in respect of the Primary Childhood Immunisation Scheme, €0.22m in respect of the Health (Amendment) Act 1996 and €6.20m in respect of the Methadone Treatment Scheme.
- Allowances paid to Doctors include an amount of €5.13m paid as superannuation to Retired District Medical Officers and their dependants.
- Payments to Pharmacists include an amount of €1.59m in respect of drugs/medicines dispensed under the Health (Amendment) Act 1996, an amount of €11.32m in respect of the cost of Methadone dispensed under the Methadone Treatment Scheme and an amount of €0.85m in respect of DTS prescriptions.

- Payments to Dentists include an amount of €60,610 in respect of treatments under the Health (Amendment) Act 1996.
- Payments to Optometrists/Ophthalmologists include an amount of €75,870 in respect of treatments under the Health (Amendment) Act 1996.
- The corresponding figures for 2009 are
 - Total of Payments €2,642.99m.
 - Doctors' Fees €357.80m and Doctors' Allowances €141.87m.
 - Pharmacists' Fees and Mark-Up €405.02m, Drugs and Medicines €1,273.77m.

- Payments to Dentists under the DTS Scheme €86.83m.
- Payments to Optometrists/Opthalmologists €23.80m.
- Investment in General Practice Development €2.88m.
- High Tech Drugs Scheme Payment to Wholesalers €315.36m, Patient Care Fees €15.94m.
- Administration €19.72m.

Number of Agreements

Doctors 2,740	Pharmacists 1,671	Dentists 1,582	Optometrists 574
---------------	-------------------	----------------	------------------

The number of agreements between the Health Service Executive and General Practitioners for the provision of services to GMS persons reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on entry to the GMS. In December 2010 there were 2,740 such agreements.

Number of Agreements as at 31st December 2010

Health Service Executive	Doctors	Pharmacists	Dentists	Optometrists
East Coast Area	293	152	123	43
South West Area	345	202	207	77
Northern Area	315	193	169	53
Midland	156	104	74	47
Mid-Western	234	151	134	47
North Eastern	203	152	100	67
North Western	160	100	70	34
South Eastern	273	185	159	66
Southern	470	257	336	71
Western	291	175	210	69
National	*2,740	#1,671	†1 , 582	574
Corresponding figures for 2009	2,663	1,630	1,570	555

^{* 482} GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.

^{# 12} Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS schemes at year end are included above.

^{+ 190} Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.

Persons Eligible for Services

GMS 1,615,809 GPVC 117,423 DP 1,557,048 LTI 134,926

Persons who are unable without undue hardship to arrange General Practitioner medical and surgical services plus dental and optometric services for themselves and their dependants are provided with such services under the GMS Scheme. Since the 1st October 2010, a person who is supplied by a Community Pharmacy Contractor with a drug, medicine or medical or surgical appliance on the prescription of a Registered Medical Practitioner, Registered Dentist or Registered Nurse Prescriber is charged 50 cent per item subject to a limit of €10 per family per month and this charge is recouped from payment to the Pharmacist. An eligible person is entitled to select a Doctor of his/her choice, from among those Doctors who have entered into agreements with the Health Service Executive. Drugs, medicines and appliances prescribed by participating Doctors for their GMS patients are provided through Community Pharmacies. Dental and ophthalmic services are provided by Dentists and Optometrists/Ophthalmologists who have contracted with the Health Service Executive. GMS prescription forms may be dispensed in any Pharmacy that has an agreement with the Health Service Executive to dispense GMS prescription forms. In rural areas, where a Doctor has a centre of practice three miles or more

from the nearest Community Pharmacy participating in the Scheme, the Doctor dispenses for those persons served from the centre who opt to have their medicines dispensed by him/her. The number of eligible GMS persons at year end included 45,206 persons who were entitled and had opted to have their medicines dispensed by their GPs.

Under the terms of the Drugs Payment Scheme persons who do not have a medical card may apply for a Drugs Payment Scheme card on an individual or on a family unit basis. Prescribed medicines, which are reimbursable under the GMS Scheme, costing in excess of a specified amount per month, currently €120 per family, is claimed by the Pharmacy and is paid by the Primary Care Reimbursement Service.

On approval by the Health Service Executive, persons who suffer from one or more of a schedule of illnesses are entitled to obtain, without charge, irrespective of income, necessary drugs/medicines and/or appliances under the LTI Scheme. The Primary Care Reimbursement Service makes payments on behalf of the Health Service Executive for LTI claims submitted by Pharmacies.

Number of Eligible Persons as at 31st December 2010

Health Service Executive	GMS	GPVC	DP	LTI
Eastern Areas	451,360	24,406	525,606	66,911
Midland	105,079	8,231	99,784	8,056
Mid-Western	144,125	9,398	164,541	9,025
North Eastern	163,395	12,785	139,757	10,967
North Western	125,554	10,230	58,727	7,489
South Eastern	205,672	15,572	143,700	14,355
Southern	236,322	23,528	260,032	10,180
Western	184,302	13,273	164,901	7,943
National	1,615,809	117,423	1,557,048	134,926
% of Population	38.11%	2.77%	36.72%	3.18%
Corresponding figures for 2009	1,478,560	98,325	1,587,448	127,636

GMS – General Medical Services Scheme. GPVC – GP Visit Card Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme.

Fees €348.13m Allowances €145.70m

Payments to General Practitioners are categorised as fees and/or allowances. For the majority of GPs who operate under the 1989 agreement the principle fee is the capitation per person which is weighted for gender, age and distance from a Doctor's centre of practice – capitation fees totalled €225,237,744 in 2010 – a decrease of €717,034 on 2009. Fees totalling €757,826 were paid to 9 GPs who continue to provide services under the Fee-Per-Item of service agreements.

Apart from 'Out-of-Hours' fees and fees for a range of special services the cost of services provided in normal hours by GPs for GMS persons, including the prescribing of necessary medicines, is encompassed by the capitation fee. All GMS persons can avail of full GP services and in many cases they can benefit from specialist clinics provided by GPs for issues such as Women's Health, Family Planning and Asthma.

In addition to a capitation fee an outside normal hours fee is payable for non routine consultations when an eligible GMS person is seen by their GP or another GP acting on his/her behalf from 5pm in the evening to 9am on the following morning (Monday to Friday) and all hours on Saturdays, Sundays and Bank Holidays. The number of 'Out-of-Hours' claims decreased to 703,623 in 2010 compared with 837,143 in 2009 – and the cost of such claims decreased to €40,786,101 from €49,507,291 in 2009. Special fees are payable for a range of 18 services such as excisions, suturing, vaccinations, catheterization, family planning etc. The most frequent claimed special service in 2010 was Influenza Vaccination (371,659) followed by Excisions (123,808) and E.C.G. treatments (92,123) – there was a total of more than 790,908 special services provided in 2010 – special fees totalling €30,370,507 were paid in 2010.

Annual and Study Leave together with locum, nursing and secretarial support plus other practice support payments account for most of the €145,703,446 allowances paid in the year. The total paid in 2009 was €141,865,756.

Total of Payments to Doctors by Health Service Executive


Health Service Executive	2010
East Coast Area	€29,631,918
South West Area	€55,001,600
Northern Area	€48,570,680
Midland	€33,360,104
Mid-Western	€43,392,157
North Eastern	€45,856,821
North Western	€36,479,276
South Eastern	€62,001,485
Southern	€81,018,845
Western	€58,520,611
National	€493,833,497
Corresponding figure for 2009	€499,665,359

Total Payments accumulated by Regional Health Area					
Dublin Mid-Leinster	€117,993,622				
Dublin North East	€94,427,500				
West	€138,392,045				
South	€143,020,330				

The Total of Payments to Doctors includes payments in respect of eligible persons with Medical Cards and GP Visit Cards. The Total of Payments to Doctors also includes payments of: €9,049,544 under the Primary Childhood Immunisation Scheme; €217,975 to Doctors who provided services under the Health (Amendment) Act 1996; Heartwatch €1,574,300; National Cancer Screening Service £16,450,476 and £6,203,618 under the Methadone Treatment Scheme.

Volume of Claims by Doctors

National - Number of Claims - 2010



Number of Claims in each Health Service Executive Area

Health Service Executive	Fee-Per-Item	Special Type	Special Service	Out-of-Hours
East Coast Area	293	14,463	46,901	27,928
South West Area	16,854	42,232	76,927	62,973
Northern Area	4,301	29,708	69,459	33,934
Midland	1,661	23,446	53,417	55,364
Mid-Western	14,721	27,366	64,984	62,143
North Eastern	434	17,544	65,727	8,350
North Western	7	16,192	66,598	52,084
South Eastern	2,881	26,217	104,735	126,113
Southern	20,243	62,577	134,755	183,650
Western	13	38,609	107,405	91,084
National	61,408	298,354	790,908	703,623
Corresponding figures for 2009	59,632	261,884	713,658	837,143

A majority of Doctors are paid an annual capitation fee for each eligible person – the rate of payment is determined by the age/gender of the person and distance between each person's residence and the centre of practice of their Doctor-of-Choice. A minority of Doctors (9) who have continued to provide services under the Fee-Per-Item of Service agreement are paid a fee for each Doctor/Patient contact.

A Special Type Consultation (STC) fee is payable when a GMS eligible person is unable to contact their registered Doctor and is seen as an emergency case by another. General Practitioners qualify for payment of 'special fees' for the special items of service separately identified under the Capitation agreement and the Fee-Per-Item agreement.

GMS €1,233.26m DP €173.44m LTI €126.92m EEA €1.74m

A GMS person who is provided with a properly completed GMS prescription form by his/her GP can choose to have such prescription forms dispensed in any of the Pharmacies who have entered into agreements with the Health Service Executive for the provision of services under Section 59 of the Health Act, 1970.

In 2010 there were 17.51m prescription forms containing over 54m prescription items dispensed at a cost of over €1,220,397,029 i.e. an average cost of €22.47 per dispensed item. More than 93% of all eligible GMS persons were prescribed for in the year. The average cost of medicines per GMS person in 2010 was €814.24.

Payments made to Pharmacies under the GMS and DTS Schemes are inclusive of the ingredient cost of medicines, dispensing fees and VAT.

Total of Payments to Pharmacies by Health Service Executive

Health Service Executive	GMS €	*DP €	LTI €	#EEA €
East Coast Area	76,808,873	18,923,628	14,624,625	62,869
South Western Area	137,087,511	28,153,066	21,196,634	117,566
Northern Area	140,892,330	27,401,133	19,682,718	70,599
Midland	84,031,459	10,445,520	7,578,007	102,548
Mid-Western	113,777,116	12,659,796	7,505,324	185,344
North Eastern	107,747,376	14,245,063	11,577,379	116,941
North Western	79,199,842	5,657,576	7,564,925	216,811
South Eastern	161,636,712	16,394,868	12,992,635	190,734
Southern	195,950,585	26,131,558	15,501,349	384,585
Western	136,129,755	13,422,864	8,698,183	296,449
National	€1,233,261,559	€173,435,072	€126,921,779	€1,744,446
Corresponding figures for 2009	€1,260,244,615	€259,928,189	€139,759,172	€1,957,613

Under DP, LTI and EEA Schemes Pharmacies are reimbursed the ingredient cost of items dispensed, dispensing fees, mark-up and VAT. For details please see page 28.

The cost of the High Tech Drugs Scheme was €360.40m – at year end there were 54,974 persons registered under this Scheme – Patient Care Fees totalled €15.48m and payments for drugs and medicines totalled €345.76m.

In the year the Health Service Executive processed claims valued at €389.35m on drugs acting on the 'cardiovascular system' (GMS €276.68m, DP €87.19m and LTI €25.48m). The second highest cost category was drugs acting on the 'nervous system' €344.47m (GMS €272.50m, DP €54.99m, LTI €16.98m). The third highest amount paid was for drugs acting on the 'alimentary tract and metabolism system' €262.65m (GMS €183.40m, DP €45.06m, LTI €34.19m).


Total Payments accumulated by Regional Health Area							
	GMS €	*DP €	LTI €	#EEA €			
Dublin Mid-Leinster	297,927,843	57,522,214	43,399,266	282,983			
Dublin North East	248,639,706	41,646,196	31,260,097	187,540			
South	357,587,297	31,740,236	23,768,432	698,604			
West	329,106,713	42,526,426	28,493,984	575,319			

EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.

Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 - €1,591,335; Methadone Treatment Scheme - €11,324,565; DTS Scheme - €852,859; Pharmacy Training Grant - €256,200 and Patient Care Fees totalling €15,484,876 under the High Tech Drugs Scheme (Payments to Wholesalers under the High Tech Drugs Scheme amounted to €345,758,331). Included in the above GMS figures is an amount of €12,769,728 which was paid in respect of Non GMS Reimbursable Items dispensed under Discretionary Hardship Arrangements.

^{*} DP – Payment to Pharmacies in respect of Fertility Treatment for The Rotunda Hospital and The National Maternity Hospital are included in the above table.

Volume of Claims by Pharmacies



GMS prescription forms processed for payment in the year totalled 17.51m – the total of prescribed items was more than 54m – these accounted for approximately 78.59% of all items paid for by the Primary Care Reimbursement Service in 2010.

Approximately 38.49% of GMS forms contained a single item – more than 19.06% contained 2 items – the average number of items per form was 3.10 (2009 - 3.11).

GMS dispensed items paid for by the Primary Care Reimbursement Service in 2010 increased by more than 3,702,741 – the decrease in the number of DP items was less than 2,302,079 – the overall increase in the number of pharmacy claims processed by the Primary Care Reimbursement Service in the year was more than 1.4m.

Number of Items in each Health Service Executive Area

Health Service Executive	*GMS	DP	LTI	EEA	HTD	#Other
East Coast Area	3,490,707	1,218,248	306,535	3,227	32,928	40,741
South West Area	6,430,920	1,694,209	457,328	5,759	58,161	131,448
Northern Area	5,973,123	1,612,643	413,668	3,574	42,457	116,799
Midland	3,680,650	700,339	179,196	4,776	24,616	20,148
Mid-Western	5,118,362	849,815	183,652	9,398	31,239	26,512
North Eastern	4,801,614	932,729	262,108	5,221	31,592	26,841
North Western	3,443,653	370,775	171,856	10,689	24,932	10,428
South Eastern	7,099,308	1,131,497	310,575	9,605	41,166	32,602
Southern	8,642,212	1,704,690	332,569	19,669	62,614	40,654
Western	5,744,111	855,501	190,270	14,527	41,133	25,058
National	54,424,660	11,070,446	2,807,757	86,445	390,838	471,231
Corresponding figures for 2009	50,721,919	13,372,525	2,855,361	85,520	357,365	433,301

^{*}This group includes: GMS claim items and Stock Order items.

#This group includes: 65,471 claim items in respect of the Health (Amendment) Act 1996; 275,733 items under the Methadone Treatment Scheme and 130,027 prescription items under the DTS Scheme.

GMS – General Medical Services Scheme. **DP** – Drugs Payment Scheme. **LTI** – Long Term Illness Scheme. **EEA** – European Economic Area. **HTD** – High Tech Drugs Scheme. **Other** – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.

Payments to Dentists

Above the line €54.10m	Below the line €21.60m

Dentists were paid a total of €75,707,451 in 2010, in respect of treatments provided for more than 382,404 GMS persons under the DTS Scheme.

The following treatments were available to all eligible GMS persons.

ROUTINE: Routine treatments are categorised as either 'Above the Line' or 'Below the Line';

'Above the Line' treatments are uncomplicated procedures viz. Amalgam; Extractions;

'Below the Line' treatments are advanced procedures viz. Protracted Periodontal; Prosthetics.

'Below the Line' treatments – prior Health Service Executive approval for a specific course of treatment under this category is required. Full denture treatment is available, with prior Health Service Executive approval, to all edentulous GMS persons over 16 years.

Payments to Dentists in each Health Service Executive Area


Health Service Executive	2010	
Eastern Areas	€19,057,294	
Midland	€4,774,744	
Mid-Western	€6,686,831	
North Eastern	€6,957,400	
North Western	€4,783,978	
South Eastern	€10,581,386	
Southern	€12,973,497	
Western	€9,892,321	
National	€75,707,451	
Corresponding figure for 2009	€86,772,492	

Total Payments accumulated by Regional Health Area				
Dublin Mid-Leinster	€16,751,201			
Dublin North East	€14,038,236			
South	€23,554,884			
West	€21,363,130			

Dentists were also paid a total of €60,610 in 2010 in respect of treatments under the Health (Amendment) Act 1996.

Volume of Claims by Dentists

National - Volume of Treatments - 2010



Volume of Treatments by Dentists in each Health Service Executive Area

Health Service Executive	⁺Above the Line	⁺Below the Line	No. of persons treated under DTS
Eastern Areas	348,006	21,867	99,698
Midland	78,461	7,004	23,481
Mid-Western	116,353	9,965	34,066
North Eastern	120,419	9,197	35,406
North Western	85,765	5,713	26,858
South Eastern	173,387	16,961	50,913
Southern	226,653	17,529	64,599
Western	155,296	16,110	47,383
National	1,304,340	104,346	382,404
Corresponding figures for 2009	1,439,431	145,167	343,067

ROUTINE - Routine treatments are categorised as either 'Above the Line' or 'Below the Line':

'Above the Line' (ATL) treatments are uncomplicated procedures;

'Below the Line' (BTL) treatments are advanced procedures.

+ The most frequently used ATL service was Amalgam Restoration, which was used by 160,300 patients followed by Oral Examination. In the BTL category the most frequently used service was Protracted Periodontal followed by Prosthetics and Radiographs.

Payments to Optometrists/Ophthalmologists

Under the Health Service Executive Community Ophthalmic Services Scheme, Optometric/Ophthalmic services are provided to adult medical card holders, which include free eye examinations and necessary spectacles/appliances.

Payments in respect of spectacles provided under the Children's Scheme are also made by the Primary Care Reimbursement Service on behalf of the majority of Health Service Executive Areas.

Payments in respect of eye examinations and necessary spectacles/ appliances are provided under the Teenager's Scheme for eligible medical card holders on behalf of certain Health Service Executive Areas. In the 12-month period to the end of December 2010 claims were received on behalf of 269,076 GMS persons for 637,850 treatments costing €25,178,002.

Eye examinations by Optometrists/Ophthalmologists totalled 273,124; complete spectacles (distance, reading and bi-focals) provided under the Scheme totalled 364,726. The balance of treatments included replacement lenses and frames, tinted lenses, prisms and contact lenses. A breakdown of treatments and payments in each Health Service Executive Area is shown hereunder.

Payments to Optometrists/Ophthalmologists in each Health Service Executive Area


Health Service Executive	2010	
Eastern Areas	€6,872,946	
Midland	€1,757,890	
Mid-Western	€2,375,310	
North Eastern	€2,004,039	
North Western	€1,753,750	
South Eastern	€3,612,768	
Southern	€3,968,192	
Western	€2,833,107	
National	€25,178,002	
Corresponding figure for 2009	€22,184,541	

Total Payments accumulated by Regional Health Area					
Dublin Mid-Leinster	€6,456,002				
Dublin North East	€4,178,873				
South	€7,580,960				
West	€6,962,167				

Opticians were also paid in respect of: Health (Amendment) Act 1996 €75,870; Optical services for Teenagers €230,715; Optical services for Children €1,401,894.

Volume of Treatments by Optometrists/Ophthalmologists

National - Volume of Treatments - 2010




Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area

Health Service Executive	Eye Exams	Appliances	Volume of Treatments	No. of Persons Treated
Eastern Areas	73,992	93,301	167,293	71,279
Midland	18,513	24,031	42,544	17,803
Mid-Western	25,673	35,579	61,252	25,482
North Eastern	21,199	31,145	52,344	21,587
North Western	20,392	26,575	46,967	21,016
South Eastern	38,285	55,505	93,790	40,130
Southern	44,216	56,018	100,234	41,394
Western	30,854	42,572	73,426	30,385
National	273,124	364,726	637,850	269,076
Corresponding figures for 2009	242,336	322,270	564,606	238,844

Cost per Person

National 2010



Cost per Person in each Health Service Executive Area

		GMS			DP	DTS	HSE-COS
Health Service Executive	Doctor Cost €	Pharmacy Cost €	Total Cost €	Pharmacy Cost €	Net Cost Per Claimant €	Per Person Treated €	Per Adult Treated €
Eastern Areas	279.98	806.68	1,086.66	1,989.10	406.31	191.15	96.42
Midland	294.41	831.42	1,125.83	1,805.58	320.74	203.35	98.74
Mid-Western	282.64	841.12	1,123.76	1,614.05	305.16	196.29	93.22
North Eastern	260.28	767.89	1,028.17	1,901.05	320.74	196.50	92.84
North Western	268.66	721.11	989.77	1,817.18	313.93	178.12	83.45
South Eastern	280.24	819.43	1,099.67	1,831.50	325.75	207.83	90.03
Southern	311.79	877.55	1,189.34	1,884.20	326.60	200.83	95.86
Western	296.19	811.44	1,107.63	1,683.41	302.21	208.77	93.24
National	€284.92	€814.24	€1,099.16	€1,880.55	€350.69	€197.98	€93.57
Corresponding figures for 2009	€337.94	€907.85	€1,245.79	€2,126.23	€391.97	€252.93	€92.88


The Doctor cost above does not include superannuation paid to retired DMOs.

The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2010.

Medical and pharmaceutical services delivered to GMS persons decreased in cost from €1,245.79 in 2009 to €1,099.16 in 2010 a decrease of €146.63 per person – the cost of medical services per person decreased in cost from €337.94 in 2009 to €284.92 a decrease of 15.69% – the cost per person of pharmaceutical services decreased from €907.85 in 2009 to €814.24 in 2010 a decrease of 10.31%.

Major Therapeutic Classification of Drugs, Medicines and Appliances – General Medical Services Scheme






Majo	r Therapeutic Classification	€m	%
Α	Alimentary Tract and Metabolism	183.40	14.87
В	Blood and Blood Forming Organs	54.45	4.41
С	Cardiovascular System	276.68	22.43
D	Dermatologicals	24.93	2.02
G	Genito Urinary System and Sex Hormones	49.93	4.05
Н	Systemic Hormonal Preps. excl. Sex Hormones and Insulins	14.46	1.17
J	Anti-infectives for Systemic Use	36.33	2.95
L	Antineoplastic and Immunomodulating Agents	11.06	0.90
M	Musculo-Skeletal System	68.10	5.52
N	Nervous System	272.50	22.10
P	Antiparasitic Products, Insecticides and Repellents	0.98	0.08
R	Respiratory System	115.01	9.33
S	Sensory Organs	22.79	1.85
V	Clinical Nutritional Products	46.40	3.76
	Diagnostic Products	23.47	1.90
	Ostomy Appliances	13.96	1.13
	Urinary Appliances	7.59	0.62
	Needles/Syringes/Lancets	5.74	0.46
	Other Therapeutic Products	2.55	0.21
	Dressings	1.68	0.14
	Allergens	0.02	0.00
	Miscellaneous	1.24	0.10
	Total	€1,233.27m	100%

Major Therapeutic Classification of Drugs, Medicines and Appliances - Drugs Payment Scheme

National 2010




Majo	r Therapeutic Classification	€m	%
Α	Alimentary Tract and Metabolism	45.06	13.41
В	Blood and Blood Forming Organs	14.39	4.28
С	Cardiovascular System	87.19	25.95
D	Dermatologicals	12.47	3.71
G	Genito Urinary System and Sex Hormones	21.18	6.30
Н	Systemic Hormonal Preps. excl. Sex Hormones and Insulins	3.96	1.18
J	Anti-infectives for Systemic Use	9.76	2.90
L	Antineoplastic and Immunomodulating Agents	5.36	1.60
M	Musculo-Skeletal System	19.37	5.76
N	Nervous System	54.99	16.36
P	Antiparasitic Products, Insecticides and Repellents	1.00	0.30
R	Respiratory System	38.12	11.35
S	Sensory Organs	4.67	1.39
V	Clinical Nutritional Products	8.01	2.38
	Ostomy Appliances	5.62	1.67
	Urinary Appliances	2.01	0.60
	Diagnostic Products	1.32	0.39
	Dressings	0.37	0.11
	Needles/Syringes/Lancets	0.36	0.11
	Other Therapeutic Products	0.35	0.11
	Allergens	0.15	0.05
	Miscellaneous	0.31	0.09
	Total	€336.02m	100%

Note: The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by an individual or family.

Major Therapeutic Classification of Drugs, Medicines and Appliances - Long Term Illness Scheme

National 2010



Majo	r Therapeutic Classification	€m	%
Α	Alimentary Tract and Metabolism	34.19	26.94
В	Blood and Blood Forming Organs	2.95	2.32
С	Cardiovascular System	25.48	20.08
D	Dermatologicals	0.11	0.08
G	Genito Urinary System and Sex Hormones	1.30	1.03
Н	Systemic Hormonal Preps. excl. Sex Hormones and Insulins	0.72	0.57
J	Anti-infectives for Systemic Use	1.50	1.19
L	Antineoplastic and Immunomodulating Agents	0.09	0.07
M	Musculo-Skeletal System	0.38	0.30
N	Nervous System	16.98	13.37
Р	Antiparasitic Products, Insecticides and Repellents	0.00	0.00
R	Respiratory System	0.49	0.39
S	Sensory Organs	0.21	0.16
٧	Diagnostic Products	24.80	19.54
	Clinical Nutritional Products	7.50	5.91
	Needles/Syringes/Lancets/Swabs	7.95	6.26
	Urinary Appliances	1.10	0.86
	Nutritional/Ancillary Devices	0.53	0.42
	Dressings	0.20	0.16
	Ostomy Appliances	0.16	0.12
	Other Therapeutic Products	0.04	0.04
	Miscellaneous	0.24	0.19
	Total	€126.92m	100%

Summary of Statistical Information relating to the GMS Scheme for each of the five years 2006-2010

	2010	2009	2008	2007	2006
(i) Number of Eligible Persons in December	1,733,232	1,478,560	1,352,120	1,276,178	1,221,695
Doctors	(000's)	(000's)	(000's)	(000's)	(000's)
Total Payments	€460,338	€466,737	€459,476	€427,418	€391,029
(ii) Doctors' Payment per Person	€284.92	€337.94	€352.67	€349.03	€314.85
Pharmacies	(000's)	(000's)	(000's)	(000's)	(000's)
Total Cost of Prescriptions	€1,220,397	€1,245,935	€1,129,494	€1,032,178	€924,995
Ingredient Cost	€932,270	€962,305	€881,425	€824,323	€743,943
Dispensing Fee	€259,635	€257,968	€225,697	€188,163	€163,537
VAT	€28,492	€25,662	€22,372	€19,692	€17,516
Number of Forms	17,508	16,333	15,648	14,780	13,932
Number of Items	54,308	50,722	48,212	44,358	40,569
Cost per Form	€69.71	€76.28	€72.18	€69.84	€66.39
Cost per Item	€22.47	€24.56	€23.43	€23.27	€22.80
Ingredient Cost per Item	€17.17	€18.97	€18.28	€18.58	€18.34
Items per Form	3.10	3.11	3.08	3.00	2.91
	(000's)	(000's)	(000's)	(000's)	(000's)
Total Cost of Stock Orders	€12,865	€14,309	€15,797	€16,231	€15,230
Ingredient Cost	€9,895	€11,044	€12,188	€12,559	€11,777
Pharmacy Fees	€2,467	€2,761	€3,047	€3,140	€2,944
VAT	€503	€504	€562	€532	€509
	(000's)	(000's)	(000's)	(000's)	(000's)
Overall Cost of Medicines	€1,233,262	€1,260,244	€1,145,292	€1,048,409	€940,225
(iii) Pharmacy Payment per Person	€814.24	€907.85	€932.63	€856.14	€809.04
	(000's)	(000's)	(000's)	(000's)	(000's)
Overall Payments	€1,693,600	€1,726,981	€1,604,768	€1,475,827	€1,331,254
(iii) Overall Payment per Person	€1,099.16	€1,245.79	€1,285.30	€1,205.17	€1,123.89

Note: (i) Number of Eligible Persons in 2010 includes the number of eligible persons with Medical Cards and GP Visit Cards.

⁽ii) Doctors' Payment per Person is exclusive of superannuation paid to retired DMOs.

⁽iii) Pharmacy Payment per Person and Overall Payment per Person is based on the actual number of persons who availed of services.

Summary of Statistical Information relating to the LTI/DP Schemes for each of the five years 2006-2010

	2010	2009	2008	2007	2006
LTI Scheme					
Number of Eligible Persons in December	134,926	127,636	120,407	112,580	106,307
*Number of Claimants	67,492	65,731	62,934	59,040	53,082
	(000's)	(000's)	(000's)	(000's)	(000's)
Number of Items	2,808	2,855	2,643	2,353	2,165
Total Cost	€126,922	€139,759	€137,899	€124,458	€115,461
Cost per Item	€45.20	€48.95	€52.17	€52.90	€53.32
*Cost per Claimant	€1,880.55	€2,126.23	€2,191.17	€2,108.03	€2,175.15
DP Scheme					
Number of Eligible Persons in December	1,557,048	1,587,448	1,624,413	1,583,738	1,525,657
*Number of Claimants	494,550	663,127	687,587	667,782	597,835
	(000's)	(000's)	(000's)	(000's)	(000's)
Number of Items	11,070	13,373	13,907	13,430	11,872
Gross Cost	€336,019	€451,707	€506,806	€491,186	€442,924
Net Cost	€173,435	€259,928	€311,898	€307,334	€283,108
Gross Cost per Item	€30.35	€33.78	€36.44	€36.57	€37.31
*Net Cost per Claimant	€350.69	€391.97	€453.61	€460.23	€473.56

^{*}These figures are based on the actual number of persons who availed of services under each Scheme.

Fees and Allowances under Capitation Agreement as at 31st December 2010

Ages	Male €	Female €
Under 5 years	76.98	75.09
5-15	44.68	45.19
16-44	57.03	93.26
45-64	113.91	125.17
65-69	120.00	133.87

Above rates are exclusive of Supplementary Out-of-Hours Fee of €3.76.

The Capitation rate is €280.31 per annum for persons aged 70 years and over in the community issued with a medical card.

A Capitation rate of €448.04 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by the Health Service Executive) for continuous periods in excess of five weeks.

Out-of-Hours Payment		
Surgery (6 p.m 8 a.m.)	€45.00	
Surgery (8-9 a.m and 5-6 p.m)	€15.00	
Domiciliary	€45.00	
Additional Fee (Surgery or Domiciliary)	€15.00	

*Special Items of Service	
(i) to (ix)	€26.81
(x) and (xi)	€40.23
(xii)	€67.05
(xiii)	€45.13
(xiv)	€72.21
(xv) and (xvi)	€42.75
(xvii)	€64.12
(xviii)	€154.13

Temporary Residents/EEA Visitors/ Emergency		
Surgery	€44.26	
Domiciliary	€44.26	
Additional Fee	€15.00	
Rural Dispensing Fee	€15.41	
Fee for Second Medical Opinion	€28.60	

Practice Payments for Rural Areas		
Rural Practice Allowance		
Per Annum €17,530.89		
Opt-in GP (dispensing doctor) €41.11		
Pilot GP (dispensing doctor) €47.44		
Continuous GP (dispensing doctor) €13.49		

Practice Support	
Allowance for Practice Secretary	
up to a maximum Per Annum of	€24,312.12
Allowance for Practice Nurse	
up to a maximum Per Annum of	€38,204.77
Allowance for Practice Manager	
up to a maximum Per Annum of	€31,258.45

Contributions to Locum Expenses (Subject to the conditions of the Agreement)

Annual Leave €	€1,492.60 per week
Sick Leave	Up to a maximum of €1,492.60 per week
•	Up to a maximum of €213.23 per day

Contributions to Medical Indemnity Insurance

Calculation of contributions related to GMS panel numbers and net premium.

Asylum Seekers

A one off superannuable registration fee of €179.25 per person payable to Doctors in respect of each such patient on their GMS Scheme panels.

- * Special Items of Service.
- (i) Excisions/Cryotherapy/ Diathermy of Skin Lesions.
- (ii) Suturing of Cuts and Lacerations.
- iii) Draining of Hydroceles.
- (iv) Treatment and Plugging of Dental and Nasal Haemorrhages.
- (v) Recognised Vein Treatment.
- (vi) ECG Tests and their Interpretation.
- (vii) Instruction in the fitting of a Diaphragm.
- (viii) Removal of Adherent Foreign Bodies from the Conjunctival Surface of the Eye.
- (ix) Removal of Lodged or Impacted Foreign Bodies from the Ear, Nose and Throat.
- (x) Nebuliser Treatment in the case of Acute Asthmatic Attack.
- (xi) Bladder Catheterization.
- (xii) Attendance at case conferences (in cases where such are convened by the HSE).
- (xiii) Advice and Fitting of a Diaphragm.
- (xiv) Counselling and Fitting of an IUCD.
- (xv) Pneumococcal Vaccination.
- (xvi) Influenza Vaccination.
- (xvii) Pneumococcal/Influenza Vaccination.
- (xviii) Hepatitis B Vaccination.

Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health (Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2010

_		
Surger	y Consultations	
Day	Normal Hours	€12.83
Late	Outside Normal Hours other than (Night)	€18.25
Night	Midnight to 8.00 a.m.	€36.09
Domic	iliary Consultations	
Day		€18.93
Late		€24.79
Night		€48.61
Tempo	rary Residents/EEA Visitors/Emergency	
Surgery		€44.26
Domicilia	ary	€44.26
Rural F	Practitioner's Allowance	
Per Annu	ım	€7,613.96
Locum	and Practice Expense Allowance	
Per Annu	m	€1,482.23
Session	nal Rate – Homes for the Aged	
Per 3 Ho	our Session	€79.11

*Sp	ecial Items of Service	
(i) to	(vii)	€24.25
(viii)	and (ix)	€42.75
(x)		€64.12
(xi)		€154.13
lmn	nunisation Fees	
(i)	Registration of child with a G.P.	€40.84
(ii)	Complete course of immunisation against PT/DT, Hib, Polio and MMR	€136.08
(iii)	95% uptake bonus % not in Schedule	€65.54
Hea	lth (Amendment) Act 1996	
Surge	ery Fee	€33.00
Dom	iciliary Fee	€43.53
Met	hadone Treatment Scheme	
Level	I Contractor	€159.97
Level	2 Contractor	€176.43
Hea	rtwatch Programme	€42.50

- * Special Items of Service.
- (i) Excisions/Cryotherapy/ Diathermy of Skin Lesions.
- (ii) Suturing of Cuts and Lacerations.
- (iii) Draining of Hydroceles.
- (iv) Treatment and Plugging of Dental and Nasal Haemorrhages.
- (v) Recognised Vein Treatment.
- (vi) ECG Tests and their Interpretation.
- (vii) Instruction in the fitting of a Diaphragm.
- (viii) Pneumococcal Vaccination.
- (ix) Influenza Vaccination.
- (x) Pneumococcal/Influenza Vaccination.
- (xi) Hepatitis B Vaccination.

Scale of Fees Payable to Participating Pharmacists as at 31st December 2010

GMS Scheme	€	
*Fee-Per-Item		
- for each of the first 1,667 items dispensed by the Community Pharmacy Contractor in a month	5.00	
- for each of the next 833 items dispensed by the Community Pharmacy Contractor in that month	4.50	
- for each other item dispensed by the Community Pharmacy Contractor in that month	3.50	
Extemporaneous Fee	6.53	
Extemporaneous dispensing and compounding of		
- Powders	19.60	
- Ointments and Creams	13.07	
Non-Dispensing – exercise of professional judgement	3.27	
Phased Dispensing - each part of phased dispensing	3.27	
* A Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.		
Sumplies to Dispossing Destage		

Supplies to Dispensing Doctors

Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price with the addition of 25% on cost.

DP/LTI/EEA Schemes and Health (Amendment) Act 1996

*The Fee-Per-Item structure shown for the GMS Scheme above includes the items dispensed in these four Schemes. Reimbursement of ingredient cost plus 20% mark-up on ingredient cost plus Fee-Per-Item.

20% mark-up on Incontinence products and Dressings under DP Scheme, 50% mark-up on all other Non Drug Items.

Extemporaneously dispensed preparations are reimbursed according to Statutory Instrument S.I. No. 249 of 2009. In the case of the Drugs Payment Scheme the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are in excess of the specified monthly amount (currently €120) payable to the Pharmacy by an individual or family.

High Tech Medicines Scheme

Patient Care Fee: €62.03 per month.

Methadone Treatment Scheme

Patient Care Fee: Up to a Maximum of €62.00 per month.

Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2010

Treatment Type	Routine €
Oral Examination	33.00
Prophylaxis	31.00
Restoration (Amalgam)	50.06
Restoration (Composite) 6 anterior teeth only	51.88
Exodontics (Extraction under local anaesthetic)	39.50
Surgical Extraction – Maximum 2 units:	
Fee payable for each 15 minute unit	35.00
Maximum	70.00
1st Stage Endodontic Treatment (Anterior teeth only)	57.30
Denture Repairs	
1st Item of Repair	47.86
Each Subsequent Item	15.34
Maximum	78.54
Apicectomy/Amputation of Roots	* Dentist Estimate
Endodontics (Anterior teeth only)	* Dentist Estimate
Protracted Periodontal Treatment	* Dentist Estimate
Miscellaneous	
(e.g. Haemorrhage and Prescriptions only)	22.65
Prosthetics	
Full Upper or Lower Denture	326.22
(Other than Edentulous Persons)	
Partial Upper or Lower Acrylic Denture	239.27
Complete Upper or Lower Reline	130.59
Complete Upper and Lower Reline	217.38
Full Upper and Lower Denture (Edentulous Persons Only)	478.74

^{*} Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.

Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme

As at 31st December 2010	€			€	
Examinations			Single Vision Lens (1) (Plastic) Distance	26.78	(H)
Eye Examination Ophthalmic Optician	22.51		Single Vision Lenses (2) (Plastic) Distance	53.55	(H)
Eye Examination Ophthalmologist/			Single Vision Lens (1) (Plastic) Reading	26.78	(H)
Ophthalmic Medical Practitioner	25.55		Single Vision Lenses (2) (Plastic) Reading	53.55	(H)
Medical Eye Examination by Ophthalmologist	51.11				
Eye Examination for Contact Lenses (Grant)	68.44	(H)	Additional Specification for Lenses to All Spectacle	Types	
Eye Examination Ophthalmic (Dilation)	45.03		Special grant towards additional specification for lens (1)		
			- applies to all spectacle types	81.54	(H)
Appliances			Special grant towards additional specification for lenses (2)		
Single Vision Complete Appliances			- applies to all spectacle types	163.08	(H)
Spectacles – Distance	41.98				
Spectacles – Reading	41.98		Other Items - Single Vision		
Spectacles – Uncollected	29.26		Lenticular Lens (1 Surface)	11.60	
Contact Lenses (Pair)	41.97		Lenticular Lenses (2 Surfaces)	23.20	
Contact Lenses Standard or Disposable per pair (Grant)	64.19	(H)	Lenticular Lenses (3 Surfaces)	34.81	
Single Vision Spectacles – with Glass Lenses Distance	121.96	(H)	Lenticular Lenses (4 Surfaces)	46.41	
Single Vision Spectacles – with Glass Lenses Reading	121.96	(H)	Tinted Lens (I)	7.41	
Single Vision Spectacles – with Plastic Lenses Distance	131.02	(H)	Tinted Lenses (2)	14.83	
Single Vision Spectacles – with Plastic Lenses Reading		(H)	Tinted Lenses (3)	22.24	
			Tinted Lenses (4)	29.66	
Single Vision Lenses to Own Frame			Prism (I)	6.28	
Replacement Distance Lens (I) to own frame	16.31		Prisms (2)	12.55	
Replacement Distance Lenses (2) to own frame	32.63		Prisms (3)	18.84	
Replacement Reading Lens (I) to own frame	16.31		Prisms (4)	25.12	
Replacement Reading Lenses (2) to own frame	32.63		Prisms (5)	31.40	
			Prisms (6)	37.67	
Single Vision Lenses to Non-Standard Frame			Prisms (7)	43.95	
Single Vision Lens (1) (Glass) Distance	23.49	(H)	Prisms (8)	50.24	
Single Vision Lenses (2) (Glass) Distance	47.00	(H)	Dioptric powers higher than 8.00 (I) Lens	6.15	
Single Vision Lens (1) (Glass) Reading	23.49	(H)	Dioptric powers higher than 8.00 (2) Lenses	12.29	
Single Vision Lenses (2) (Glass) Reading	47.00	(H)	Dioptric powers higher than 8.00 (3) Lenses	18.44	

⁽H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.

Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued

As at 31st December 2010	€			€	
Dioptric powers higher than 8.00 (4) Lenses	24.59		Bifocal Lenses (2) to Non-Standard Frames	95.61	(H)
Anti-Reflective Coating on Plastic Lens (I)	18.08	(H)	Varifocal Lens (I) (Grant)	94.56	(H)
Anti-Reflective Coating on Plastic Lenses (2)	36.15	(H)	Varifocal Lenses (2) (Grant)	189.12	(H)
Dioptric powers higher than 6.00 (Plastic) (1) Lens	15.37				
Dioptric powers higher than 6.00 (Plastic) (2) Lenses	30.73		Other Items - Bifocals		
Dioptric powers higher than 6.00 (Plastic) (3) Lenses	46.10		Sphere over 6.00 and up to 9.00 extra charge (I) Lens	4.15	
Dioptric powers higher than 6.00 (Plastic) (4) Lenses	61.47		Sphere over 6.00 and up to 9.00 extra charge (2) Lenses	8.30	
Plastic Lens (1) for children as prescribed	4.69		Sphere over 9.00 extra charge (I) Lens	9.22	
Plastic Lenses (2) for children as prescribed	9.37		Sphere over 9.00 extra charge (2) Lenses	18.44	
Plastic Lens (I) Adult	4.54	(H)	Tinted Lens (I)	8.18	
Plastic Lenses (2) Adult	9.08	(H)	Tinted Lenses (2)	16.38	
			Prism (I)	8.74	
Bifocals			Prisms (2)	17.46	
Spectacles Bifocal Complete	83.53				
Fused Bifocal Spectacles	162.72	(H)	Repairs		
Varifocals Spectacles – Glass or Plastic	250.16	(H)	Replacement Frame to own lenses	12.16	
			Replacement Front to own lenses	5.83	
Bifocal Lenses			Replacement Side (I) to own frame	2.45	
Replacement Bifocal Lens (I) to own frame	37.14		Replacement Sides (2) to own frame	4.90	
Replacement Bifocal Lenses (2) to own frame	74.27		Complete New Frames	90.60	(H)
Bifocal Lens (1) To Non-Standard Frames	47.80	(H)			

⁽H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.

DETAILED STATISTICAL ANALYSIS OF CLAIMS AND PAYMENTS 2010




Table I GMS: Summary of Statistical Information for each of the Five Years 2006-2010

Year ended December:-	2010	2009	2008	2007	2006	Year ended December:-	2010	2009	2008	2007	2006
(i) Number of Eligible Persons in December	1,733,232	1,478,560	1,352,120	1,276,178	1,221,695	Number of Doctor Contracts	2,740	2,663	2,599	2,347	2,315
						Number of Pharmacist Contracts	1,671	1,630	1,620	1,587	1,530
DOCTORS	(2000)	(000's)	(2°000)	(2°000)	(2000)		(000's)	(2000)	(2°000)	(000's)	(000's)
Total Payments	€460,338	€466,737	€459,476	€427,418	€391,029	Total Cost of Stock Orders	€12,865	€14,309	€15,797	€16,231	€15,230
						Ingredient Cost	€9,895	€11,044	€12,188	€12,559	€11,777
(ii) Doctors' Payment	€284.92	€337.94	€352.67	€349.03	€314.85	Pharmacy Fees	€2,467	€2,761	€3,047	€3,140	€2,944
per Person						VAT	€503	€504	€562	€532	€509
PHARMACIES											
Total Cost of Prescriptions	€1,220,397	€1,245,935	€1,129,494	€1,032,178	€924,995	Overall Cost of Medicines	€1,233,262	€1,260,244	€1,145,292	€1,048,409	€940,225
Ingredient Cost	€932,270	€962,305	€881,425	€824,323	€743,943		€814.24	€907.85	€932.63	€856.14	€809.04
Dispensing Fee	€259,635	€257,968	€225,697	€188,163	€163,537	Payment per Person					
VAT	€28,492	€25,662	€22,372	€19,692	€17,516						
Number of Forms	17,508	16,333	15,648	14,780	13,932						
Number of Items	54,308	50,722	48,212	44,358	40,569	Overall Payments	€1,693,600	€1,726,981	€1,604,768	€1,475,827	€1,331,254
Cost per Form	€69.71	€76.28	€72.18	€69.84	€66.39	(iii) Overall Payment per Person	€1,099.16	€1,245.79	€1,285.30	€1,205.17	€1,123.89
Cost per Item	€22.47	€24.56	€23.43	€23.27	€22.80	-					
Ingredient Cost per Item	€17.17	€18.97	€18.28	€18.58	€18.34						
Items per Form	3.10	3.11	3.08	3.00	2.91						

Note: (i) Number of Eligible Persons in 2010 includes the number of eligible persons with Medical Cards and GP Visit Cards.

⁽ii) Doctors' Payment per Person is exclusive of superannuation paid to retired DMOs.

⁽iii) Pharmacy Payment per Person and Overall Payment per Person is based on the actual number of persons who availed of services.

Table I.I LTI/DP: Summary of Statistical Information for each of the Five Years 2006-2010

Year ended December:-	2010	2009	2008	2007	2006	Year ended December:-	2010	2009	2008	2007	2006
LTI Scheme Number of Eligible Persons in December	134,926	127,636	120,407	112,580	106,307	DP Scheme Number of Eligible Persons in December	1,557,048	1,587,448	1,624,413	1,583,738	1,525,657
*Number of Claimants	67,492	65,731	62,934	59,040	53,082	*Number of Claimants	494,550	663,127	687,587	667,782	597,835
	(000's)	(000's)	(2°000)	(000's)	(000's)		(000's)	(000's)	(000's)	(2°000)	(000's)
Number of Items	2,808	2,855	2,643	2,353	2,165	Number of Items	11,070	13,373	13,907	13,430	11,872
Total Cost	€126,922	€139,759	€137,899	€124,458	€115,461	Gross Cost	€336,019	€451,707	€506,806	€491,186	€442,924
Cost per Item	€45.20	€48.95	€52.17	€52.90	€53.32	Net Cost	€173,435	€259,928	€311,898	€307,334	€283,108
*Cost per Claimant	€1,880.55	€2,126.23	€2,191.17	€2,108.03	€2,175.15	Gross Cost per Item	€30.35	€33.78	€36.44	€36.57	€37.31
						*Net Cost per Claimant	€350.69	€391.97	€453.61	€460.23	€473.56

^{*}These figures are based on the actual number of persons who availed of services under each Scheme.

Table 2 Number of Agreements

Health Service	Doc	tors	Pharn	nacists	Den	tists	Optom	etrists
Executive	2010	2009	2010	2009	2010	2009	Optometris 2010 43 77 53 47 47 67 34 66 71 69	2009
East Coast Area	293	283	152	141	123	125	43	41
South Western Area	345	343	202	203	207	189	77	76
Northern Area	315	298	193	189	169	160	53	50
Midland	156	151	104	100	74	76	47	46
Mid-Western	234	234	151	149	134	136	47	45
North Eastern	203	193	152	150	100	103	67	62
North Western	160	159	100	98	70	78	34	33
South Eastern	273	264	185	181	159	152	66	65
Southern	470	452	257	251	336	341	71	70
Western	291	286	175	168	210	210	69	67
NATIONAL	2,740	2,663	1,671	1,630	1,582	1,570	574	555

Note: (i) Where Doctors have panel numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the doctors HSE Area.

⁽ii) 482 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.

⁽iii) 190 Dentists (188 – 2009) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.

⁽iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS Schemes at year-end are included above.

⁽v) Above figures relate to the position as at 31st December 2010.

Table 3 GMS: Payments to Doctors

		2010	2009
		€	€
FEES	- Item of Service Contract	757,826	769,487
	- Capitation	225,237,744	225,954,778
	- Special Claims/Services	45,326,326	44,124,618
	- Out-of-Hours	40,786,101	49,507,291
	- Dispensing	2,148,999	2,285,357
	- Asylum Seekers	377,142	846,494
	- GP Visit Cards	-	1,383,375
ALLOWANCES	- Annual Leave	9,577,326	10,437,384
	- Locum and Practice Expenses	12,038	12,643
	- Sick Leave	1,881,783	2,223,277
	- Maternity Leave/Paternity Leave	1,004,257	1,351,647
	- Rural Practice	3,463,881	3,761,836
	- Secretarial/Nursing	80,559,638	74,616,329
	- Study Leave	1,701,105	1,785,347
	- Medical Indemnity Insurance	3,619,863	2,816,513
	- Rostering/Out-of-Hours	12,680,604	12,511,152
	- Practice Development	4,351,743	4,353,527
	- Practice Support Grant	2,001,310	2,671,843
SALARIES	- Former District Medical Officers	1,489,159	1,696,801
	- Benefits to retired DMOs and their dependants	5,134,708	5,537,300
SUPERANNUATION FUND	- Contribution	23,360,739	23,627,456
TOTAL		€465,472,292	€472,274,455

Table 4 GMS: Cost of Prescriptions

Haraldh Camaian	Ingredie	ent Cost	Dispens	sing Fee	VA	AT .	То	otal
Health Service Executive	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €
East Coast Area	58,402,749	60,233,490	16,482,160	17,422,789	1,749,267	1,613,143	76,634,176	79,269,422
South Western Area	107,283,814	110,468,331	29,976,860	29,933,769	3,431,434	3,075,991	140,692,108	143,478,091
Northern Area	105,024,439	110,257,084	28,803,913	29,238,738	3,113,803	2,900,229	136,942,155	142,396,051
Midland	63,754,750	66,313,109	17,782,011	17,708,193	2,011,161	1,834,861	83,547,922	85,856,163
Mid-Western	85,613,224	88,610,101	24,366,887	23,931,783	2,643,919	2,319,769	112,624,030	114,861,653
North Eastern	80,912,163	82,676,183	22,774,805	22,385,331	2,604,905	2,249,767	106,291,873	107,311,281
North Western	59,195,992	61,038,782	16,510,082	16,259,762	1,796,939	1,592,292	77,503,013	78,890,836
South Eastern	120,875,425	122,874,913	34,491,382	33,699,763	3,781,512	3,396,313	159,148,319	159,970,989
Southern	150,059,793	155,975,463	41,000,396	40,611,288	4,380,940	3,997,631	195,441,129	200,584,382
Western	101,147,947	103,857,704	27,445,994	26,776,671	2,978,363	2,681,780	131,572,304	133,316,155
National	€932,270,296	€962,305,160	€259,634,490	€257,968,087	€28,492,243	€25,661,776	€1,220,397,029	€1,245,935,023

Note: Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.

Table 5 GMS: Cost of Stock Order Forms

	Ingredie	ent Cost	*Pharm	acy Fee	VA	λΤ	To	otal
Health Service Executive	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €
East Coast Area	116,349	111,493	28,405	28,126	29,943	29,898	174,697	169,517
South Western Area	96,294	86,341	24,070	21,594	24,992	23,168	145,356	131,103
Northern Area	135,762	137,431	33,934	34,367	30,526	33,327	200,222	205,125
Midland	368,894	463,139	92,197	115,809	22,446	25,484	483,537	604,432
Mid-Western	883,170	841,912	220,795	210,536	49,121	43,400	1,153,086	1,095,848
North Eastern	1,118,433	1,063,718	279,223	265,943	57,847	51,229	1,455,503	1,380,890
North Western	1,321,216	1,481,938	329,951	370,489	45,662	55,179	1,696,829	1,907,606
South Eastern	1,920,604	2,579,326	477,716	644,769	90,073	96,197	2,488,393	3,320,292
Southern	359,072	358,812	89,539	89,737	60,845	54,488	509,456	503,037
Western	3,575,011	3,919,974	890,616	979,988	91,824	91,780	4,557,451	4,991,742
National	€9,894,805	€11,044,084	€2,466,446	€2,761,358	€503,279	€504,150	€12,864,530	€14,309,592

Note: (i) Stock Order Forms are provided by HSE Areas for use by Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are entitled to be dispensed to.

⁽ii) * Pharmacies are reimbursed for stock order items on the basis of the reimbursement price, with the addition of 25% on cost.

⁽iii) The above figures include needles, syringes and dressings which are available for Doctors' use.

Table 6 DTS: Payments to Dentists

	Above	the Line	Below t	the Line	То	tal
Health Service Executive	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €
Eastern Areas	14,400,735	16,981,125	4,656,559	5,516,151	19,057,294	22,497,276
Midland	3,219,794	3,748,497	1,554,950	1,863,214	4,774,744	5,611,711
Mid-Western	4,769,522	4,980,966	1,917,309	2,452,033	6,686,831	7,432,999
North Eastern	5,071,832	5,502,224	1,885,568	2,488,644	6,957,400	7,990,868
North Western	3,475,675	3,456,832	1,308,303	1,348,171	4,783,978	4,805,003
South Eastern	7,201,384	7,467,429	3,380,002	4,131,261	10,581,386	11,598,690
Southern	9,448,816	10,821,398	3,524,681	4,223,607	12,973,497	15,045,005
Western	6,515,554	7,667,247	3,376,767	4,123,693	9,892,321	11,790,940
National	€54,103,312	€60,625,718	€21,604,139	€26,146,774	€75,707,451	€86,772,492

Note: Dentists were also paid a total €60,610 in 2010 (€62,114 in 2009) in respect of fees under Health (Amendment) Act 1996.

Table 7 GMS: Payment per Person

		2010			2009	
Health Service Executive	Doctors €	Pharmacies €	Total €	Doctors €	Pharmacies €	Total €
Eastern Areas	279.98	806.68	1,086.66	334.39	896.72	1,231.11
Midland	294.41	831.42	1,125.83	349.89	943.28	1,293.17
Mid-Western	282.64	841.12	1,123.76	331.55	936.25	1,267.80
North Eastern	260.28	767.89	1,028.17	320.18	884.91	1,205.09
North Western	268.66	721.11	989.77	319.92	787.19	1,107.11
South Eastern	280.24	819.43	1,099.67	325.38	908.98	1,234.36
Southern	311.79	877.55	1,189.34	371.65	975.65	1,347.30
Western	296.19	811.44	1,107.63	342.17	900.00	1,242.17
National	€284.92	€814.24	€1,099.16	€337.94	€907.85	€1,245.79

Note: The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies (Tables 4 and 5) in respect of the actual cost per person who availed of services.

Table 8 GMS: Number of Doctors in Eligible Person Cost Categories

2010 (2009 in brackets)

Number of Doo	ctors	with an	annu	al cost	per e	ligible	perso	n of:-												
Health Service Executive	Up to	o €300	€301	-€350	€351	-€400	€401	-€450	€451	-€500	€501	-€550	€551	-€600	€601	-€650	€651	-€700	€701	& Ove
Eastern Areas	151	(156)	5	(3)	5	(3)	8	(4)	11	(5)	13	(11)	23	(18)	27	(12)	20	(13)	494	(540)
Midland	12	(18)		_	ı	(-)	_	(1)	I	(-)	ı	(3)	2	(-)	3	(2)	2	(2)	105	(103)
Mid-Western	21	(21)	ı	(1)	ı	(-)	_	(1)	3	(1)	2	(1)	4	(1)	6	(5)	5	(4)	156	(168)
North Eastern	19	(17)	3	(-)	2	(1)	3	(4)	3	(1)	6	(4)	13	(-)	10	(5)	10	(13)	107	(128)
North Western	9	(9)	2	(-)		_	2	(2)	7	(2)	3	(6)	2	(3)	6	(2)	10	(6)	100	(115)
South Eastern	21	(27)	_	(2)	ı	(-)	2	(3)	5	(3)	5	(2)	2	(4)	6	(4)	15	(4)	192	(203)
Southern	45	(48)	3	(2)	3	(2)	3	(4)	6	(5)	11	(4)	7	(3)	8	(7)	7	(4)	332	(336)
Western	20	(28)	I	(1)	2	(1)	3	(3)	6	(5)	5	(2)	12	(4)	6	(6)	9	(5)	189	(206)
National	298	(324)	15	(9)	15	(7)	21	(22)	42	(22)	46	(33)	65	(33)	72	(43)	78	(51)	1,675	(1,799)

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.

⁽ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2010.

⁽iii) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 9 GMS: Number of Eligible Persons

Health Service Executive	Number of (including de and % of pop eligible	pendants) oulation*	Health Service Executive	Number of (including de and % of po eligibl	pendants) pulation*
	Decembe	r 2010		Decembe	er 2010
	No.	%		No.	%
HSE DUBLIN MID-LEINSTER			HSE WEST		
Dublin South	23,933	0.56	Galway	93,764	2.21
Dublin South East	18,311	0.43	Mayo	62,148	1.47
Dublin South City	29,929	0.71	Roscommon	28,390	0.67
Dublin South West	57,177	1.35	Donegal	85,764	2.02
Dublin West	49,908	1.18	Sligo/Leitrim	39,790	0.94
Kildare/West Wicklow	61,265	1.44	Clare	46,227	1.09
Wicklow	38,781	0.91	North Tipperary/East Limerick	28,738	0.68
Laois/Offaly	57,887	1.37	Limerick	69,160	1.63
Longford/Westmeath	47,192	1.11	TOTAL HSE WEST	453,981	10.71
TOTAL HSE DUBLIN MID-LEINSTER	384,383	9.06			
			HSE SOUTH		
HSE DUBLIN NORTH EAST			Cork South Lee	54,528	1.29
Dublin North West	62,599	1.48	Cork North Lee	71,300	1.68
North Central Dublin	39,483	0.93	West Cork	21,452	0.50
North Dublin	69,974	1.65	Kerry	54,125	1.28
Cavan/Monaghan	53,302	1.26	North Cork	34,917	0.82
Louth	53,718	1.27	Carlow/Kilkenny	53,688	1.27
Meath	56,375	1.33	Waterford	52,660	1.24
TOTAL HSE DUBLIN NORTH EAST	335,451	7.92	South Tipperary	38,325	0.90
			Wexford	60,999	1.44
			TOTAL HSE SOUTH	441,994	10.42
			NATIONAL	1,615,809	38.11

Note: *The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,239,848.

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups

								А	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	Und	der 5 Ye	ars	5-	II Y ear	^s	12	-15 Y ea	rs	16	-24 Y ea	ırs	25	-34 Y ea	ırs	3!	5-44 Y ea	ırs
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Dublin South	449	474	923	675	697	1,372	364	384	748	689	587	1,276	962	666	1,628	981	738	1,719
Dublin South East	331	364	695	532	570	1,102	256	298	554	485	443	928	666	512	1,178	741	621	1,362
Dublin South City	869	882	1,751	1,199	1,236	2,435	564	528	1,092	1,046	793	1,839	1,913	1,353	3,266	1,670	1,702	3,372
Dublin South West	2,213	2,321	4,534	3,300	3,554	6,854	1,590	1,801	3,391	3,117	2,423	5,540	3,837	2,665	6,502	3,283	2,514	5,797
Dublin West	2,288	2,415	4,703	3,292	3,453	6,745	1,536	1,566	3,102	2,830	2,235	5,065	3,908	2,435	6,343	3,226	2,628	5,854
Kildare/West Wicklow	2,480	2,602	5,082	3,688	4,003	7,691	1,759	1,744	3,503	2,897	2,458	5,355	4,252	2,989	7,241	4,135	3,490	7,625
Wicklow	1,309	1,438	2,747	1,965	2,081	4,046	1,040	1,064	2,104	1,967	1,782	3,749	2,521	1,879	4,400	2,506	1,978	4,484
Laois/Offaly	2,244	2,456	4,700	3,292	3,419	6,711	1,571	1,575	3,146	2,857	2,344	5,201	3,828	3,039	6,867	3,611	3,192	6,803
Longford/ Westmeath	1,784	1,896	3,680	2,606	2,776	5,382	1,261	1,365	2,626	2,283	2,010	4,293	3,021	2,375	5,396	2,906	2,605	5,511
North West Dublin	2,755	2,942	5,697	4,112	4,316	8,428	1,638	1,781	3,419	2,951	2,381	5,332	4,727	3,338	8,065	4,263	3,622	7,885
Dublin North Central	1,201	1,201	2,402	1,650	1,840	3,490	982	991	1,973	1,738	1,415	3,153	2,428	1,807	4,235	2,207	1,888	4,095
National	56,345	59,587	115,932	82,433	87,448	169,881	41,113	43,428	84,541	79,067	70,136	149,203	102,306	81,412	183,718	97,215	86,716	183,931
% of Eligible Persons	3.49%	3.69%	7.17%	5.10%	5.41%	10.51%	2.54%	2.69%	5.23%	4.89%	4.34%	9.23%	6.33%	5.04%	11.37%	6.02%	5.37%	11.38%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

								Α	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	45	-54 Y ea	rs	55	-64 Y ea	rs	65	-69 Y ea	rs	70	-74 Y ea	rs	75 Yea	ars and	Over		AII	
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Dublin South	921	806	1,727	1,069	776	1,845	768	380	1,148	1,918	1,349	3,267	5,223	3,057	8,280	14,019	9,914	23,933
Dublin South East	613	550	1,163	751	501	1,252	750	306	1,056	1,560	1,213	2,773	4,052	2,196	6,248	10,737	7,574	18,311
Dublin South City	1,342	1,439	2,781	1,388	1,379	2,767	874	632	1,506	1,593	1,332	2,925	3,967	2,228	6,195	16,425	13,504	29,929
Dublin South West	2,624	2,209	4,833	3,084	2,307	5,391	1,608	1,193	2,801	2,237	1,822	4,059	4,582	2,893	7,475	31,475	25,702	57,177
Dublin West	2,441	2,054	4,495	2,386	1,991	4,377	1,130	781	1,911	1,428	1,191	2,619	2,940	1,754	4,694	27,405	22,503	49,908
Kildare/West Wicklow	2,868	2,643	5,511	2,883	2,562	5,445	1,701	1,393	3,094	2,003	1,856	3,859	4,030	2,829	6,859	32,696	28,569	61,265
Wicklow	1,932	1,742	3,674	1,898	1,670	3,568	1,155	835	1,990	1,531	1,344	2,875	3,095	2,049	5,144	20,919	17,862	38,781
Laois/Offaly	2,682	2,622	5,304	2,770	2,463	5,233	1,627	1,228	2,855	1,910	1,755	3,665	4,153	3,249	7,402	30,545	27,342	57,887
Longford/ Westmeath	2,204	2,090	4,294	2,196	2,024	4,220	1,257	937	2,194	1,579	1,497	3,076	3,820	2,700	6,520	24,917	22,275	47,192
North West Dublin	2,682	2,588	5,270	2,492	2,092	4,584	1,473	939	2,412	2,144	1,607	3,751	4,839	2,917	7,756	34,076	28,523	62,599
Dublin North Central	1,780	1,637	3,417	1,599	1,591	3,190	1,105	721	1,826	2,080	1,633	3,713	5,128	2,861	7,989	21,898	17,585	39,483
National	76,674	73,368	150,042	78,694	71,595	150,289	46,390	36,076	82,466	60,453	54,430	114,883	137,648	93,275	230,923	858,338	757,471	1,615,809
% of Eligible Persons	4.75%	4.54%	9.29%	4.87%	4.43%	9.30%	2.87%	2.23%	5.10%	3.74%	3.37%	7.11%	8.52%	5.77%	14.29%	53.12%	46.88%	100.00%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

								A	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	Und	ler 5 Y e	ars	5-	II Yeaı	rs	12	-15 Y ea	rs	16	-24 Y ea	rs	25	-34 Y ea	ırs	3!	5-44 Y ea	ars
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
North Dublin	2,680	2,798	5,478	4,057	4,261	8,318	1,787	1,963	3,750	3,298	2,579	5,877	4,493	2,897	7,390	4,658	3,603	8,261
Cavan/ Monaghan	1,851	1,959	3,810	2,837	2,936	5,773	1,533	1,596	3,129	2,884	2,622	5,506	3,366	2,913	6,279	3,157	2,928	6,085
Louth	2,125	2,221	4,346	3,136	3,165	6,301	1,483	1,560	3,043	2,870	2,627	5,497	3,741	3,057	6,798	3,475	3,203	6,678
Meath	2,439	2,467	4,906	3,248	3,541	6,789	1,531	1,641	3,172	2,794	2,535	5,329	3,947	3,064	7,011	3,830	3,417	7,247
Galway	3,198	3,320	6,518	4,702	5,041	9,743	2,435	2,416	4,851	4,752	4,315	9,067	6,206	5,367	11,573	5,775	5,329	11,104
Mayo	1,783	1,941	3,724	2,914	3,028	5,942	1,515	1,737	3,252	3,233	2,951	6,184	3,272	2,904	6,176	3,438	3,106	6,544
Roscommon	803	887	1,690	1,365	1,390	2,755	719	764	1,483	1,402	1,219	2,621	1,521	1,276	2,797	1,581	1,461	3,042
Donegal	2,911	3,130	6,041	4,402	4,777	9,179	2,391	2,621	5,012	4,590	4,476	9,066	5,186	4,592	9,778	5,439	4,992	10,431
Sligo/Leitrim	1,245	1,303	2,548	1,751	1,886	3,637	897	1,086	1,983	1,819	1,742	3,561	2,200	2,010	4,210	2,147	1,975	4,122
Clare	1,584	1,638	3,222	2,375	2,363	4,738	1,171	1,255	2,426	2,443	2,320	4,763	2,759	2,381	5,140	2,789	2,444	5,233
North Tipperary/ East Limerick	938	947	1,885	1,427	1,519	2,946	759	783	1,542	1,452	1,308	2,760	1,733	1,498	3,231	1,693	1,518	3,211
National	56,345	59,587	115,932	82,433	87,448	169,881	41,113	43,428	84,541	79,067	70,136	149,203	102,306	81,412	183,718	97,215	86,716	183,931
% of Eligible Persons	3.49%	3.69%	7.18%	5.10%	5.41%	10.51%	2.54%	2.69%	5.23%	4.89%	4.34%	9.23%	6.33%	5.04%	11.37%	6.02%	5.37%	11.39%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

								A	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	45	-54 Y ea	rs	55	-64 Y ea	rs	65	-69 Y ea	rs	70	-74 Y ea	ırs	75 Yea	ırs and	Over		All	
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
North Dublin	3,119	2,536	5,655	3,041	2,199	5,240	2,357	1,427	3,784	3,399	2,865	6,264	5,910	4,047	9,957	38,799	31,175	69,974
Cavan/ Monaghan	2,531	2,451	4,982	2,418	2,352	4,770	1,335	1,137	2,472	1,619	1,510	3,129	4,242	3,125	7,367	27,773	25,529	53,302
Louth	2,448	2,476	4,924	2,321	2,125	4,446	1,265	995	2,260	1,714	1,519	3,233	3,789	2,403	6,192	28,367	25,351	53,718
Meath	2,474	2,434	4,908	2,413	2,100	4,513	1,484	1,147	2,631	1,701	1,647	3,348	3,811	2,710	6,521	29,672	26,703	56,375
Galway	4,576	4,618	9,194	4,237	4,262	8,499	2,415	2,052	4,467	3,096	2,899	5,995	7,407	5,346	12,753	48,799	44,965	93,764
Mayo	3,226	3,129	6,355	3,526	3,607	7,133	1,891	1,765	3,656	2,055	2,045	4,100	5,266	3,816	9,082	32,119	30,029	62,148
Roscommon	1,475	1,455	2,930	1,541	1,481	3,022	832	741	1,573	957	1,035	1,992	2,599	1,886	4,485	14,795	13,595	28,390
Donegal	4,300	4,177	8,477	4,581	4,326	8,907	2,275	2,228	4,503	2,433	2,361	4,794	5,426	4,150	9,576	43,934	41,830	85,764
Sligo/Leitrim	1,948	1,999	3,947	2,066	2,072	4,138	1,157	966	2,123	1,473	1,437	2,910	3,810	2,801	6,611	20,513	19,277	39,790
Clare	2,281	2,202	4,483	2,338	2,165	4,503	1,302	1,155	2,457	1,581	1,486	3,067	3,561	2,634	6,195	24,184	22,043	46,227
North Tipperary/ East Limerick	1,351	1,342	2,693	1,407	1,247	2,654	878	629	1,507	1,006	990	1,996	2,535	1,778	4,313	15,179	13,559	28,738
National	76,674	73,368	150,042	78,694	71,595	150,289	46,390	36,076	82,466	60,453	54,430	114,883	137,648	93,275	230,923	858,338	757,471	1,615,809
% of Eligible Persons	4.75%	4.54%	9.29%	4.87%	4.43%	9.30%	2.87%	2.23%	5.10%	3.74%	3.37%	7.11%	8.52%	5.77%	14.29%	53.12%	46.88%	100.00%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

		-			•			A	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	Und	ler 5 Ye	ars	5-	II Year	rs	12	-15 Y ea	rs	16	-24 Y ea	rs	25	-34 Y ea	ırs	3!	5-44 Y ea	ars
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Limerick	2,258	2,508	4,766	3,089	3,246	6,335	1,624	1,707	3,331	3,333	3,042	6,375	4,287	3,742	8,029	3,893	3,824	7,717
Cork – South Lee	1,758	1,794	3,552	2,290	2,565	4,855	1,191	1,163	2,354	2,159	2,089	4,248	3,454	2,770	6,224	2,982	2,773	5,755
Cork – North Lee	2,633	2,807	5,440	3,640	3,880	7,520	1,758	1,921	3,679	3,443	3,095	6,538	4,926	3,988	8,914	4,474	4,157	8,631
West Cork	554	572	1,126	894	986	1,880	525	506	1,031	954	927	1,881	963	777	1,740	1,077	919	1,996
Kerry	1,572	1,663	3,235	2,353	2,484	4,837	1,234	1,258	2,492	2,344	2,220	4,564	3,018	2,666	5,684	3,004	2,867	5,871
North Cork	1,216	1,321	2,537	1,597	1,764	3,361	852	821	1,673	1,583	1,478	3,061	2,290	1,680	3,970	2,081	1,929	4,010
Carlow/ Kilkenny	1,793	1,904	3,697	2,735	2,789	5,524	1,339	1,449	2,788	2,919	2,605	5,524	3,424	3,091	6,515	3,264	3,080	6,344
Waterford	1,814	1,899	3,713	2,499	2,752	5,251	1,231	1,383	2,614	2,717	2,364	5,081	3,388	2,769	6,157	3,122	2,872	5,994
South Tipperary	1,122	1,296	2,418	1,701	1,874	3,575	948	967	1,915	1,992	1,895	3,887	2,249	1,878	4,127	2,096	1,924	4,020
Wexford	2,145	2,221	4,366	3,110	3,256	6,366	1,629	1,734	3,363	3,226	2,856	6,082	3,820	3,034	6,854	3,711	3,417	7,128
National	56,345	59,587	115,932	82,433	87,448	169,881	41,113	43,428	84,541	79,067	70,136	149,203	102,306	81,412	183,718	97,215	86,716	183,931
% of Eligible Persons	3.49%	3.69%	7.18%	5.10%	5.41%	10.51%	2.54%	2.69%	5.23%	4.89%	4.34%	9.23%	6.33%	5.04%	11.37%	6.02%	5.37%	11.39%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

								A	ge Cla	ssificati	on							
Health	As at	Decem	ber 20	10														
Service Executive	45	-54 Y ea	rs	55	-64 Y ea	rs	65	-69 Y ea	rs	70	-74 Y ea	ırs	75 Yea	ars and	Over		AII	
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Limerick	3,308	3,286	6,594	3,609	3,433	7,042	2,193	1,709	3,902	2,707	2,524	5,231	5,880	3,958	9,838	36,181	32,979	69,160
Cork – South Lee	2,581	2,448	5,029	2,544	2,242	4,786	1,813	1,281	3,094	2,655	2,243	4,898	6,029	3,704	9,733	29,456	25,072	54,528
Cork – North Lee	3,477	3,364	6,841	3,684	3,356	7,040	2,181	1,677	3,858	2,563	2,288	4,851	4,800	3,188	7,988	37,579	33,721	71,300
West Cork	1,133	1,053	2,186	1,158	1,102	2,260	762	569	1,331	923	897	1,820	2,405	1,796	4,201	11,348	10,104	21,452
Kerry	2,564	2,551	5,115	2,933	2,781	5,714	1,792	1,510	3,302	2,153	2,117	4,270	5,331	3,710	9,041	28,298	25,827	54,125
North Cork	1,631	1,565	3,196	1,883	1,696	3,579	988	786	1,774	1,231	1,142	2,373	3,260	2,123	5,383	18,612	16,305	34,917
Carlow/ Kilkenny	2,636	2,672	5,308	2,536	2,389	4,925	1,466	1,168	2,634	1,758	1,666	3,424	4,063	2,942	7,005	27,933	25,755	53,688
Waterford	2,546	2,513	5,059	2,733	2,588	5,321	1,613	1,272	2,885	1,872	1,734	3,606	4,089	2,890	6,979	27,624	25,036	52,660
South Tipperary	1,904	1,863	3,767	2,133	1,988	4,121	1,090	975	2,065	1,415	1,314	2,729	3,312	2,389	5,701	19,962	18,363	38,325
Wexford	3,076	2,854	5,930	3,076	2,728	5,804	1,853	1,542	3,395	2,159	2,112	4,271	4,294	3,146	7,440	32,099	28,900	60,999
		·			·													
National	76,674	73,368	150,042	78,694	71,595	150,289	46,390	36,076	82,466	60,453	54,430	114,883	137,648	93,275	230,923	858,338	757,471	1,615,809
% of Eligible Persons	4.75%	4.54%	9.29%	4.87%	4.43%	9.30%	2.87%	2.23%	5.10%	3.74%	3.37%	7.11%	8.52%	5.77%	14.29%	53.12%	46.88%	100.00%

Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation

							Mileage	Classif	ication						
Health Service	As at [Decemb	er 2010)											
Executive	Up	to 3 M	iles	3	3-5 Mile	s	5	-7 Mile	s	7	-10 Mile	es	Ove	er IO M	iles
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Dublin South	55.17	39.04	94.21	2.65	1.76	4.41	0.61	0.49	1.10	0.08	0.07	0.15	0.07	0.06	0.13
Dublin South East	52.98	37.07	90.05	4.16	3.00	7.16	1.10	0.94	2.04	0.27	0.26	0.53	0.14	0.08	0.22
Dublin South City	53.07	43.57	96.64	0.94	0.82	1.76	0.75	0.62	1.37	0.09	0.07	0.16	0.04	0.05	0.09
Dublin South West	50.80	41.30	92.10	3.49	2.96	6.45	0.58	0.53	1.11	0.14	0.12	0.26	0.04	0.04	0.08
Dublin West	52.35	42.92	95.27	1.67	1.38	3.05	0.63	0.54	1.17	0.16	0.16	0.32	0.10	0.08	0.18
Kildare/West Wicklow	36.80	32.03	68.83	7.26	6.48	13.74	4.71	3.98	8.69	2.45	2.21	4.66	2.15	1.94	4.09
Wicklow	38.12	32.24	70.36	5.64	4.79	10.43	6.53	5.70	12.23	1.87	1.74	3.61	1.79	1.59	3.38
Laois/Offaly	32.91	29.33	62.24	5.86	5.48	11.34	10.52	9.13	19.65	3.38	3.22	6.60	0.10	0.08	0.18
Longford/Westmeath	33.59	29.92	63.51	5.44	4.98	10.42	10.22	8.93	19.15	3.43	3.26	6.69	0.13	0.12	0.25
North West Dublin	49.70	41.33	91.03	3.10	2.68	5.78	1.03	0.93	1.96	0.40	0.41	0.81	0.21	0.22	0.43
Dublin North Central	53.41	42.53	95.94	1.35	1.36	2.71	0.47	0.42	0.89	0.16	0.15	0.31	0.07	0.07	0.14
National	36.74	31.88	68.62	5.73	5.20	10.93	8.42	7.73	16.15	1.59	1.46	3.05	0.65	0.60	1.25

Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation continued

							Mileage	Classi	fication						
Health Service	As at [Decemb	er 2010)											
Executive	Up	to 3 Mi	iles	3	8-5 Mile	s	5	- 7 M ile	s	7.	-10 Mile	es	Ove	er IO M	iles
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
North Dublin	50.84	40.80	91.64	2.21	1.69	3.90	1.31	1.04	2.35	0.63	0.61	1.24	0.47	0.41	0.88
Cavan/Monaghan	28.67	26.29	54.96	8.66	8.04	16.70	13.64	12.61	26.25	1.00	0.81	1.81	0.14	0.14	0.28
Louth	39.35	35.40	74.75	5.31	4.69	10.00	7.96	6.96	14.92	0.13	0.12	0.25	0.05	0.03	0.08
Meath	33.23	29.63	62.86	6.74	6.15	12.89	11.23	10.32	21.55	1.16	1.00	2.16	0.27	0.27	0.54
Galway	30.05	26.85	56.90	6.96	6.53	13.49	11.22	10.93	22.15	2.75	2.59	5.34	1.07	1.05	2.12
Mayo	29.03	26.27	55.30	6.95	6.70	13.65	9.25	9.01	18.26	4.34	4.20	8.54	2.10	2.14	4.24
Roscommon	19.92	17.84	37.76	9.42	9.12	18.54	18.93	17.47	36.40	3.32	3.08	6.40	0.53	0.38	0.91
Donegal	24.80	23.29	48.09	8.56	8.39	16.95	12.32	11.99	24.31	4.09	3.75	7.84	1.46	1.35	2.81
Sligo/Leitrim	27.48	25.83	53.31	9.26	8.62	17.88	13.56	12.76	26.32	0.92	0.90	1.82	0.32	0.34	0.66
Clare	31.42	28.27	59.69	7.42	6.86	14.28	11.87	11.10	22.97	1.19	1.06	2.25	0.42	0.39	0.81
North Tipperary/ East Limerick	30.81	26.95	57.76	5.40	4.98	10.38	14.13	13.03	27.16	2.04	1.77	3.81	0.43	0.45	0.88
National	36.74	31.88	68.62	5.73	5.20	10.93	8.42	7.73	16.15	1.59	1.46	3.05	0.65	0.60	1.25

Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation continued

							Mileage	Classi	fication						
Health Service	As at I	Decemb	er 2010)											
Executive	Up	to 3 M	iles	3	8-5 Mile	s	5	-7 M ile	S	7	-10 Mile	es	Ove	er IO M	iles
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Limerick	37.85	34.83	72.68	6.07	5.28	11.35	8.01	7.23	15.24	0.28	0.25	0.53	0.10	0.10	0.20
Cork-South Lee	38.95	33.15	72.10	6.39	5.41	11.80	8.24	7.06	15.30	0.35	0.29	0.64	0.09	0.06	0.15
Cork-North Lee	39.57	35.84	75.41	5.23	4.28	9.51	7.13	6.46	13.59	0.50	0.47	0.97	0.28	0.24	0.52
West Cork	23.24	19.82	43.06	7.24	6.83	14.07	13.84	12.12	25.96	5.73	5.37	11.10	2.85	2.96	5.81
Kerry	30.44	27.46	57.90	6.21	5.80	12.01	8.78	7.98	16.76	3.78	3.69	7.47	3.08	2.79	5.87
North Cork	29.43	25.46	54.89	7.70	6.85	14.55	14.83	13.25	28.08	0.83	0.69	1.52	0.52	0.45	0.97
Carlow/Kilkenny	34.47	31.61	66.08	6.08	5.79	11.87	11.11	10.26	21.37	0.31	0.27	0.58	0.06	0.04	0.10
Waterford	39.30	35.36	74.66	4.57	4.18	8.75	6.59	6.43	13.02	1.66	1.31	2.97	0.34	0.26	0.60
South Tipperary	29.30	26.55	55.85	6.55	5.91	12.46	15.21	14.67	29.88	0.87	0.65	1.52	0.15	0.13	0.28
Wexford	31.62	28.82	60.44	5.75	5.09	10.84	13.74	12.25	25.99	1.14	0.89	2.03	0.38	0.33	0.71
National	36.74	31.88	68.62	5.73	5.20	10.93	8.42	7.73	16.15	1.59	1.46	3.05	0.65	0.60	1.25

Table 9.3 GPVC: Number of Eligible Persons

Health Service	Number of person dependants) a population* el	ınd % of	Health Service	Number of person dependants) a population* eli	nd % of
Executive	December	2010	Executive	December	2010
	No.	%		No.	%
HSE DUBLIN MID-LEINSTER			HSE WEST		
Dublin South	1,052	0.02	Galway	7,663	0.19
Dublin South East	938	0.02	Mayo	3,817	0.09
Dublin South City	899	0.02	Roscommon	1,793	0.04
Dublin South West	2,613	0.06	Donegal	6,849	0.16
Dublin West	3,790	0.09	Sligo/Leitrim	3,381	0.08
Kildare/West Wicklow	3,729	0.09	Clare	2,713	0.06
Wicklow	2,178	0.05	North Tipperary/East Limerick	2,003	0.05
Laois/Offaly	4,524	0.11	Limerick	4,682	0.11
Longford/Westmeath	3,707	0.09	TOTAL HSE WEST	32,901	0.78
TOTAL HSE DUBLIN MID-LEINSTER	23,430	0.55			
			HSE SOUTH		
HSE DUBLIN NORTH EAST			Cork South Lee	5,684	0.13
Dublin North West	3,983	0.09	Cork North Lee	6,721	0.16
North Central Dublin	1,750	0.04	West Cork	2,285	0.05
North Dublin	3,474	0.08	Kerry	4,971	0.12
Cavan/Monaghan	4,240	0.10	North Cork	3,867	0.09
Louth	3,705	0.09	Carlow/Kilkenny	4,653	0.11
Meath	4,840	0.12	Waterford	3,308	0.08
TOTAL HSE DUBLIN NORTH EAST	21,992	0.52	South Tipperary	2,426	0.06
			Wexford	5,185	0.12
			TOTAL HSE SOUTH	39,100	0.92
			NATIONAL	117,423	2.77

Note: *The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,239,848.

Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups

								A	ge Cla	ssificat	ion							
Health	As at	Decen	nber 20	010														
Service Executive	Und	ler 5 Ye	ears	5-	I I Y eaı	rs	12	- I 5 Y ea	rs	16-	24 Y ea	ırs	25-	34 Y ea	ırs	35	5-44 yeaı	rs
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	1,250	1,300	2,550	1,859	1,887	3,746	925	932	1,857	1,267	771	2,038	2,188	1,206	3,394	2,448	1,935	4,383
Midland	492	483	975	683	640	1,323	319	377	696	388	274	662	809	549	1,358	747	671	1,418
Mid-Western	508	482	990	647	721	1,368	327	388	715	541	352	893	928	612	1,540	896	795	1,691
North Eastern	680	759	1,439	971	1,042	2,013	402	451	853	655	442	1,097	1,212	815	2,027	1,277	1,151	2,428
North Western	449	481	930	696	782	1,478	432	403	835	641	436	1,077	920	580	1,500	876	789	1,665
South Eastern	799	829	1,628	1,054	1,131	2,185	548	585	1,133	961	625	1,586	1,624	1,014	2,638	1,481	1,307	2,788
Southern	1,233	1,236	2,469	1,606	1,701	3,307	871	859	1,730	1,334	912	2,246	2,313	1,497	3,810	2,159	1,996	4,155
Western	691	753	1,444	890	919	1,809	428	422	850	675	497	1,172	1,331	847	2,178	1,240	1,198	2,438
													J	ı		1		
National	6,102	6,323	12,425	8,406	8,823	17,229	4,252	4,417	8,669	6,462	4,309	10,771	11,325	7,120	18,445	11,124	9,842	20,966
% of Eligible Persons	5.20%	5.38%	10.58%	7.16%	7.51%	14.67%	3.62%	3.76%	7.38%	5.50%	3.67%	9.17%	9.64%	6.06%	15.71%	9.47%	8.38%	17.86%

Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups continued

								Δ	ge Cla	ssificat	ion							
Health	As at	Decen	nber 20	010														
Service Executive	45	-54 Y ea	ırs	55-	- 64 Y ea	ırs	65	- 69 Y ea	ırs	70-	74 Y ea	ars	75 Y ea	rs and	lover		All	
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	1,694	1,274	2,968	1,293	1,034	2,327	524	572	1,096	18	25	43	5	3	8	13,471	10,939	24,410
Midland	511	483	994	300	280	580	88	126	214	6	4	10	_	1	1	4,343	3,888	8,231
Mid-Western	597	541	1,138	418	360	778	117	139	256	9	12	21	2	_	2	4,990	4,402	9,392
North Eastern	775	709	1,484	533	501	1,034	169	218	387	10	11	21	I	_	I	6,685	6,099	12,784
North Western	717	697	1,414	465	509	974	137	197	334	6	13	19	_	I	I	5,339	4,888	10,227
South Eastern	1,075	875	1,950	674	624	1,298	155	207	362	8	2	10	_	_	_	8,379	7,199	15,578
Southern	1,593	1,343	2,936	1,124	963	2,087	322	418	740	19	28	47	I	_	I	12,575	10,953	23,528
Western	937	837	1,774	599	578	1,177	167	225	392	14	22	36	2	1	3	6,974	6,299	13,273
National	7,899	6,759	14,658	5,406	4,849	10,255	1,679	2,102	3,781	90	117	207	11	6	17	62,756	54,667	117,423
% of Eligible Persons	6.73%	5.75%	12.48%	4.60%	4.13%	8.73%	1.43%	1.79%	3.22%	0.08%	0.10%	0.18%	0.01%	0.01%	0.02%	53.44%	4.55%	100.00%

Table 10 GMS: Size of Panels of Doctors

As at December 2010 (2009 in brackets)

Health Service	Numbe	er of Docto	ors with	panels of:-								
Executive	Up t	to 250	25	-500	501-	1,000	1,001	-1,500	1,501	-2,000	2,001	-2,500
East Coast Area	66	(55)	49	(51)	64	(59)	14	(11)		_		_
South Western Area	41	(40)	29	(37)	96	(100)	56	(46)	26	(21)	4	(3)
Northern Area	41	(34)	38	(43)	66	(69)	45	(45)	24	(11)	5	(3)
Midland	16	(9)	12	(14)	42	(45)	35	(35)	18	(12)	I	(-)
Mid-Western	26	(23)	33	(36)	73	(83)	44	(32)	14	(12)	2	(1)
North Eastern	19	(10)	9	(16)	60	(71)	59	(51)	22	(11)	5	(3)
North Western	12	(10)	20	(23)	51	(50)	41	(39)	14	(15)	6	(3)
South Eastern	16	(14)	24	(24)	110	(120)	60	(56)	22	(19)	7	(1)
Southern	85	(84)	67	(61)	153	(155)	69	(63)	14	(10)	4	(3)
Western	34	(30)	41	(45)	101	(108)	56	(51)	19	(9)	2	(1)
National	356	(309)	322	(350)	816	(860)	479	(429)	173	(120)	36	(18)

Table II GMS: Payments to Doctors in each Health Service Executive Area

Health Service Executive	2010 €	2009 €
East Coast Area	26,935,195	28,086,765
South Western Area	49,992,878	50,599,550
Northern Area	44,386,873	45,733,538
Midland	30,297,742	30,794,005
Mid-Western	40,117,150	40,618,410
North Eastern	43,660,859	43,156,720
North Western	35,382,535	36,550,156
South Eastern	59,845,673	59,744,270
Southern	75,013,546	76,157,054
Western	54,705,133	55,296,686
National	€460,337,584	€466,737,154

Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims

Health Service		emporary t Claims	No. o Visitor	f EEA Claims		nergency ims	Second Opinion			Out-of- Claims		l No. Iaims
Executive	2010	2009	2010	2009	2010	2009	2010	2009	2010	2009	2010	2009
East Coast Area	8,252	6,254	2,373	2,573	3,829	2,797	9	6	27,928	32,706	42,391	44,336
South Western Area	20,570	16,546	4,773	5,174	16,880	12,937	9	14	62,973	81,815	105,205	116,486
Northern Area	15,142	11,307	2,025	2,394	12,536	14,092	5	_	33,934	45,482	63,642	73,275
Midland	17,734	17,254	2,295	2,533	3,369	2,388	48	9	55,364	68,574	78,810	90,758
Mid-Western	13,763	14,843	5,393	5,340	7,286	4,540	924	644	62,143	69,117	89,509	94,484
North Eastern*	11,878	11,966	2,358	2,428	3,283	1,904	25	19	8,350	10,169	25,894	26,486
North Western	7,035	5,463	6,694	7,238	2,418	2,084	45	70	52,084	68,358	68,276	83,213
South Eastern	17,768	15,013	4,778	4,676	3,643	2,830	28	34	126,113	135,943	152,330	158,496
Southern	42,401	34,170	12,031	12,277	6,901	5,165	1,244	1,012	183,650	215,184	246,227	267,808
Western	21,992	17,798	7,815	8,381	8,720	7,560	82	151	91,084	109,795	129,693	143,685
National	176,535	150,614	50,535	53,014	68,865	56,297	2,419	1,959	703,623	837,143	1,001,977	1,099,027

^{*} Note: HSE North Eastern Area figures do not include statistics from North East Doc.

Table 12.1 GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims

Health Service	Cost of Te Resident		Cost o Visitor		Cost of E	mergency ims		Second Opinion ims		Out-of- Claims		Cost aims
Executive	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €
East Coast Area	393,454	312,097	110,436	124,816	175,878	134,897	280	192	1,305,512	1,610,238	1,985,560	2,182,240
South Western Area	1,018,899	865,291	221,942	253,212	910,918	684,341	280	457	2,986,192	4,104,053	5,138,231	5,907,354
Northern Area	708,572	553,250	94,098	116,882	556,296	677,326	150	_	1,554,897	2,223,675	2,914,013	3,571,133
Midland	833,628	849,597	106,876	123,449	154,761	115,819	1,475	291	2,674,514	3,502,092	3,771,254	4,591,248
Mid-Western	644,732	743,035	250,412	259,478	343,566	226,722	28,613	20,883	3,012,519	3,531,354	4,279,842	4,781,472
North Eastern*	566,330	594,459	109,507	118,280	156,031	94,913	777	610	398,112	515,104	1,230,757	1,323,366
North Western	329,983	271,337	311,815	353,272	110,174	102,791	1,397	2,319	2,533,537	3,497,795	3,286,906	4,227,514
South Eastern	829,023	737,735	222,162	227,003	167,517	137,081	863	1,138	5,871,783	6,695,156	7,091,348	7,798,113
Southern	2,100,515	1,793,957	561,869	599,846	344,464	278,383	38,442	32,851	8,739,734	10,821,508	11,785,024	13,526,545
Western	1,055,012	902,781	364,074	408,267	400,770	367,017	2,547	4,989	4,409,494	5,585,294	6,231,897	7,268,348
National	8,480,148	7,623,539	2,353,191	2,584,505	3,320,375	2,819,290	74,824	63,730	33,486,294	42,086,269	47,714,832	55,177,333

^{*} Note HSE North Eastern Area figures do not include statistics from North East Doc.

Table 13 GMS: Analysis of Special Items of Service

Туре	of Service		Number	of Claims	Cost o	f Claims
			2010	2009	2010 €	2009 €
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	123,808	103,183	3,590,371	3,336,932
(ii)	Suturing:	Cuts and Lacerations	40,288	36,416	1,168,474	1,178,427
(iii)	Hydroceles:	Draining of	1,274	1,378	36,912	43,880
(iv)	Haemorrhages:	Dental/Nasal	2,191	2,427	63,422	78,640
(v)	Veins:	Recognised treatment	4,800	4,499	138,239	145,061
(vi)	ECG:	Tests and interpretation	92,123	76,757	2,669,677	2,480,452
(vii)	Diaphragm:	Instruction in the fitting of	1,129	1,186	32,732	38,754
(viii)	Eye:	Removal of adherent foreign body	10,014	9,580	290,295	310,301
(ix)	Ear/Nose/Throat:	Removal of foreign body	33,303	28,774	964,735	929,154
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	57,691	50,945	2,493,436	2,334,488
(xi)	Bladder:	Catheterization	7,410	6,877	322,164	316,521
(xii)	Case Conference:	Convened by HSE	445	834	29,707	59,826
(xiii)	Diaphragm:	Advice and fitting of	1,030	743	50,166	37,765
(xiv)	IUCD:	Counselling and fitting of	12,327	10,006	962,735	790,666
(xv)	Pneumococcal:	Vaccination	14,332	14,588	612,650	625,251
(xvi)	Influenza:	Vaccination	371,659	349,890	15,887,673	14,961,300
(xvii)	Pneumococcal/Influenza:	Vaccination	14,123	13,482	905,535	863,658
(xviii)	Hepatitis B:	Vaccination	2,961	2,093	151,584	122,777
Natio	nal		790,908	713,658	€30,370,507	€28,653,853

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area

Туре	of Service		East Co	ast Area	South Western Area		
			Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €	
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	8,063	233,787	12,039	349,321	
(ii)	Suturing:	Cuts and Lacerations	1,367	39,623	2,854	82,854	
(iii)	Hydroceles:	Draining of	41	1,192	68	1,976	
(iv)	Haemorrhages:	Dental/Nasal	58	1,685	108	3,124	
(v)	Veins:	Recognised treatment	7	202	528	15,325	
(vi)	ECG:	Tests and interpretation	4,437	128,548	6,389	185,313	
(vii)	Diaphragm:	Instruction in the fitting of	18	522	242	7,008	
(viii)	Eye:	Removal of Adherent foreign body	242	7,012	958	27,849	
(ix)	Ear/Nose/Throat:	Removal of foreign body	1,811	52,451	3,274	94,913	
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	1,407	61,045	4,364	189,378	
(xi)	Bladder:	Catheterization	229	9,962	250	10,859	
(xii)	Case Conference:	Convened by HSE	42	3,040	10	735	
(xiii)	Diaphragm:	Advice and fitting of	47	2,294	115	5,617	
(xiv)	IUCD:	Counselling and fitting of	759	59,285	1,548	120,925	
(xv)	Pneumococcal:	Vaccination	858	36,680	1,514	64,705	
(xvi)	Influenza:	Vaccination	26,350	1,126,452	40,747	1,741,609	
(xvii)	Pneumococcal/Influenza:	Vaccination	1,060	67,967	1,633	104,692	
(xviii)	Hepatitis B:	Vaccination	105	5,395	286	14,438	
Total			46,901	€1,837,142	76,927	€3,020,641	

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Туре	of Service		Northe	rn Area	Mid	land
			Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	9,304	270,011	7,642	221,665
(ii)	Suturing:	Cuts and Lacerations	2,545	73,898	3,898	113,078
(iii)	Hydroceles:	Draining of	12	350	67	1,945
(iv)	Haemorrhages:	Dental/Nasal	125	3,629	818	23,678
(v)	Veins:	Recognised treatment	12	350	905	26,181
(vi)	ECG:	Tests and interpretation	5,499	159,525	7,217	209,356
(vii)	Diaphragm:	Instruction in the fitting of	42	1,214	55	1,600
(viii)	Eye:	Removal of Adherent foreign body	534	15,519	898	26,052
(ix)	Ear/Nose/Throat:	Removal of foreign body	3,382	98,107	2,761	80,025
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	2,309	100,110	4,558	198,169
(xi)	Bladder:	Catheterization	144	6,273	618	26,910
(xii)	Case Conference:	Convened by HSE	15	1,087	24	1,749
(xiii)	Diaphragm:	Advice and fitting of	83	4,059	132	6,424
(xiv)	IUCD:	Counselling and fitting of	1,314	102,520	840	65,700
(xv)	Pneumococcal:	Vaccination	1,873	80,071	994	42,493
(xvi)	Influenza:	Vaccination	40,488	1,730,848	21,307	910,874
(xvii)	Pneumococcal/Influenza:	Vaccination	1,374	88,101	602	38,600
(xviii)	Hepatitis B:	Vaccination	404	20,754	81	4,162
Total			69,459	€2,756,426	53,417	€1,998,661

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Туре	of Service		Mid-W	estern/	North	Eastern
			Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	7,693	222,980	11,033	319,817
(ii)	Suturing:	Cuts and Lacerations	3,279	95,032	3,631	105,306
(iii)	Hydroceles:	Draining of	93	2,684	92	2,667
(iv)	Haemorrhages:	Dental/Nasal	111	3,211	64	1,851
(v)	Veins:	Recognised treatment	388	10,512	1,305	37,813
(vi)	ECG:	Tests and interpretation	6,588	190,764	6,194	179,596
(vii)	Diaphragm:	Instruction in the fitting of	74	2,150	51	1,482
(viii)	Eye:	Removal of Adherent foreign body	547	15,860	433	12,566
(ix)	Ear/Nose/Throat:	Removal of foreign body	2,736	78,549	2,760	80,071
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	3,975	172,098	5,438	236,176
(xi)	Bladder:	Catheterization	599	26,012	495	21,517
(xii)	Case Conference:	Convened by HSE	76	5,578	11	796
(xiii)	Diaphragm:	Advice and fitting of	134	6,466	161	7,885
(xiv)	IUCD:	Counselling and fitting of	799	62,299	1,089	85,137
(xv)	Pneumococcal:	Vaccination	1,038	44,375	1,013	43,306
(xvi)	Influenza:	Vaccination	35,483	1,516,886	30,440	1,301,310
(xvii)	Pneumococcal/Influenza:	Vaccination	1,186	76,046	1,107	70,981
(xviii)	Hepatitis B:	Vaccination	185	9,502	410	20,967
Total			64,984	€2,541,004	65,727	€2,529,244

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Туре	of Service		North \	V estern	South	Eastern
			Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	10,486	304,181	15,330	444,738
(ii)	Suturing:	Cuts and Lacerations	3,812	110,515	6,012	174,415
(iii)	Hydroceles:	Draining of	130	3,772	170	4,923
(iv)	Haemorrhages:	Dental/Nasal	121	3,503	120	3,474
(v)	Veins:	Recognised treatment	18	522	256	7,446
(vi)	ECG:	Tests and interpretation	11,773	340,852	14,873	431,084
(vii)	Diaphragm:	Instruction in the fitting of	277	8,011	74	2,147
(viii)	Eye:	Removal of Adherent foreign body	924	26,818	985	28,535
(ix)	Ear/Nose/Throat:	Removal of foreign body	2,404	69,688	3,397	98,476
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	5,964	258,417	7,354	318,938
(xi)	Bladder:	Catheterization	1,271	55,280	1,174	51,092
(xii)	Case Conference:	Convened by HSE	28	2,017	108	5,667
(xiii)	Diaphragm:	Advice and fitting of	58	2,837	77	3,761
(xiv)	IUCD:	Counselling and fitting of	902	70,440	2,004	156,658
(xv)	Pneumococcal:	Vaccination	1,023	43,733	1,969	84,153
(xvi)	Influenza:	Vaccination	26,294	1,124,066	48,616	2,078,154
(xvii)	Pneumococcal/Influenza:	Vaccination	943	60,465	1,968	126,188
(xviii)	Hepatitis B:	Vaccination	170	8,649	248	12,742
Total			66,598	€2,493,766	104,735	€4,032,591

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Туре	of Service		Sout	hern	Wes	tern
			Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy:	Skin Lesions	22,883	662,296	19,335	561,574
(ii)	Suturing:	Cuts and Lacerations	7,086	205,329	5,804	168,426
(iii)	Hydroceles:	Draining of	246	7,115	355	10,287
(iv)	Haemorrhages:	Dental/Nasal	293	8,454	373	10,813
(v)	Veins:	Recognised treatment	801	23,106	580	16,782
(vi)	ECG:	Tests and interpretation	14,116	408,604	15,037	436,035
(vii)	Diaphragm:	Instruction in the fitting of	110	3,196	186	5,402
(viii)	Eye:	Removal of Adherent foreign body	2,976	86,015	1,517	44,068
(ix)	Ear/Nose/Throat:	Removal of foreign body	6,033	174,817	4,745	137,638
(x)	Nebuliser:	Treatment in the case of acute asthmatic attack	10,089	427,877	12,233	531,228
(xi)	Bladder:	Catheterization	1,361	59,119	1,269	55,141
(xii)	Case Conference:	Convened by HSE	99	6,706	32	2,332
(xiii)	Diaphragm:	Advice and fitting of	125	6,043	98	4,779
(xiv)	IUCD:	Counselling and fitting of	2,113	164,895	959	74,875
(xv)	Pneumococcal:	Vaccination	2,107	90,074	1,943	83,061
(xvi)	Influenza:	Vaccination	60,884	2,602,765	41,050	1,754,710
(xvii)	Pneumococcal/Influenza:	Vaccination	2,852	182,870	1,398	89,624
(xviii)	Hepatitis B:	Vaccination	581	29,852	491	25,124
Total			134,755	€5,149,133	107,405	€4,011,899

Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service

NATIONAL

2010 (2009 in brackets)

Doctors with	Visiting Rate	Visiting Rate:-*												
panels of:-	4-4.9	5-5.9	6-6.9	7-7.9	8-8.9	9-9.9	10-10.9	11-11.9	I2 and Over					
100-249	_	-	_	-	-	-	-	-	-					
250-499	- (1)	_	I (I)	_	-	_	_	_	_					
500-999	_	I (2)	l –	_	_	_	_	_	_					
1,000-1,499	_	_	_	1 (1)	_	_	_	_	_					
Over 1,500	_	_	_	I (-)	-	- (1)	- (I)	_	I (–)					
TOTAL	- (1)	I (2)	2 (1)	2 (1)	-	- (1)	- (I)	_	I (-)					

Note: (i) The overall visiting rate in 2010 of the Doctors who continued on a Fee-Per-Item of service contract was 8.31 (Surgery: 8.20 Domiciliary: 0.11), (2009 – Total: 8.26 Surgery: 8.13 Domiciliary: 0.13).

⁽ii) Only Doctors with panels of 100 persons or over are included in the above table.

⁽iii) *Visiting Rate is the total number of consultations divided by the total number of persons on panel.

Table 15 GMS: Cost of Medicines by Gender within Age Groups

								A	ge Cla	ssification	on							
Health Service	Under 5 Years		5-	5-11 Years		12	- I 5 Y ea	ırs	I 6-24 Years		25-34 Years		rs	35-44 Years				
Executive	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €
Eastern Areas	93.50	110.61	102.27	68.56	78.47	73.67	87.10	92.01	89.62	226.71	176.54	204.21	328.61	305.92	319.34	491.84	445.65	470.98
Midland	115.91	114.29	115.07	83.70	91.74	87.82	98.33	95.92	97.10	257.01	196.83	229.41	359.91	331.12	347.20	561.04	478.48	522.17
Mid-Western	131.33	136.35	133.92	102.39	117.43	110.04	99.30	155.02	127.89	277.30	208.40	244.24	390.73	361.49	377.14	552.32	494.70	524.56
North Eastern	83.25	104.39	94.01	69.82	77.56	73.78	78.19	82.88	80.60	212.90	152.61	18 4 .17	279.90	242.61	263.13	388.06	356.12	372.82
North Western	82.25	91.42	86.98	56.49	80.93	69.20	66.34	80.21	73.69	187.33	148.04	167.99	282.81	235.21	260.34	390.64	362.50	377.17
South Eastern	93.90	113.36	103.94	73.72	96.93	85.68	90.23	117.64	104.43	252.17	195.98	225.62	343.23	333.08	338.60	503.29	459.96	482.46
Southern	127.50	153.47	140.83	97.17	111.59	104.67	118.34	129.04	123.74	286.82	225.66	257.26	387.46	371.18	380.17	556.23	523.62	540.53
Western	106.78	116.53	111.80	75.89	94.13	85.25	82.03	95.42	88.90	237.76	187.46	213.88	348.82	306.06	328.95	461.50	443.03	452.67
National	€102.39	€117.77	€110.30	€76.88	€91.04	€84.17	€90.32	€104.18	€97.44	€241.40	€186.53	€215.61	€339.91	€313.17	€328.06	€489.71	€448.65	€470.35
% of National Average	13.42%	15.43%	14.45%	10.07%	11.93%	11.03%	11.83%	13.65%	12.77%	31.63%	24.44%	28.25%	44.53%	41.03%	42.98%	64.16%	58.78%	61.62%

Table 15 GMS: Cost of Medicines by Gender within Age Groups continued

		Age Classification																
Health Service	45-54 Years		55	55-64 Years 65-69 Ye			- 69 Y ea	ars 70-74 Years			75 Years & Over			Total				
Executive	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €
Eastern Areas	892.91	808.53	853.04	1,331.26	1,289.61	1,312.38	1,506.04	1,643.66	1,561.06	1,521.41	1,481.55	1,503.51	1,862.84	1,790.85	1,835.48	841.94	726.85	790.20
Midland	996.93	890.41	944.64	1,525.25	1,402.39	1,466.93	1,660.28	1,761.78	1,703.80	1,702.97	1,704.78	1,703.84	2,144.30	2,016.72	2,089.79	882.64	778.26	833.35
Mid-Western	886.25	828.54	857.62	1,325.39	1,251.98	1,290.00	1,442.86	1,450.85	1,446.41	1,503.87	1,393.55	1,450.29	1,736.57	1,726.28	1,732.34	830.14	741.05	787.75
North Eastern	718.81	674.05	696.57	1,136.07	1,154.97	1,145.12	1,353.67	1,429.98	1,387.65	1,496.85	1,437.69	1,468.36	1,786.03	1,751.63	1,771.92	678.27	606.04	643.97
North Western	617.13	595.16	606.21	1,031.44	994.12	1,013.14	1,266.84	1,245.62	1,256.61	1,302.90	1,297.44	1,300.21	1,645.12	1,566.98	1,611.56	659.51	590.36	625.85
South Eastern	898.11	833.42	866.19	1,298.35	1,273.39	1,286.35	1,485.14	1,520.91	1,501.29	1,563.52	1,495.46	1,530.41	1,850.59	1,780.42	1,821.18	810.69	732.07	773.21
Southern	956.81	862.49	910.50	1,375.51	1,343.42	1,360.17	1,514.43	1,543.21	1,526.97	1,542.75	1,496.18	1,520.54	1,739.47	1,733.76	1,737.19	883.52	794.18	841.55
Western	768.63	723.60	746.20	1,144.47	1,094.47	1,119.41	1,306.63	1,352.20	1,328.05	1,430.52	1,409.00	1,419.87	1,745.56	1,694.28	1,724.04	758.73	690.50	725.93
National	€854.68	€784.98	€820.60	€1,280.28	€1,235.02	€1,258.72	€1,455.13	€1,507.51	€1,478.04	€1,513.39	€1,466.30	€1,491.08	€1,812.97	€1,757.72	€1,790.65	€806.34	€714.41	€763.25
% of National Average	111.98%	102.85%	107.51%	167.74%	161.81%	164.92%	190.65%	197.51%	193.65%	198.28%	192.11%	195.36%	237.53%	230.29%	234.61%	105.65%	93.60%	100.00%

Table 16 GMS: Number of Prescription Forms and Items

Health Service Executive	Number	of Forms	Number	of Items	Items per Form		
Health Service Executive	2010	2009	2010	2009	2010	2009	
East Coast Area	1,069,987	993,022	3,487,693	3,252,646	3.26	3.28	
South Western Area	2,023,789	1,884,323	6,427,743	5,995,036	3.18	3.18	
Northern Area	1,793,302	1,720,016	5,970,590	5,683,891	3.33	3.30	
Midland	1,181,149	1,112,330	3,676,790	3,464,279	3.11	3.11	
Mid-Western	1,633,307	1,528,655	5,109,996	4,783,532	3.13	3.13	
North Eastern	1,581,461	1,438,637	4,786,318	4,423,611	3.03	3.07	
North Western	1,218,124	1,145,110	3,426,880	3,211,631	2.81	2.80	
South Eastern	2,303,273	2,124,830	7,073,893	6,546,461	3.07	3.08	
Southern	2,780,296	2,610,466	8,635,135	8,093,563	3.11	3.10	
Western	1,923,329	1,775,985	5,713,145	5,267,269	2.97	2.97	
National	17,508,017	16,333,374	54,308,183	50,721,919	3.10	3.11	

Table 16.1 GMS: Number of Stock Order Forms and Items

Health Service Executive	Number	of Forms	Number	of Items	Items per Form		
Health Service Executive	2010	2009	2010	2009	2010	2009	
East Coast Area	643	613	3,014	2,726	4.69	4.45	
South Western Area	780	751	3,177	3,013	4.07	4.01	
Northern Area	588	719	2,533	2,822	4.31	3.92	
Midland	689	730	3,860	4,089	5.60	5.60	
Mid-Western	1,477	1,316	8,366	7,487	5.66	5.69	
North Eastern	2,708	2,313	15,296	13,085	5.65	5.66	
North Western	2,837	3,061	16,773	17,660	5.91	5.77	
South Eastern	4,276	4,568	25,415	27,928	5.94	6.11	
Southern	1,360	1,286	7,077	6,757	5.20	5.25	
Western	4,890	5,091	30,966	32,998	6.33	6.48	
National	20,248	20,448	116,477	118,565	5.75	5.80	

Note: (i) Stock Order Forms are provided by HSE Areas for use by Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are entitled to be dispensed to.

⁽ii) The above figures include needles, syringes and dressings which are available for Doctors' use.

Table 16.2 GMS: Payment to Pharmacists in Respect of Prescriptions

Health Service	Co	ost	Cost p	er Form	Cost p	er Item	Ingredient Cost per Item		
Executive	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	2010 €	2009 €	
East Coast Area	76,634,176	79,269,422	71.62	79.83	21.97	24.37	16.75	18.52	
South Western Area	140,692,108	143,478,091	69.52	76.14	21.89	23.93	16.69	18.43	
Northern Area	136,942,155	142,396,051	76.36	82.79	22.94	25.05	17.59	19.40	
Midland	83,547,922	85,856,163	70.73	77.19	22.72	24.78	17.34	19.14	
Mid-Western	112,624,030	114,861,653	68.95	75.14	22.04	24.01	16.75	18.52	
North Eastern	106,291,873	107,311,281	67.21	74.59	22.21	24.26	16.90	18.69	
North Western	77,503,013	78,890,836	63.62	68.89	22.62	24.56	17.27	19.01	
South Eastern	159,148,319	159,970,989	69.10	75.29	22.50	24.44	17.09	18.77	
Southern	195,441,129	200,584,382	70.30	76.84	22.63	24.78	17.38	19.27	
Western	131,572,304	133,316,155	68.41	75.07	23.03	25.31	17.70	19.72	
National	€1,220,397,029	€1,245,935,023	€69.71	€76.28	€22.47	€24.56	€17.17	€18.97	

Table 16.3 GMS: Number of Items on Prescription Forms

Buse suintien fermes besiner	20	010	2009		
Prescription forms having:-	No. of Forms	% of Total	No. of Forms	% of Total	
One Item	6,744,821	38.49	6,260,489	38.08	
Two Items	3,339,872	19.06	3,133,752	19.06	
Three Items	1,892,069	10.80	1,788,810	10.88	
Four Items	1,288,139	7.35	1,230,428	7.48	
Five Items	1,040,607	5.94	993,697	6.04	
Six Items	941,146	5.37	912,282	5.55	
Seven Items	1,013,721	5.78	981,195	5.97	
Eight or more Items	1,263,407	7.21	1,140,953	6.94	

Table 16.4 DP: Number of Items on Claim Forms

Claim farma having	20	10	2009		
Claim forms having:-	No. of Forms	% of Total	No. of Forms	% of Total	
One Item	1,419,270	38.23	2,004,397	40.84	
Two Items	703,868	18.96	993,484	20.24	
Three Items	450,192	12.13	616,005	12.55	
Four Items	335,217	9.03	430,221	8.77	
Five Items	255,643	6.89	301,242	6.14	
Six Items	185,682	5.00	202,985	4.14	
Seven Items	126,701	3.41	132,144	2.69	
Eight or more Items	235,910	6.35	227,500	4.63	

Table 16.5 LTI: Number of Items on Claim Forms

Claire farme having	20	10	2009		
Claim forms having:-	No. of Forms	% of Total	No. of Forms	% of Total	
One Item	294,979	33.50	305,806	33.97	
Two Items	150,979	17.14	154,991	17.21	
Three Items	105,561	11.99	107,973	11.99	
Four Items	93,022	10.56	92,888	10.32	
Five Items	79,474	9.02	78,834	8.76	
Six Items	60,780	6.90	60,763	6.75	
Seven Items	40,915	4.65	41,885	4.65	
Eight or more Items	54,950	6.24	57,202	6.35	

Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense

Health Service Executive	20	010	20	009
	No. of Doctors	No. of Persons	No. of Doctors	No. of Persons
Eastern Areas	_	-	-	-
Midland	8	4,703	8	4,450
Mid-Western	11	2,612	11	2,572
North Eastern	5	1,527	5	1,414
North Western	30	12,827	31	12,053
South Eastern	17	7,105	19	7,667
Southern	9	933	11	1,544
Western	32	15,499	32	15,139
National	112	45,206	117	44,839

Note: * In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest Community Pharmacy the Doctor dispenses for persons served from that centre who opt to be dispensed to. The Doctor is paid a dispensing fee for each such person. A Doctor's medicine requirements are obtained on a Stock Order from a Community Pharmacy – the stock ordered is approved in advance by a HSE Area.

Table 18 GMS: Advance Payments to Pharmacists

	Amount Advanced to Pharm	nacists as at 31st December:-
Health Service Executive	2010 €	2009 €
Eastern	3,264,521	3,362,872
Midland	756,146	809,506
Mid-Western	905,500	1,054,886
North Eastern	1,323,443	1,345,799
North Western	1,028,383	1,100,378
South Eastern	1,395,183	1,666,976
Southern	1,742,774	1,920,544
Western	1,510,271	1,592,977
NATIONAL	€11,926,221	€12,853,938

Table 19 GMS: Notes on Some of the More Commonly Prescribed Products

AMOXICILLIN	Amoxicillin, alone or potentiated by an inhibitor of bacterial enzymes is a	BECLOMETASONE	Beclometasone is a potent steroid having an anti-inflammatory action
AMOXICILLIN AND ENZYME INHIBITOR	broad spectrum Penicillin antibiotic indicated for the treatment of a wide range of infections.		within the lungs. It is used mainly by inhalation for the treatment of bronchial asthma.
SALBUTAMOL	Salbutamol is a beta-adrenergic stimulant used mainly in the treatment of chronic asthma and chronic bronchitis.	AMLODIPINE	Amlodipine is a calcium – channel blocker (similar to nifedipine) with peripheral and coronary vasodilator properties. It is given by mouth in the management of hypertension and of angina pectoris.
DICLOFENAC	Diclofenac is a Non-Steroidal Anti- inflammatory Drug (NSAID) mainly used to treat pain and inflammation associated with muscular conditions and rheumatoid arthritis.	ACETYLSALICYLIC ACID-ASPIRIN	Acetylsalicylic Acid — Aspirin has anti- inflammatory and additionally analgesic and antipyretic (body temperature lowering) action. Acetylsalicylic Acid — Aspirin also has action against thrombosis or clot formation by inhibition of platelet cell aggregration in the blood.
ATORVASTATIN AND PRAVASTATIN	Atorvastatin and Pravastatin are indicated, in combination with dietary measures, for lowering cholesterol levels.	ATENOLOL	Atenolol is a beta blocker. Members of this class of drugs are used in the treatment of hypertension, angina pectoris and cardiac arrythmias.
FUROSEMIDE FUROSEMIDE WITH POTASSIUM SPARING DIURETICS	The diuretic Furosemide, alone or in combination with potassium – sparing diuretics, is used to treat hypertension.	OMEPRAZOLE LANSOPRAZOLE	Omeprazole and Lansoprazole are proton pump inhibitors which prevent secretion of gastric acid. They are used in the treatment of reflux oesophagitis and peptic ulceration.

Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
ı	Acetylsalicylic Acid-Aspirin (Antithrombotic)	2,598,610	4.77	5,196,051	0.55
2	Atorvastatin	1,844,356	3.39	71,385,529	7.58
3	Levothyroxine Sodium	1,109,106	2.04	1,950,591	0.21
4	Bisoprolol	972,171	1.79	4,588,404	0.49
5	Paracetamol	969,784	1.78	1,426,599	0.15
6	Calcium, Combinations	948,746	1.74	6,649,153	0.71
7	Salbutamol (Inhaled)	935,483	1.72	4,470,905	0.47
8	Amlodipine	823,907	1.51	7,511,296	0.80
9	Ramipril	773,076	1.42	5,474,528	0.58
10	Esomeprazole	761,024	1.40	30,934,153	3.28
П	Amoxicillin and Enzyme Inhibitor	732,019	1.35	4,578,549	0.49
12	Warfarin	706,694	1.30	1,528,060	0.16
13	Lansoprazole	689,995	1.27	22,756,232	2.42
14	Omeprazole	657,307	1.21	17,186,823	1.82
15	Furosemide	642,876	1.18	569,323	0.06
16	Clinical Nutritional Products	600,598	1.10	43,681,431	4.64
17	Rosuvastatin	587,368	1.08	15,988,064	1.70
18	Diclofenac (Systemic)	568,754	1.05	4,743,253	0.50
19	Metformin	558,220	1.03	1,613,052	0.17
20	Zopiclone	550,710	1.01	2,766,898	0.29
21	Prednisolone (Systemic)	511,612	0.94	1,805,004	0.19
22	Pantoprazole	508,325	0.93	8,749,362	0.93
23	Diazepam	500,529	0.92	465,927	0.05
24	Pravastatin	494,196	0.91	9,323,028	0.99
25	Salmeterol and other drugs for obstructive airway diseases	483,763	0.89	32,366,449	3.44
26	Perindopril	464,370	0.85	7,878,464	0.84
27	Diagnostic Products	460,192	0.85	17,251,562	1.83
28	Escitalopram	457,003	0.84	13,291,194	1.41
29	Atenolol	439,520	0.81	1,766,189	0.19
30	Alprazolam	432,543	0.79	690,661	0.07
31	Zolpidem	421,885	0.78	1,176,068	0.12
32	Amoxicillin	400,186	0.74	1,246,153	0.13
33	Paracetamol, Combs. excl. Psycholeptics	388,110	0.71	2,410,702	0.26
34	Codeine, Combs. excl. Psycholeptics	361,604	0.66	2,919,563	0.31
35	Gliclazide	352,035	0.65	2,039,655	0.22

Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Diclofenac (Topical)	349,096	0.64	1,560,096	0.17
37	Clopidogrel	345,622	0.64	16,756,535	1.78
38	Folic Acid	336,684	0.62	299,068	0.03
39	Ferrous Fumarate	333,142	0.61	573,877	0.06
40	Tramadol	331,061	0.61	2,874,022	0.31
41	Lactulose	329,473	0.61	1,064,887	0.11
42	Venlafaxine	323,424	0.59	6,995,920	0.74
43	Alendronic Acid	322,901	0.59	9,679,189	1.03
44	Tiotropium Bromide	313,173	0.58	14,779,036	1.57
45	Artificial tears and other indifferent preparations	311,911	0.57	1,742,153	0.18
46	Carbocisteine	309,792	0.57	971,593	0.10
47	Doxazosin	292,987	0.54	7,052,166	0.75
48	Beclometasone (Inhaled)	287,288	0.53	4,819,448	0.51
49	Alginic Acid	283,986	0.52	1,539,651	0.16
50	Citalopram	283,912	0.52	3,787,658	0.40
51	Domperidone	283,595	0.52	741,953	0.08
52	Glucosamine	282,792	0.52	4,283,074	0.45
53	Pregabalin	281,703	0.52	23,938,065	2.54
54	Macrogol, Combinations	269,807	0.50	4,027,429	0.43
55	Needles/Syringes/Lancets	255,576	0.47	3,298,373	0.35
56	Clarithromycin	254,557	0.47	3,560,729	0.38
57	Drospirenone and Estrogen	248,707	0.46	1,684,209	0.18
58	Bendroflumethiazide	248,566	0.46	391,462	0.04
59	Lercanidipine	247,266	0.45	3,073,875	0.33
60	Digoxin	243,719	0.45	191,293	0.02
61	Bendroflumethiazide and Potassium	241,946	0.44	798,976	0.08
62	Ibuprofen	236,356	0.43	556,700	0.06
63	Lisinopril	222,338	0.41	1,707,091	0.18
64	Valsartan	221,388	0.41	4,907,188	0.52
65	Tamsulosin	219,971	0.40	5,569,705	0.59
66	Mirtazapine	219,492	0.40	3,176,750	0.34
67	Formoterol and other drugs for obstructive airway diseases	216,664	0.40	11,833,463	1.26
68	Allopurinol	215,177	0.40	826,651	0.09
69	Isosorbide Mononitrate	208,153	0.38	1,666,937	0.18
70	Nebivolol	202,497	0.37	2,737,058	0.29

Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Olanzapine	198,882	0.37	21,297,097	2.26
72	Amitriptyline	196,031	0.36	288,763	0.03
73	Furosemide and Potassium-Sparing Agents	194,227	0.36	621,371	0.07
74	Temazepam	190,939	0.35	368,5 4 5	0.04
75	Simvastatin	186,531	0.34	3,253,614	0.35
76	Losartan	184,599	0.34	4,014,684	0.43
77	Quetiapine	181,483	0.33	10,354,010	1.10
78	Flurazepam	181,053	0.33	733,203	0.08
79	Sodium Valproate	179,682	0.33	1,862,653	0.20
80	Betamethasone (Topical)	173,973	0.32	741,498	0.08
81	Ranitidine	173,368	0.32	2,767,088	0.29
82	Betahistine	172,248	0.32	1,176,409	0.12
83	Flucloxacillin	170,588	0.31	1,300,811	0.14
84	Mefenamic Acid	165,260	0.30	600,704	0.06
85	Levonorgestrel and Estrogen (Fixed Comb. Contraceptive)	164,345	0.30	550,938	0.06
86	Risedronic Acid	163,448	0.30	5,541,448	0.59
87	Other Emollients and Protectives	161,812	0.30	376,399	0.04
88	Montelukast	161,692	0.30	5,870,757	0.62
89	Sertraline	157,834	0.29	3,253,065	0.35
90	Valsartan and Diuretics	156,899	0.29	3,915,064	0.42
91	Nicotine	155,080	0.28	4,836,476	0.51
92	Latanoprost	148,950	0.27	3,593,672	0.38
93	Metoprolol	147,731	0.27	201,953	0.02
94	Etoricoxib	145,776	0.27	4,324,456	0.46
95	Glyceryl Trinitrate	145,433	0.27	1,343,516	0.14
96	Tolterodine	144,068	0.26	6,216,939	0.66
97	Fluoxetine	143,755	0.26	2,332,799	0.25
98	Ostomy Requisites	141,364	0.26	13,268,472	1.41
99	Hypromellose	138,913	0.26	829,734	0.09
100	Telmisartan	136,586	0.25	3,162,255	0.34
	Total	39,243,949	72.12%	€620,843,548	65.93%

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
Ι	Atorvastatin	71,385,529	7.58	1,844,356	3.39
2	Clinical Nutritional Products	43,681,431	4.64	600,598	1.10
3	Salmeterol and other drugs for obstructive airway diseases	32,366,449	3.44	483,763	0.89
4	Esomeprazole	30,934,153	3.28	761,024	1.40
5	Pregabalin	23,938,065	2.54	281,703	0.52
6	Lansoprazole	22,756,232	2.42	689,995	1.27
7	Olanzapine	21,297,097	2.26	198,882	0.37
8	Diagnostic Products	17,251,562	1.83	460,192	0.85
9	Omeprazole	17,186,823	1.82	657,307	1.21
10	Clopidogrel	16,756,535	1.78	345,622	0.64
П	Rosuvastatin	15,988,064	1.70	587,368	1.08
12	Tiotropium Bromide	14,779,036	1.57	313,173	0.58
13	Escitalopram	13,291,194	1.41	457,003	0.84
14	Ostomy Requisites	13,268,472	1.41	141,364	0.26
15	Formoterol and other drugs for obstructive airway diseases	11,833,463	1.26	216,664	0.40
16	Quetiapine	10,354,010	1.10	181,483	0.33
17	Alendronic Acid	9,679,189	1.03	322,901	0.59
18	Pravastatin	9,323,028	0.99	494,196	0.91
19	Fentanyl	8,764,404	0.93	62,116	0.11
20	Pantoprazole	8,749,362	0.93	508,325	0.93
21	Perindopril	7,878,464	0.84	464,370	0.85
22	Amlodipine	7,511,296	0.80	823,907	1.51
23	Urinary Requisites	7,240,200	0.77	78,100	0.14
24	Donepezil	7,124,643	0.76	120,571	0.22
25	Doxazosin	7,052,166	0.75	292,987	0.54
26	Venlafaxine	6,995,920	0.74	323,424	0.59
27	Risperidone	6,775,361	0.72	133,160	0.24
28	Calcium, Combinations	6,649,153	0.71	948,746	1.74
29	Lamotrigine	6,581,472	0.70	126,199	0.23
30	Tolterodine	6,216,939	0.66	144,068	0.26
31	Memantine	6,148,491	0.65	66,667	0.12
32	Montelukast	5,870,757	0.62	161,692	0.30
33	Tamsulosin	5,569,705	0.59	219,971	0.40
34	Risedronic Acid	5,541,448	0.59	163,448	0.30
35	Ramipril	5,474,528	0.58	773,076	1.42

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Levetiracetam	5,443,226	0.58	63,919	0.12
37	Simvastatin and Ezetimibe	5,392,535	0.57	106,051	0.19
38	Acetylsalicylic Acid-Aspirin (Antithrombotic)	5,196,051	0.55	2,598,610	4.77
39	Valsartan	4,907,188	0.52	221,388	0.41
40	Nicotine	4,836,476	0.51	155,080	0.28
41	Budesonide (Inhaled)	4,833,614	0.51	72,845	0.13
42	Beclometasone (Inhaled)	4,819,448	0.51	287,288	0.53
43	Buprenorphine	4,813,007	0.51	85,273	0.16
44	Diclofenac (Systemic)	4,743,253	0.50	568,754	1.05
45	Bisoprolol	4,588,404	0.49	972,171	1.79
46	Amoxicillin and Enzyme Inhibitor	4,578,549	0.49	732,019	1.35
47	Salbutamol (Inhaled)	4,470,905	0.47	935,483	1.72
48	Aripiprazole	4,433,196	0.47	26,734	0.05
49	Etoricoxib	4,324,456	0.46	145,776	0.27
50	Insulin Glargine, Long Acting	4,310,046	0.46	57,694	0.11
5 I	Glucosamine	4,283,074	0.45	282,792	0.52
52	Varenicline	4,111,061	0.44	54,562	0.10
53	Macrogol, Combinations	4,027,429	0.43	269,807	0.50
54	Losartan	4,014,684	0.43	184,599	0.34
55	Gabapentin	3,943,775	0.42	85,960	0.16
56	Valsartan and Diuretics	3,915,064	0.42	156,899	0.29
57	Anastrazole	3,909,550	0.41	39,328	0.07
58	Duloxetine	3,847,738	0.41	105,869	0.19
59	Mesalazine	3,835,891	0.41	58,391	0.11
60	Citalopram	3,787,658	0.40	283,912	0.52
61	Rabeprazole	3,735,145	0.40	126,630	0.23
62	Salbutamol and other drugs for obstructive airway diseases	3,716,894	0.39	128,624	0.24
63	Ezetimibe	3,696,812	0.39	97,022	0.18
64	Alendronic Acid, Combinations	3,670,942	0.39	113,920	0.21
65	Latanoprost	3,593,672	0.38	148,950	0.27
66	Clarithromycin	3,560,729	0.38	254,557	0.47
67	Insulin Aspart, Fast Acting	3,413,812	0.36	55,582	0.10
68	Orlistat	3,356,196	0.36	55,319	0.10
69	Tinzaparin	3,339,305	0.35	14,784	0.03
70	Needles/Syringes/Lancets	3,298,373	0.35	255,576	0.47

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Simvastatin	3,253,614	0.35	186,531	0.34
72	Sertraline	3,253,065	0.35	157,834	0.29
73	Calcipotriol, Combinations	3,180,944	0.34	39,733	0.07
74	Mirtazapine	3,176,750	0.34	219,492	0.40
75	Sildenafil	3,165,375	0.34	104,290	0.19
76	Telmisartan	3,162,255	0.34	136,586	0.25
77	Solifenacin	3,132,183	0.33	65,211	0.12
78	Ibandronic Acid	3,077,621	0.33	100,358	0.18
79	Lercanidipine	3,073,875	0.33	247,266	0.45
80	Oxycodone	3,042,313	0.32	87,976	0.16
81	Omega-3-triglycerides	3,027,448	0.32	116,570	0.21
82	Codeine Combs. excl. Psycholeptics	2,919,563	0.31	361,604	0.66
83	Tramadol	2,874,022	0.31	331,061	0.61
84	Ranitidine	2,767,088	0.29	173,368	0.32
85	Zopiclone	2,766,898	0.29	550,710	1.01
86	Insulin Detemir, Long Acting	2,765,154	0.29	32,540	0.06
87	Nebivolol	2,737,058	0.29	202,497	0.37
88	Perindopril and Diuretics	2,564,272	0.27	113,869	0.21
89	Fluticasone (Inhaled)	2,555,795	0.27	49,618	0.09
90	Levodopa Decarboxylase Inhibitor and COMT Inhibitor	2,495,660	0.26	23,118	0.04
91	Insulin Aspart, Comb. Intermediate/Fast Acting	2,483,233	0.26	31,235	0.06
92	Timolol, Combinations	2,456,592	0.26	96,037	0.18
93	Strontium Ranelate	2,419,627	0.26	55,320	0.10
94	Paracetamol Combs. excl. Psycholeptics	2,410,702	0.26	388,110	0.71
95	Fluoxetine	2,332,799	0.25	143,755	0.26
96	Candesartan	2,256,666	0.24	100,440	0.18
97	Sitagliptin	2,130,113	0.23	48,131	0.09
98	Alfuzosin	2,120,317	0.23	77,652	0.14
99	Losartan and Diuretics	2,101,805	0.22	85,085	0.16
100	Rivastigmine	2,080,918	0.22	23,295	0.04
	Total	€740,746,524	78.67%	28,599,881	52.51%

Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Τ	Acetylsalicylic Acid-Aspirin (Antithrombotic)	547,430	4.94	1,148,144	0.50
2	Atorvastatin	514,347	4.65	21,135,739	9.13
3	Levothyroxine Sodium	269,126	2.43	498,637	0.22
4	Rosuvastatin	240,722	2.17	6,760,806	2.92
5	Esomeprazole	229,344	2.07	9,858,315	4.26
6	Salbutamol (Inhaled)	218,747	1.98	992,025	0.43
7	Bisoprolol	217,530	1.96	1,017,473	0.44
8	Calcium, Combinations	214,411	1.94	1,640,509	0.71
9	Diclofenac (Systemic)	169,278	1.53	1,649,616	0.71
10	Amlodipine	168,704	1.52	1,473,541	0.64
11	Salmeterol and other drugs for obstructive airway diseases	146,487	1.32	9,680,255	4.18
12	Omeprazole	144,723	1.31	3,770,391	1.63
13	Lansoprazole	140,709	1.27	5,202,276	2.25
14	Ramipril	138,593	1.25	971,623	0.42
15	Amoxicillin and Enzyme Inhibitor	128,712	1.16	806,725	0.35
16	Codeine Combs. excl. Psycholeptics	125,210	1.13	1,012,300	0.44
17	Prednisolone (Systemic)	122,611	1.11	512,643	0.22
18	Escitalopram	106,154	0.96	3,279,537	1.42
19	Clinical Nutritional Products	105,786	0.96	5,014,792	2.17
20	Perindopril	104,424	0.94	1,827,783	0.79
21	Pantoprazole	100,098	0.90	1,765,644	0.76
22	Clopidogrel	95,979	0.87	4,802,488	2.07
23	Warfarin	95,136	0.86	211,997	0.09
24	Formoterol and other drugs for obstructive airway diseases	93,646	0.85	5,272,303	2.28
25	Zopiclone	91,024	0.82	450,611	0.19
26	Glucosamine	88,214	0.80	1,384,766	0.60
27	Atenolol	86,569	0.78	343,684	0.15
28	Pravastatin	85,140	0.77	1,620,816	0.70
29	Venlafaxine	85,039	0.77	1,891,779	0.82
30	Montelukast	84,547	0.76	3,146,745	1.36
31	Zolpidem	84,048	0.76	247,959	0.11
32	Paracetamol	80,847	0.73	121,374	0.05
33	Alprazolam	73,403	0.66	111,747	0.05
34	Pregabalin	71,196	0.64	6,256,657	2.70
35	Clarithromycin	70,937	0.64	1,103,766	0.48

Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Folic Acid	70,767	0.64	54,505	0.02
37	Valsartan	63,707	0.58	1,435,344	0.62
38	Doxazosin	62,999	0.57	1,620,887	0.70
39	Nebivolol	62,210	0.56	871,967	0.38
40	Omega-3-triglycerides	61,156	0.55	1,687,165	0.73
41	Diazepam	60,504	0.55	41,727	0.02
42	Alendronic Acid	58,143	0.53	1,802,534	0.78
43	Allopurinol	57,905	0.52	241,218	0.10
44	Beclometasone (Inhaled)	55,806	0.50	957,336	0.41
45	Tramadol	55,734	0.50	490,771	0.21
46	Valsartan and Diuretics	54,598	0.49	1,381,416	0.60
47	Diclofenac (Topical)	52,927	0.48	269,086	0.12
48	Citalopram	50,510	0.46	657,368	0.28
49	Simvastatin and Ezetimibe	49,960	0.45	2,557,400	1.10
50	Etoricoxib	49,264	0.45	1,549,147	0.67
5 I	Tiotropium Bromide	48,869	0.44	2,310,649	1.00
52	Amoxicillin	48,377	0.44	194,960	0.08
53	Lercanidipine	48,127	0.43	623,010	0.27
54	Amitriptyline	47,131	0.43	80,254	0.03
55	Furosemide	47,043	0.42	47,331	0.02
56	Losartan	46,089	0.42	1,036,426	0.45
57	Domperidone	45,541	0.41	120,833	0.05
58	Ezetimibe	44,938	0.41	1,722,267	0.74
59	Artificial tears and other indifferent preparations	44,908	0.41	327,301	0.14
60	Telmisartan	43,658	0.39	1,017,669	0.44
61	Methotrexate	43,593	0.39	479,812	0.21
62	Bendroflumethiazide	43,134	0.39	68,006	0.03
63	Lisinopril	42,762	0.39	314,799	0.14
64	Tadalafil	42,466	0.38	1,205,137	0.52
65	Alginic Acid	42,086	0.38	246,467	0.11
66	Drospirenone and Estrogen	41,028	0.37	282,284	0.12
67	Ostomy Requisites	40,080	0.36	3,615,815	1.56
68	Mometasone	39,848	0.36	588,932	0.25
69	Mesalazine	39,788	0.36	3,294,067	1.42
70	Bendroflumethiazide and Potassium	38,944	0.35	129,791	0.06

Table 19.3 DPS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Olmesartan Medoxomil	38,866	0.35	779,391	0.34
72	Cetirizine	38,787	0.35	175,514	0.08
73	Fluticasone Furoate	37,632	0.34	458,919	0.20
74	Tamsulosin	37,039	0.33	959,003	0.41
75	Olanzapine	36,673	0.33	3,181,473	1.37
76	Betamethasone (Topical)	36,327	0.33	171,045	0.07
77	Fluticasone (Nasal)	36,188	0.33	235,665	0.10
78	Risedronic Acid	35,590	0.32	1,201,252	0.52
79	Sertraline	35,076	0.32	746,411	0.32
80	Antifungal Combs. (Topical)	34,938	0.32	128,440	0.06
81	Ranitidine	34,821	0.31	547,071	0.24
82	Simvastatin	34,805	0.31	602,177	0.26
83	Mefenamic Acid	34,537	0.31	119,580	0.05
84	Sildenafil	32,709	0.30	977,477	0.42
85	Estradiol	32,581	0.29	366,990	0.16
86	Metformin	32,553	0.29	84,808	0.04
87	Duloxetine	32,117	0.29	1,228,676	0.53
88	Lithium	31,700	0.29	62,033	0.03
89	Ibandronic Acid	31,667	0.29	960,762	0.41
90	Fluoxetine	31,004	0.28	514,814	0.22
91	Carbocisteine	30,773	0.28	102,996	0.04
92	Perindopril and Diuretics	30,519	0.28	686,882	0.30
93	Desloratadine	29,596	0.27	319,055	0.14
94	Candesartan	29,328	0.26	658,935	0.28
95	Quetiapine	28,398	0.26	1,716,324	0.74
96	Losartan and Diuretics	28,257	0.26	706,356	0.31
97	Mirtazapine	28,235	0.26	395,883	0.17
98	Macrogol, Combinations	27,796	0.25	423,901	0.18
99	Levocetirizine	27,570	0.25	289,888	0.13
100	Diltiazem	27,063	0.24	378,177	0.16
	Total	8,066,616	72.86%	€159,489,045	68.90%

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
ı	Atorvastatin	21,135,739	9.13	514,347	4.65
2	Esomeprazole	9,858,315	4.26	229,344	2.07
3	Salmeterol and other drugs for obstructive airway diseases	9,680,255	4.18	146,487	1.32
4	Rosuvastatin	6,760,806	2.92	240,722	2.17
5	Pregabalin	6,256,657	2.70	71,196	0.64
6	Formoterol and other drugs for obstructive airway diseases	5,272,303	2.28	93,646	0.85
7	Lansoprazole	5,202,276	2.25	140,709	1.27
8	Clinical Nutritional Products	5,014,792	2.17	105,786	0.96
9	Clopidogrel	4,802,488	2.07	95,979	0.87
10	Omeprazole	3,770,391	1.63	144,723	1.31
П	Ostomy Requisites	3,615,815	1.56	40,080	0.36
12	Mesalazine	3,294,067	1.42	39,788	0.36
13	Escitalopram	3,279,537	1.42	106,154	0.96
14	Olanzapine	3,181,473	1.37	36,673	0.33
15	Montelukast	3,146,745	1.36	84,547	0.76
16	Simvastatin and Ezetimibe	2,557,400	1.10	49,960	0.45
17	Follitropin Beta	2,422,385	1.05	510	0.00
18	Tiotropium Bromide	2,310,649	1.00	48,869	0.44
19	Calcipotriol, Combinations	2,237,655	0.97	24,886	0.22
20	Venlafaxine	1,891,779	0.82	85,039	0.77
21	Perindopril	1,827,783	0.79	104,424	0.94
22	Alendronic Acid	1,802,534	0.78	58,143	0.53
23	Pantoprazole	1,765,644	0.76	100,098	0.90
24	Ezetimibe	1,722,267	0.74	44,938	0.41
25	Quetiapine	1,716,324	0.74	28,398	0.26
26	Omega-3-triglycerides	1,687,165	0.73	61,156	0.55
27	Plastic IUCD with Progestogens	1,685,158	0.73	14,200	0.13
28	Diclofenac (Systemic)	1,649,616	0.71	169,278	1.53
29	Calcium, Combinations	1,640,509	0.71	214,411	1.94
30	Doxazosin	1,620,887	0.70	62,999	0.57
31	Pravastatin	1,620,816	0.70	85,140	0.77
32	Etoricoxib	1,549,147	0.67	49,264	0.45
33	Amlodipine	1,473,541	0.64	168,704	1.52
34	Valsartan	1,435,344	0.62	63,707	0.58
35	Progesterone	1,414,228	0.61	10,893	0.10

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Glucosamine	1,384,766	0.60	88,214	0.80
37	Valsartan and Diuretics	1,381,416	0.60	54,598	0.49
38	Anastrazole	1,365,003	0.59	13,571	0.12
39	Urinary Requisites	1,314,347	0.57	10,307	0.09
40	Varenicline	1,281,226	0.55	16,708	0.15
41	Duloxetine	1,228,676	0.53	32,117	0.29
42	Fentanyl	1,214,045	0.52	7,038	0.06
43	Tadalafil	1,205,137	0.52	42,466	0.38
44	Risedronic Acid	1,201,252	0.52	35,590	0.32
45	Lamotrigine	1,152,264	0.50	26,404	0.24
46	Acetylsalicylic Acid-Aspirin (Antithrombotic)	1,148,144	0.50	547,430	4.94
47	Orlistat	1,129,966	0.49	18,345	0.17
48	Clarithromycin	1,103,766	0.48	70,937	0.64
49	Tinzaparin	1,049,219	0.45	5,828	0.05
50	Losartan	1,036,426	0.45	46,089	0.42
5 I	Telmisartan	1,017,669	0.44	43,658	0.39
52	Bisoprolol	1,017,473	0.44	217,530	1.96
53	Gabapentin	1,012,519	0.44	19,911	0.18
54	Codeine Combs. excl. Psycholeptics	1,012,300	0.44	125,210	1.13
55	Salbutamol (Inhaled)	992,025	0.43	218,747	1.98
56	Sildenafil	977,477	0.42	32,709	0.30
57	Sumatriptan	977,376	0.42	16,342	0.15
58	Fumaric Acid Derivatives, Combinations	974,024	0.42	1,624	0.01
59	Ramipril	971,623	0.42	138,593	1.25
60	Ibandronic Acid	960,762	0.41	31,667	0.29
61	Tamsulosin	959,003	0.41	37,039	0.33
62	Beclometasone (Inhaled)	957,336	0.41	55,806	0.50
63	Nebivolol	871,967	0.38	62,210	0.56
64	Isotretinoin	851,021	0.37	12,745	0.12
65	Fluticasone (Inhaled)	835,575	0.36	21,174	0.19
66	Alendronic Acid, Combinations	827,948	0.36	25,786	0.23
67	Tolterodine	824,596	0.36	18,704	0.17
68	Lignocaine (Local Anaesthetic)	821,547	0.35	3,547	0.03
69	Strontium Ranelate	811,623	0.35	18,357	0.17
70	Amoxicillin and Enzyme Inhibitor	806,725	0.35	128,712	1.16

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Olmesartan Medoxomil	779,391	0.34	38,866	0.35
72	Aripiprazole	747,286	0.32	4,994	0.05
73	Sertraline	746,411	0.32	35,076	0.32
74	Rabeprazole	732,317	0.32	23,282	0.21
75	Losartan and Diuretics	706,356	0.31	28,257	0.26
76	Perindopril and Diuretics	686,882	0.30	30,519	0.28
77	Diagnostic Products	671,984	0.29	19,043	0.17
78	Solifenacin	668,452	0.29	13,719	0.12
79	Proguanil, Combinations	659,616	0.28	9,695	0.09
80	Candesartan	658,935	0.28	29,328	0.26
81	Citalopram	657,368	0.28	50,510	0.46
82	Budesonide (Inhaled)	648,690	0.28	15,984	0.14
83	Telmisartan and Diuretics	635,680	0.27	25,347	0.23
84	Lercanidipine	623,010	0.27	48,127	0.43
85	Zolmitriptan	617,410	0.27	13,806	0.12
86	Letrozole	614,159	0.27	6,660	0.06
87	Simvastatin	602,177	0.26	34,805	0.31
88	Modafinil	600,598	0.26	2,911	0.03
89	Mometasone	588,932	0.25	39,848	0.36
90	Oxycodone	561,413	0.24	14,897	0.13
91	Ranitidine	547,071	0.24	34,821	0.31
92	Etonogestrel	545,736	0.24	4,118	0.04
93	Fluoxetine	514,814	0.22	31,004	0.28
94	Prednisolone (Systemic)	512,643	0.22	122,611	1.11
95	Tacrolimus (Topical)	500,728	0.22	7,627	0.07
96	Risperidone	499,487	0.22	11,296	0.10
97	Levothyroxine Sodium	498,637	0.22	269,126	2.43
98	Latanoprost	496,405	0.21	21,762	0.20
99	Tramadol	490,771	0.21	55,734	0.50
100	Methotrexate	479,812	0.21	43,593	0.39
	Total	€185,271,903	80.05%	6,868,277	62.01%

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
I	Diagnostic Products	283,805	10.11	12,829,302	15.83
2	Metformin	252,828	9.00	823,452	1.02
3	Acetylsalicylic Acid-Aspirin (Antithrombotic)	247,234	8.81	522,920	0.65
4	Atorvastatin	180,923	6.44	7,066,391	8.72
5	Needles/Syringes/Lancets	157,753	5.62	3,921,282	4.84
6	Gliclazide	131,090	4.67	806,645	1.00
7	Ramipril	86,277	3.07	624,185	0.77
8	Insulin Aspart, Fast Acting	83,872	2.99	5,044,817	6.23
9	Perindopril	63,572	2.26	1,222,889	1.51
10	Rosuvastatin	56,940	2.03	1,598,455	1.97
П	Amlodipine	55,899	1.99	523,088	0.65
12	Insulin Glargine, Long Acting	49,303	1.76	3,669,222	4.53
13	Sodium Valproate	46,990	1.67	561,784	0.69
14	Lamotrigine	46,860	1.67	2,952,219	3.64
15	Bisoprolol	43,515	1.55	210,639	0.26
16	Carbamazepine	38,921	1.39	322,787	0.40
17	Clinical Nutritional Products	35,453	1.26	4,888,354	6.03
18	Insulin Detemir, Long Acting	32,501	1.16	2,688,415	3.32
19	Levetiracetam	28,046	1.00	2,471,263	3.05
20	Pravastatin	25,892	0.92	496,885	0.61
21	Doxazosin	24,472	0.87	670,823	0.83
22	Lisinopril	21,007	0.75	162,843	0.20
23	Sitagliptin	20,698	0.74	926,876	1.14
24	Atenolol	20,674	0.74	86,309	0.11
25	Phenytoin	19,225	0.68	122,233	0.15
26	Losartan	17,898	0.64	420,461	0.52
27	Valsartan	17,186	0.61	396,997	0.49
28	Metformin and Sitagliptin	15,378	0.55	750,367	0.93
29	Lercanidipine	15,198	0.54	200,383	0.25
30	Levothyroxine Sodium	14,963	0.53	33,319	0.04
31	Folic Acid	14,362	0.51	16,062	0.02
32	Clopidogrel	14,302	0.51	710,226	0.88
33	Furosemide	12,388	0.44	13,546	0.02
34	Nebivolol	12,362	0.44	188,419	0.23
35	Simvastatin	12,294	0.44	219,780	0.27

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Insulin Aspart, Comb. Intermediate/Fast Acting	11,914	0.42	832,745	1.03
37	Valsartan and Diuretics	11,137	0.40	291,313	0.36
38	Telmisartan	10,007	0.36	240,330	0.30
39	Simvastatin and Ezetimibe	9,344	0.33	486,336	0.60
40	Tadalafil	9,243	0.33	262,289	0.32
41	Warfarin	9,182	0.33	21,586	0.03
42	Bendroflumethiazide	9,045	0.32	14,007	0.02
43	Sildenafil	8,970	0.32	270,982	0.33
44	Omega-3-triglycerides	8,766	0.31	255,503	0.32
45	Ezetimibe	8,757	0.31	336,189	0.41
46	Insulin Lispro, Fast Acting	8,734	0.31	511,136	0.63
47	Glimepiride	8,260	0.29	48,133	0.06
48	Insulin (Human), Intermediate Acting	8,157	0.29	288,909	0.36
49	Olmesartan Medoxomil	8,008	0.29	165,277	0.20
50	Candesartan	7,975	0.28	187,046	0.23
5 I	Phenobarbital	7,948	0.28	29,893	0.04
52	Liraglutide	7,647	0.27	1,051,705	1.30
53	Insulin (Human), Comb. Intermediate/Fast Acting	7,627	0.27	406,901	0.50
54	Indapamide	7,537	0.27	27,767	0.03
55	Pioglitazone	7,516	0.27	386,462	0.48
56	Glucagon	7,422	0.26	210,310	0.26
57	Topiramate	7,371	0.26	518,468	0.64
58	Levodopa and Decarboxylase Inhibitor	7,342	0.26	128,076	0.16
59	Pancreatic Enzymes	7,221	0.26	749,305	0.92
60	Losartan and Diuretics	6,079	0.22	159,700	0.20
61	Fenofibrate	6,055	0.22	123,765	0.15
62	Metformin and Rosiglitazone	5,843	0.21	313,504	0.39
63	Calcium, Combinations	5,631	0.20	43,794	0.05
64	Urinary Requisites	5,572	0.20	710,594	0.88
65	Lisinopril and Diuretics	5,503	0.20	42,926	0.05
66	Omeprazole	5,486	0.20	153,879	0.19
67	Oxcarbazepine	5,472	0.19	171,562	0.21
68	Irbesartan	5,464	0.19	136,346	0.17
69	Metoprolol	5,461	0.19	8,167	0.01
70	Pregabalin	5,390	0.19	496,104	0.61

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Bendroflumethiazide and Potassium	5,223	0.19	17,365	0.02
72	Insulin Glulisine, Fast Acting	4,939	0.18	249,091	0.31
73	Rosiglitazone	4,754	0.17	255,897	0.32
74	Diltiazem	4,709	0.17	70,085	0.09
75	Telmisartan and Diuretics	4,650	0.17	118,718	0.15
76	Lansoprazole	4,405	0.16	154,743	0.19
77	Esomeprazole	4,295	0.15	180,999	0.22
78	Baclofen	4,213	0.15	38,815	0.05
79	Enalapril	4,043	0.14	32,324	0.04
80	Gabapentin	4,037	0.14	247,518	0.31
81	Levodopa Decarboxylase Inhibitor and COMT Inhibitor	3,919	0.14	435,760	0.54
82	Insulin (Human), Fast Acting	3,911	0.14	110,352	0.14
83	Exenatide	3,865	0.14	412,386	0.51
84	Ropinirole	3,666	0.13	449,526	0.55
85	Clobazam	3,645	0.13	25,454	0.03
86	Salbutamol (Inhaled)	3,639	0.13	22,602	0.03
87	Valsartan and Amlodipine	3,549	0.13	102,112	0.13
88	Rasagiline	3,244	0.12	323,980	0.40
89	Zonisamide	3,199	0.11	354,177	0.44
90	Evening Primrose Oil (Naudicelle)	3,142	0.11	77,949	0.10
91	Quinapril	3,119	0.11	38,893	0.05
92	Atenolol and other Diuretics	3,087	0.11	15,283	0.02
93	Isosorbide Mononitrate	3,057	0.11	25,255	0.03
94	Perindopril and Diuretics	3,040	0.11	86,429	0.11
95	Clonazepam	2,985	0.11	68,294	0.08
96	Selegiline	2,968	0.11	92,839	0.11
97	Allopurinol	2,947	0.10	15,005	0.02
98	Pramipexole	2,885	0.10	464,105	0.57
99	Nifedipine	2,881	0.10	40,051	0.05
100	Metformin and Pioglitazone	2,850	0.10	136,236	0.17
	Total	2,578,033	91.82%	€72,906,890	90.02%

Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
Ι	Diagnostic Products	12,829,302	15.83	283,805	10.11
2	Atorvastatin	7,066,391	8.72	180,923	6.44
3	Insulin Aspart, Fast Acting	5,044,817	6.23	83,872	2.99
4	Clinical Nutritional Products	4,888,354	6.03	35,453	1.26
5	Needles/Syringes/Lancets	3,921,282	4.84	157,753	5.62
6	Insulin Glargine, Long Acting	3,669,222	4.53	49,303	1.76
7	Lamotrigine	2,952,219	3.64	46,860	1.67
8	Insulin Detemir, Long Acting	2,688,415	3.32	32,501	1.16
9	Levetiracetam	2,471,263	3.05	28,046	1.00
10	Rosuvastatin	1,598,455	1.97	56,940	2.03
П	Perindopril	1,222,889	1.51	63,572	2.26
12	Liraglutide	1,051,705	1.30	7,647	0.27
13	Sitagliptin	926,876	1.14	20,698	0.74
14	Insulin Aspart, Comb. Intermediate/Fast Acting	832,745	1.03	11,914	0.42
15	Metformin	823,452	1.02	252,828	9.00
16	Gliclazide	806,645	1.00	131,090	4.67
17	Apomorphine	783,392	0.97	991	0.04
18	Metformin and Sitagliptin	750,367	0.93	15,378	0.55
19	Pancreatic Enzymes	749,305	0.92	7,221	0.26
20	Urinary Requisites	710,594	0.88	5,572	0.20
21	Clopidogrel	710,226	0.88	14,302	0.51
22	Doxazosin	670,823	0.83	24,472	0.87
23	Ramipril	624,185	0.77	86,277	3.07
24	Sodium Valproate	561,784	0.69	46,990	1.67
25	Amlodipine	523,088	0.65	55,899	1.99
26	Acetylsalicylic Acid-Aspirin (Antithrombotic)	522,920	0.65	247,234	8.81
27	Topiramate	518,468	0.64	7,371	0.26
28	Insulin Lispro, Fast Acting	511,136	0.63	8,734	0.31
29	Pravastatin	496,885	0.61	25,892	0.92
30	Pregabalin	496,104	0.61	5,390	0.19
31	Simvastatin and Ezetimibe	486,336	0.60	9,344	0.33
32	Pramipexole	464,105	0.57	2,885	0.10
33	Ropinirole	449,526	0.55	3,666	0.13
34	Levodopa, Decarboxylase Inhibitor and COMT Inhibitor	435,760	0.54	3,919	0.14
35	Losartan	420,461	0.52	17,898	0.64

Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Exenatide	412,386	0.51	3,865	0.14
37	Insulin (Human), Comb. Intermediate/Fast Acting	406,901	0.50	7,627	0.27
38	Valsartan	396,997	0.49	17,186	0.61
39	Pioglitazone	386,462	0.48	7,516	0.27
40	Zonisamide	354,177	0.44	3,199	0.11
41	Ezetimibe	336,189	0.41	8,757	0.31
42	Meropenem	329,240	0.41	167	0.01
43	Rasagiline	323,980	0.40	3,244	0.12
44	Carbamazepine	322,787	0.40	38,921	1.39
45	Metformin and Rosiglitazone	313,504	0.39	5,843	0.21
46	Nutritional/Ancillary Devices	303,496	0.37	2,483	0.09
47	Valsartan and Diuretics	291,313	0.36	11,137	0.40
48	Insulin (Human), Intermediate Acting	288,909	0.36	8,157	0.29
49	Colistin Parenteral	285,913	0.35	1,891	0.07
50	Sildenafil	270,982	0.33	8,970	0.32
51	Tadalafil	262,289	0.32	9,243	0.33
52	Rosiglitazone	255,897	0.32	4,754	0.17
53	Omega-3-triglycerides	255,503	0.32	8,766	0.31
54	Insulin Glulisine, Fast Acting	249,091	0.31	4,939	0.18
55	Gabapentin	247,518	0.31	4,037	0.14
56	Telmisartan	240,330	0.30	10,007	0.36
57	Rotigotine	227,812	0.28	1,280	0.05
58	Simvastatin	219,780	0.27	12,294	0.44
59	Bisoprolol	210,639	0.26	43,515	1.55
60	Glucagon	210,310	0.26	7,422	0.26
61	Lercanidipine	200,383	0.25	15,198	0.54
62	Nebivolol	188,419	0.23	12,362	0.44
63	Other Alimentary Tract/Metabolism Products	188,157	0.23	1,767	0.06
64	Candesartan	187,046	0.23	7,975	0.28
65	Esomeprazole	180,999	0.22	4,295	0.15
66	Oxcarbazepine	171,562	0.21	5,472	0.19
67	Olmesartan Medoxomil	165,277	0.20	8,008	0.29
68	Lisinopril	162,843	0.20	21,007	0.75
69	Orlistat	160,912	0.20	2,615	0.09
70	Losartan and Diuretics	159,700	0.20	6,079	0.22

Table 19.6 LTI: The Top 100 Products of Highest cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Lansoprazole	154,743	0.19	4,405	0.16
72	Omeprazole	153,879	0.19	5,486	0.20
73	Modafinil	151,716	0.19	880	0.03
74	Desmopressin	147,313	0.18	2,141	0.08
75	Irbesartan	136,346	0.17	5,464	0.19
76	Metformin and Pioglitazone	136,236	0.17	2,850	0.10
77	Midazolam	132,259	0.16	2,158	0.08
78	Azithromycin	131,927	0.16	2,166	0.08
79	Multivitamins and Trace Elements	131,108	0.16	2,415	0.09
80	Levodopa and Decarboxylase Inhibitor	128,076	0.16	7,342	0.26
81	Fenofibrate	123,765	0.15	6,055	0.22
82	Phenytoin	122,233	0.15	19,225	0.68
83	Telmisartan and Diuretics	118,718	0.15	4,650	0.17
84	Insulin (Human), Fast Acting	110,352	0.14	3,911	0.14
85	Dressings	105,105	0.13	1,775	0.06
86	Lacosamide	102,321	0.13	1,187	0.04
87	Valsartan and Amlodipine	102,112	0.13	3,549	0.13
88	Ostomy Requisites	100,580	0.12	1,192	0.04
89	Levocarnitine	99,863	0.12	270	0.01
90	Tolterodine	98,508	0.12	2,168	0.08
91	Selegiline	92,839	0.11	2,968	0.11
92	Melatonin	91,054	0.11	1,353	0.05
93	Salmeterol and other drugs for obstructive airway diseases	89,859	0.11	1,278	0.05
94	Perindopril and Diuretics	86,429	0.11	3,040	0.11
95	Atenolol	86,309	0.11	20,674	0.74
96	Perindopril and Amlodipine	85,576	0.11	2,423	0.09
97	Candesartan and Diuretics	78,587	0.10	2,783	0.10
98	Olanzapine	78,365	0.10	822	0.03
99	Evening Primrose Oil (Naudicelle)	77,949	0.10	3,142	0.11
100	Diltiazem	70,085	0.09	4,709	0.17
	Total	€76,171,412	94.04%	2,475,119	88.20%

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
I	Adalimumab	39,178	9.99	54,285,269	17.72
2	Etanercept	37,412	9.54	42,470,280	13.87
3	Tacrolimus	28,352	7.23	7,493,723	2.45
4	Mycophenolic Acid	27,538	7.02	5,883,844	1.92
5	Bicalutamide	24,353	6.21	2,217,896	0.72
6	Ciclosporin	17,582	4.48	2,028,214	0.66
7	Darbepoetin alfa	15,471	3.94	7,083,532	2.31
8	Triptorelin	14,713	3.75	5,447,910	1.78
9	Interferon beta-la	14,389	3.67	16,558,800	5.41
10	Pegfilgrastim	11,997	3.06	14,901,540	4.86
П	Teriparatide	11,728	2.99	5,355,432	1.75
12	Erythropoietin	11,128	2.84	9,067,167	2.96
13	Leuprorelin	10,778	2.75	5,374,985	1.76
14	Somatropin	9,409	2.40	6,746,060	2.20
15	Interferon beta-1b	8,413	2.14	9,863,895	3.22
16	Capecitabine	7,237	1.85	1,806,003	0.59
17	Methoxy Polyethylene Glycol – Epoetin beta	5,845	1.49	1,270,338	0.42
18	Cinacalcet	5,628	1.43	1,909,359	0.62
19	Glatiramer Acetate	5,461	1.39	6,635,831	2.17
20	Goserelin	5,169	1.32	1,826,923	0.60
21	Follitropin beta	4,863	1.24	4,119,631	1.35
22	Dornase alfa	4,359	1.11	4,072,792	1.33
23	Filgrastim	3,922	1.00	2,835,425	0.93
24	Palivizumab	3,906	1.00	4,072,318	1.33
25	Choriogonadotropin alfa	3,845	0.98	193,247	0.06
26	Imatinib	2,957	0.75	7,962,472	2.60
27	Octreotide	2,922	0.74	3,299,257	1.08
28	Follitropin alfa	2,902	0.74	3,397,704	1.11
29	Sildenafil	2,702	0.69	1,969,501	0.64
30	Ribavirin	2,444	0.62	1,331,229	0.43
31	Human Menopausal Gonadotrophin	2,123	0.54	1,433,060	0.47
32	Peginterferon alfa-2a	2,097	0.53	2,105,734	0.69
33	Riluzole	2,083	0.53	686,271	0.22
34	Lenalidomide	2,029	0.52	13,482,422	4.40
35	Bosentan	1,991	0.51	6,073,440	1.98

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Temozolomide	1,878	0.48	2,206,027	0.72
37	Parathyroid Hormone	1,856	0.47	841,326	0.27
38	Tobramycin	1,698	0.43	4,297,014	1.40
39	Ganirelix	1,424	0.36	427,346	0.14
40	Fulvestrant	1,343	0.34	886,239	0.29
41	Thalidomide	1,311	0.33	844,515	0.28
42	Sirolimus	1,269	0.32	320,912	0.11
43	Anagrelide	1,259	0.32	666,495	0.22
44	Entecavir	1,211	0.31	695,893	0.23
45	Linezolid	1,208	0.31	1,823,492	0.60
46	Erlotinib	1,118	0.29	2,563,302	0.84
47	Paricalcitol	1,087	0.28	192,205	0.06
48	Lutropin alfa	1,028	0.26	570,471	0.19
49	Lanreotide	1,005	0.26	1,159,568	0.38
50	Lamivudine	978	0.25	97,242	0.03
5 I	Sunitinib	972	0.25	3,151,564	1.03
52	Valganciclovir	903	0.23	1,353,313	0.44
53	Deferasirox	897	0.23	811,701	0.27
54	Degarelix	833	0.21	165,622	0.05
55	Voriconazole	689	0.18	1,841,609	0.60
56	Adefovir Dipivoxil	636	0.16	348,031	0.11
57	Buserelin	610	0.16	95,875	0.03
58	Golimumab	592	0.15	993,283	0.32
59	Sorafenib	587	0.15	2,028,046	0.66
60	Lapatinib	572	0.15	1,227,157	0.40
61	Nafarelin	556	0.14	93,089	0.03
62	Peginterferon alfa-2b	537	0.14	393,448	0.13
63	Posaconazole	462	0.12	915,646	0.30
64	Etoposide	455	0.12	42,441	0.01
65	Ibandronic Acid	434	0.11	116,089	0.04
66	Anakinra	431	0.11	446,940	0.15
67	Clodronic Acid	409	0.10	117,436	0.04
68	Interferon alfa-2b	408	0.10	337,715	0.11
69	Vinorelbine	388	0.10	160,198	0.05
70	Flutamide	378	0.10	51,081	0.02

Note: Based on data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Interferon alfa-2a	350	0.09	103,809	0.03
72	Cetrorelix	316	0.08	82,344	0.03
73	Lenograstim	303	0.08	235,414	0.08
74	Dasatinib	301	0.08	1,359,430	0.44
75	Pegvisomant	281	0.07	1,145,115	0.37
76	Fludarabine	277	0.07	219,815	0.07
77	Vancomycin Oral	270	0.07	51,166	0.02
78	Sitaxentan	265	0.07	688,141	0.22
79	Nilotinib	242	0.06	1,112,039	0.36
80	Everolimus	212	0.05	763,058	0.25
81	lloprost	167	0.04	618,892	0.20
82	Ustekinumab	151	0.04	671,133	0.22
83	Sodium Phenylbutyrate	143	0.04	194,950	0.06
84	Ambrisentan	126	0.03	363,241	0.12
85	Risedronic Acid	116	0.03	26,841	0.01
86	Bexarotene	81	0.02	224,718	0.07
87	Sodium Oxybate	77	0.02	49,268	0.02
88	Epoprostenol	35	0.01	372,012	0.12
89	Deferiprone	33	0.01	17,556	0.01
90	Topotecan	22	0.01	30,645	0.01
91	Miglustat	19	0.01	217,996	0.07
92	Histrelin	18	0.01	33,780	0.01
93	Urofollitropin	18	0.00	22,255	0.01
94	Nitisinone	17	0.00	60,309	0.02
95	Certolizumab Pegol	11	0.00	46,353	0.02
96	Zinc Acetate	11	0.00	1,387	0.00
97	Aldesleukin	10	0.00	14,111	0.00
98	Follitropin alfa and Lutropin alfa	10	0.00	14,014	0.00
99	Emtricitabine .	6	0.00	387	0.00
100	Becaplermin	4	0.00	1,955	0.00
	Total	392,240	100.00%	€306,285,969	100.00%

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
ı	Adalimumab	54,285,269	17.72	39,178	9.99
2	Etanercept	42,470,280	13.87	37,412	9.54
3	Interferon beta-la	16,558,800	5.41	14,389	3.67
4	Pegfilgrastim	14,901,540	4.86	11,997	3.06
5	Lenalidomide	13,482,422	4.40	2,029	0.52
6	Interferon beta-1b	9,863,895	3.22	8,413	2.14
7	Erythropoietin	9,067,167	2.96	11,128	2.84
8	Imatinib	7,962,472	2.60	2,957	0.75
9	Tacrolimus	7,493,723	2.45	28,352	7.23
10	Darbepoetin alfa	7,083,532	2.31	15,471	3.94
П	Somatropin	6,746,060	2.20	9,409	2.40
12	Glatiramer Acetate	6,635,831	2.17	5,461	1.39
13	Bosentan	6,073,440	1.98	1,991	0.51
14	Mycophenolic Acid	5,883,844	1.92	27,538	7.02
15	Triptorelin	5,447,910	1.78	14,713	3.75
16	Leuprorelin	5,374,985	1.76	10,778	2.75
17	Teriparatide	5,355,432	1.75	11,728	2.99
18	Tobramycin	4,297,014	1.40	1,698	0.43
19	Follitropin beta	4,119,631	1.35	4,863	1.24
20	Dornase alfa	4,072,792	1.33	4,359	1.11
21	Palivizumab	4,072,318	1.33	3,906	1.00
22	Follitropin alfa	3,397,704	1.11	2,902	0.74
23	Octreotide	3,299,257	1.08	2,922	0.74
24	Sunitinib	3,151,564	1.03	972	0.25
25	Filgrastim	2,835,425	0.93	3,922	1.00
26	Erlotinib	2,563,302	0.84	1,118	0.29
27	Bicalutamide	2,217,896	0.72	24,353	6.21
28	Temozolomide	2,206,027	0.72	1,878	0.48
29	Peginterferon alfa-2a	2,105,734	0.69	2,097	0.53
30	Ciclosporin	2,028,214	0.66	17,582	4.48
31	Sorafenib	2,028,046	0.66	587	0.15
32	Sildenafil	1,969,501	0.64	2,702	0.69
33	Cinacalcet	1,909,359	0.62	5,628	1.43
34	Voriconazole	1,841,609	0.60	689	0.18
35	Goserelin	1,826,923	0.60	5,169	1.32

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Linezolid	1,823,492	0.60	1,208	0.31
37	Capecitabine	1,806,003	0.59	7,237	1.85
38	Human Menopausal Gonadotrophin	1,433,060	0.47	2,123	0.54
39	Dasatinib	1,359,430	0.44	301	0.08
40	Valganciclovir	1,353,313	0.44	903	0.23
41	Ribavirin	1,331,229	0.43	2,444	0.62
42	Methoxy Polyethylene Glycol – Epoetin beta	1,270,338	0.42	5,845	1.49
43	Lapatinib	1,227,157	0.40	572	0.15
44	Lanreotide	1,159,568	0.38	1,005	0.26
45	Pegvisomant	1,145,115	0.37	281	0.07
46	Nilotinib	1,112,039	0.36	242	0.06
47	Golimumab	993,283	0.32	592	0.15
48	Posaconazole	915,646	0.30	462	0.12
49	Fulvestrant	886,239	0.29	1,343	0.34
50	Thalidomide	844,515	0.28	1,311	0.33
51	Parathyroid Hormone	841,326	0.27	1,856	0.47
52	Deferasirox	811,701	0.27	897	0.23
53	Everolimus	763,058	0.25	212	0.05
54	Entecavir	695,893	0.23	1,211	0.31
55	Sitaxentan	688,141	0.22	265	0.07
56	Riluzole	686,271	0.22	2,083	0.53
57	Ustekinumab	671,133	0.22	151	0.04
58	Anagrelide	666,495	0.22	1,259	0.32
59	lloprost	618,892	0.20	167	0.04
60	Lutropin alfa	570,471	0.19	1,028	0.26
61	Anakinra	446,940	0.15	431	0.11
62	Ganirelix	427,346	0.14	1,424	0.36
63	Peginterferon alfa-2b	393,448	0.13	537	0.14
64	Epoprostenol	372,012	0.12	35	0.01
65	Ambrisentan	363,241	0.12	126	0.03
66	Adefovir Dipivoxil	348,031	0.11	636	0.16
67	Interferon alfa-2b	337,715	0.11	408	0.10
68	Sirolimus	320,912	0.11	1,269	0.32
69	Lenograstim	235,414	0.08	303	0.08
70	Bexarotene	224,718	0.07	81	0.02

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Fludarabine	219,815	0.07	277	0.07
72	Miglustat	217,996	0.07	19	0.01
73	Sodium Phenylbutyrate	194,950	0.06	143	0.04
74	Choriogonadotropin alfa	193,247	0.06	3,845	0.98
75	Paricalcitol	192,205	0.06	1,087	0.28
76	Degarelix	165,622	0.05	833	0.21
77	Vinorelbine	160,198	0.05	388	0.10
78	Clodronic Acid	117,436	0.04	409	0.10
79	Ibandronic Acid	116,089	0.04	434	0.11
80	Interferon alfa-2a	103,809	0.03	350	0.09
81	Lamivudine	97,242	0.03	978	0.25
82	Buserelin	95,875	0.03	610	0.16
83	Nafarelin	93,089	0.03	556	0.14
84	Cetrorelix	82,344	0.03	316	0.08
85	Nitisinone	60,309	0.02	17	0.00
86	Vancomycin (Oral)	51,166	0.02	270	0.07
87	Flutamide	51,081	0.02	378	0.10
88	Sodium Oxybate	49,268	0.02	77	0.02
89	Certolizumab Pegol	46,353	0.02	11	0.00
90	Etoposide	42,441	0.01	455	0.12
91	Histrelin	33,780	0.01	18	0.01
92	Topotecan	30,645	0.01	22	0.01
93	Risedronic Acid	26,841	0.01	116	0.03
94	Urofollitropin	22,255	0.01	18	0.00
95	Deferiprone	17,556	0.01	33	0.01
96	Aldesleukin	14,111	0.00	10	0.00
97	Follitropin alfa and Lutropin alfa	14,014	0.00	10	0.00
98	Pazopanib	9,402	0.00	3	0.00
99	Interferon alfa-n l	4,482	0.00	1	0.00
100	Efalizumab	3,536	0.00	3	0.00
	Total	€306,299,660	100.00%	392,226	100.00%

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	7,421,528	13.64	143,640,336	15.25
A0I	Stomatological Preparations	93,087	0.17	336,606	0.04
A02	Drugs for Acid Related Disorders	3,274,473	6.02	88,357,627	9.38
A03	Drugs for Functional Gastrointestinal Disorders	506,672	0.93	2,132,239	0.23
A04	Anti-emetics and Antinauseants	22,272	0.04	1,851,007	0.20
A05	Bile and Liver Therapy	15,306	0.03	751,672	0.08
A06	Laxatives	762,269	1.40	6,167,726	0.65
A07	Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents	256,222	0.47	5,440,203	0.58
A08	Anti-obesity Preparations, excl. Diet Products	57,169	0.11	3,464,432	0.37
A09	Digestives, incl. Enzymes	14,903	0.03	1,176,948	0.12
AI0	Drugs used in Diabetes	1,281,000	2.35	25,525,476	2.71
AII	Vitamins	87,744	0.16	891,721	0.09
AI2	Mineral Supplements	1,050,379	1.93	7,544,348	0.80
AI4	Anabolic Agents for Systemic Use	32	0.00	331	0.00
В	Blood and Blood Forming Organs	4,569,454	8.39	31,147,707	3.31
BOI	Antithrombotic Agents	3,756,506	6.90	29,436,668	3.13
B02	Antihemorrhagics	13,512	0.02	185,263	0.02
B03	Anti-anemic Preparations	799,426	1.47	1,525,727	0.16
B05	Blood Substitutes and Perfusion Solutions	10	0.00	49	0.00

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
С	Cardiovascular System	13,076,598	24.03	212,513,917	22.56
C01	Cardiac Therapy	787,035	1.45	7,830,080	0.83
C02	Antihypertensives	306,704	0.56	7,261,316	0.77
C 03	Diuretics	1,695,007	3.11	4,828,893	0.51
C04	Peripheral Vasodilators	50,302	0.09	785,519	0.08
C05	Vasoprotectives	129,267	0.24	861,642	0.09
C07	Beta Blocking Agents	2,034,874	3.74	11,188,487	1.19
C08	Calcium Channel Blockers	1,369,534	2.52	14,112,118	1.50
C09	Agents Acting on the Renin-Angiotensin System	3,184,630	5.85	52,075,130	5.53
CI0	Lipid Modifying Agents	3,519,245	6.47	113,570,732	12.06
D	Dermatologicals	1,484,717	2.73	14,253,125	1.51
D0I	Antifungals for Dermatological Use	353,307	0.65	2,582,415	0.27
D02	Emollients and Protectives	231,873	0.43	612,293	0.07
D 03	Preparations for Treatment of Wounds and Ulcers	850	0.00	47,211	0.01
D 04	Antipruritics, incl. Antihistamines, Anesthetics, etc.	9	0.00	312	0.00
D05	Antipsoriatics	73,423	0.13	4,380,198	0.46
D06	Antibiotics and Chemotherapeutics for Dermatological Use	140,696	0.26	1,185,817	0.13
D 07	Corticosteroids, Dermatological Preparations	593,487	1.09	3,047,358	0.32
DI0	Anti-Acne Preparations	65,285	0.12	1,050,050	0.11
DII	Other Dermatological Preparations	25,787	0.05	1,347,471	0.14
G	Genito Urinary System and Sex Hormones	1,993,903	3.67	39,306,347	4.18
G0I	Gynecological Anti-infectives and Antiseptics	27,373	0.05	143,351	0.02
G02	Other Gynecologicals	26,962	0.05	1,846,180	0.20
G 03	Sex Hormones and Modulators of the Genital System	1,015,483	1.87	8,331,294	0.88
G04	Urologicals	924,085	1.70	28,985,522	3.08

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Н	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	1,786,929	3.29	5,822,915	0.62
HOI	Pituitary, Hypothalamic Hormones and Analogues	13,962	0.03	758,328	0.08
H02	Corticosteroids for Systemic Use	591,958	1.09	2,636,512	0.28
H03	Thyroid Therapy	1,173,419	2.16	2,203,398	0.23
H04	Pancreatic Hormones	7,457	0.01	219,618	0.03
H05	Calcium Homeostasis	133	0.00	5,059	0.00
J	Anti-infectives for Systemic Use	2,661,241	4.89	23,205,460	2.46
JOI	Antibacterials for Systemic Use	2,525,629	4.64	19,722,155	2.09
J02	Antimycotics for Systemic Use	91,368	0.17	1,162,439	0.13
J04	Antimycobacterials	5,561	0.01	127,027	0.01
J05	Antivirals for Systemic Use	38,679	0.07	2,193,814	0.23
J07	Vaccines	4	0.00	25	0.00
L	Antineoplastic and Immunomodulating Agents	272,342	0.50	9,633,276	1.02
LOI	Antineoplastic Agents	24,758	0.05	903,410	0.10
L02	Endocrine Therapy	100,116	0.18	7,386,143	0.78
L04	Immunosuppressive Agents	147,468	0.27	1,343,723	0.14

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
М	Musculo-Skeletal System	3,489,164	6.41	50,714,821	5.38
M01	Anti-inflammatory and Antirheumatic Products	1,728,975	3.18	18,501,546	1.96
M02	Topical Products for Joint and Muscular Pain	604,644	1.11	3,983,957	0.42
M03	Muscle Relaxants	48,415	0.09	817,273	0.09
M04	Antigout Preparations	224,269	0.41	937,816	0.10
M05	Drugs for treatment of Bone Diseases	781,126	1.43	25,382,740	2.69
M09	Other Drugs for Disorders of the Musculo-Skeletal System	101,735	0.19	1,091,489	0.12
N	Nervous System	10,587,109	19.44	213,092,052	22.62
N01	Anesthetics	10,615	0.02	1,447,122	0.15
N02	Analgesics	2,591,251	4.76	31,146,547	3.31
N03	Anti-epileptics	1,076,951	1.98	46,348,152	4.92
N04	Antiparkinson Drugs	258,281	0.47	8,624,782	0.92
N05	Psycholeptics	3,730,631	6.85	54,198,567	5.75
N06	Psychoanaleptics	2,500,251	4.59	60,491,008	6.42
N07	Other Nervous System Drugs	419,129	0.77	10,835,874	1.15
P	Antiparasitic Products, Insecticides and Repellents	81,839	0.15	584,668	0.06
POI	Antiprotozoals	59,553	0.11	448,398	0.05
P02	Anthelmintics	9,709	0.02	27,973	0.00
P03	Ectoparasiticides, incl. Scabicides, Insecticides and Repellents	12,577	0.02	108,297	0.01

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	4,067,914	7.47	95,767,539	10.16
R0 I	Nasal Preparations	352,159	0.65	3,332,698	0.35
R02	Throat Preparations	11,303	0.02	24,057	0.00
R03	Drugs for Obstructive Airway Diseases	2,939,392	5.40	88,123,366	9.36
R05	Cough and Cold Preparations	355,115	0.65	1,250,716	0.13
R06	Antihistamines for Systemic Use	409,760	0.75	3,031,589	0.32
R07	Other Respiratory System Products	185	0.00	5,113	0.00
S	Sensory Organs	1,289,437	2.37	13,132,120	1.39
SOI	Ophthalmologicals	1,204,001	2.21	12,797,330	1.36
S02	Otologicals	38,201	0.07	203,322	0.02
S03	Ophthalmological and Otological Preparations	47,235	0.09	131,468	0.01
٧	Various	1,642,485	3.02	89,350,818	9.48
V0I	Allergens	174	0.00	14,534	0.00
V03	Other Therapeutic Products	15,290	0.03	2,469,823	0.26
V04	Diagnostic Products	460,192	0.85	17,251,562	1.83
V 06	Clinical Nutritional Products	600,598	1.10	43,681,431	4.64
V 07	All Other Non-Therapeutic Products	566,231	1.04	25,933,468	2.75
	Needles/Syringes/Lancets	257,699	0.47	3,593,694	0.38
	Ostomy Requisites	141,364	0.26	13,268,472	1.41
	Urinary Requisites	78,100	0.14	7,240,200	0.77
	Dressings	26,884	0.05	1,110,401	0.12
	Miscellaneous	62,184	0.12	720,701	0.07
	TOTAL	54,424,660	100.00%	€942,165,101	100.00%

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	1,327,786	11.99	32,388,343	13.99
A01	Stomatological Preparations	16,197	0.15	62,071	0.03
A02	Drugs for Acid Related Disorders	730,237	6.60	22,265,848	9.62
A03	Drugs for Functional Gastrointestinal Disorders	91,160	0.82	481,688	0.21
A04	Anti-emetics and Antinauseants	8,042	0.07	563,813	0.24
A05	Bile and Liver Therapy	5,596	0.05	344,132	0.15
A06	Laxatives	73,695	0.67	668,678	0.29
A07	Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents	86,197	0.78	3,993,447	1.72
A08	Anti-obesity Preparations, excl. Diet Products	19,221	0.17	1,183,259	0.51
A09	Digestives, incl. Enzymes	1,888	0.02	108,566	0.05
AI0	Drugs used in Diabetes	57,021	0.51	792,159	0.34
AII	Vitamins	15,537	0.14	202,641	0.09
AI2	Mineral Supplements	222,872	2.01	1,705,517	0.73
AI4	Anabolic Agents for Systemic Use	89	0.00	1,109	0.00
AI6	Other Alimentary Tract/Metabolism Products	34	0.00	15,415	0.01
В	Blood and Blood Forming Organs	868,785	7.85	8,445,733	3.65
BOI	Antithrombotic Agents	759,754	6.86	8,198,154	3.54
B02	Antihemorrhagics	2,917	0.03	44,484	0.02
B03	Anti-anemic Preparations	106,113	0.96	203,091	0.09
B05	Blood Substitutes and Perfusion Solutions	I	0.00	4	0.00

Note: The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by an individual or family.

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
С	Cardiovascular System	2,990,716	27.01	61,518,589	26.57
C01	Cardiac Therapy	94,900	0.86	1,623,329	0.70
C02	Antihypertensives	65,237	0.59	1,682,421	0.73
C03	Diuretics	200,166	1.81	926,026	0.40
C04	Peripheral Vasodilators	3,317	0.03	52,465	0.02
C05	Vasoprotectives	33,472	0.30	234,980	0.10
C07	Beta Blocking Agents	451,905	4.08	2,735,246	1.18
C 08	Calcium Channel Blockers	278,381	2.51	2,884,384	1.25
C09	Agents Acting on the Renin-Angiotensin System	805,094	7.27	14,734,312	6.36
CI0	Lipid Modifying Agents	1,058,244	9.56	36,645,426	15.83
D	Dermatologicals	350,045	3.16	7,687,938	3.32
D0I	Antifungals for Dermatological Use	89,557	0.81	871,291	0.37
D02	Emollients and Protectives	23,820	0.22	73,153	0.03
D03	Preparations for Treatment of Wounds and Ulcers	479	0.00	64,024	0.03
D04	Antipruritics including Antihistamines, Anesthetics, etc.	269	0.00	14,590	0.01
D05	Antipsoriatics	40,032	0.36	3,656,549	1.58
D06	Antibiotics and Chemotherapeutics for Dermatological Use	27,080	0.25	399,875	0.17
D07	Corticosteroids Dermatological Preparations	120,781	1.09	712,705	0.31
DI0	Anti-Acne Preparations	35,483	0.32	1,129,587	0.49
DII	Other Dermatological Preparations	12,544	0.11	766,164	0.33
G	Genito Urinary System and Sex Hormones	463,077	4.18	15,554,041	6.71
G01	Gynecological Anti-infectives and Antiseptics	4,265	0.04	25,151	0.01
G 02	Other Gynecologicals	17,257	0.15	1,789,979	0.77
G 03	Sex Hormones and Modulators of the Genital System	236,835	2.14	7,230,199	3.12
G04	Urologicals	204,720	1.85	6,508,712	2.81

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Н	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	426,937	3.86	1,756,053	0.76
HOI	Pituitary, Hypothalamic Hormones and Analogues	4,608	0.04	434,021	0.19
H02	Corticosteroids for Systemic Use	143,536	1.30	756,066	0.33
H03	Thyroid Therapy	278,572	2.52	558,772	0.24
H04	Pancreatic Hormones	183	0.00	5,694	0.00
H05	Calcium Homeostasis	38	0.00	1,500	0.00
J	Anti-infectives for Systemic Use	511,648	4.62	6,233,188	2.69
JOI	Antibacterials for Systemic Use	464,717	4.20	4,563,807	1.97
J02	Antimycotics for Systemic Use	27,230	0.25	466,636	0.20
J04	Antimycobacterials	2,442	0.02	59,843	0.03
J05	Antivirals for Systemic Use	17,257	0.15	1,142,883	0.49
J07	Vaccines	2	0.00	19	0.00
L	Antineoplastic and Immunomodulating Agents	103,043	0.93	3,989,529	1.72
LOI	Antineoplastic Agents	8,639	0.08	482,000	0.21
L02	Endocrine Therapy	30,097	0.27	2,831,372	1.22
L04	Immunosuppressive Agents	64,307	0.58	676,157	0.29

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
М	Musculo-Skeletal System	792,411	7.16	12,992,714	5.61
M01	Anti-inflammatory and Antirheumatic Products	448,817	4.05	5,917,073	2.56
M02	Topical Products for Joint and Muscular Pain	85,646	0.77	589,435	0.25
M03	Muscle Relaxants	5,057	0.05	75,967	0.03
M04	Antigout Preparations	61,845	0.56	291,421	0.13
M05	Drugs for treatment of Bone Diseases	176,478	1.60	5,881,809	2.54
M09	Other Drugs for Disorders of the Musculo-Skeletal System	14,568	0.13	237,009	0.10
N	Nervous System	1,712,412	15.47	38,882,065	16.80
N01	Anesthetics	4,250	0.04	829,393	0.36
N02	Analgesics	378,578	3.42	6,162,054	2.66
N03	Anti-epileptics	174,207	1.57	9,505,378	4.11
N04	Antiparkinson Drugs	23,691	0.22	1,012,261	0.44
N05	Psycholeptics	571,659	5.16	7,859,221	3.39
N06	Psychoanaleptics	513,897	4.64	11,826,117	5.11
N07	Other Nervous System Drugs	46,130	0.42	1,687,641	0.73
P	Antiparasitic Products, Insecticides and Repellents	28,862	0.27	718,598	0.31
POI	Antiprotozoals	27,524	0.25	706,971	0.31
P02	Anthelmintics	566	0.01	3,078	0.00
P03	Ectoparasiticides, incl. Scabicides, Insecticides and Repellents	772	0.01	8,549	0.00

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	1,057,441	9.55	27,440,182	11.85
R0 I	Nasal Preparations	143,473	1.30	1,505,733	0.65
R02	Throat Preparations	1,783	0.02	3,770	0.00
R03	Drugs for Obstructive Airway Diseases	750,823	6.78	24,749,324	10.69
R05	Cough and Cold Preparations	38,174	0.34	161,925	0.07
R06	Antihistamines for Systemic Use	123,176	1.11	1,019,087	0.44
R07	Other Respiratory System Products	12	0.00	343	0.00
S	Sensory Organs	217,825	1.97	2,410,787	1.05
SOI	Ophthalmologicals	195,641	1.77	2,334,415	1.01
S02	Otologicals	7,514	0.07	41,137	0.02
S 03	Ophthalmological and Otological Preparations	14,670	0.13	35,235	0.02
٧	Various	219,458	1.98	11,509,258	4.97
VOI	Allergens	1,451	0.01	119,721	0.05
V 03	Other Therapeutic Products	1,867	0.02	284,922	0.12
V04	Diagnostic Products	19,049	0.17	672,127	0.29
V 06	Clinical Nutritional Products	105,786	0.96	5,014,792	2.17
V07	All Other Non-Therapeutic Products	91,305	0.82	5,417,696	2.34
	Ostomy Requisites	40,080	0.36	3,615,815	1.56
	Needles/Syringes/Lancets	22,606	0.20	133,458	0.06
	Urinary Requisites	10,307	0.09	1,314,347	0.57
	Dressings	8,191	0.07	223,626	0.10
	Miscellaneous	10,121	0.10	130,450	0.05
	TOTAL	11,070,446	100.00%	€231,527,018	100.00%

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Α	Alimentary Tract and Metabolism	742,157	26.44	22,383,857	27.60
A01	Stomatological Preparations	437	0.02	1,988	0.00
A02	Drugs for Acid Related Disorders	18,972	0.68	573,093	0.71
A03	Drugs for Functional Gastrointestinal Disorders	1,736	0.06	74,018	0.09
A04	Anti-emetics and Antinauseants	1,512	0.05	71,495	0.09
A05	Bile and Liver Therapy	788	0.03	42,352	0.05
A06	Laxatives	7,215	0.26	73,273	0.09
A07	Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents	911	0.03	25,785	0.03
A08	Anti-obesity Preparations, excl. Diet Products	2,695	0.10	165,912	0.20
A09	Digestives, incl. Enzymes	7,241	0.26	756,639	0.93
AI0	Drugs Used in Diabetes	679,497	24.20	19,928,373	24.59
AII	Vitamins	12,299	0.44	320,042	0.39
AI2	Mineral Supplements	6,773	0.24	58,996	0.07
AI3	Tonics	8	0.00	60	0.00
AI4	Anabolic Agents for Systemic Use	12	0.00	548	0.00
AI6	Other Alimentary Tract and Metabolism Products	2,061	0.07	291,283	0.36
В	Blood and Blood Forming Organs	290,950	10.36	1,392,696	1.72
BOI	Antithrombotic Agents	272,968	9.72	1,304,087	1.61
B02	Antihemorrhagics	890	0.03	22,694	0.03
B03	Anti-anemic Preparations	16,666	0.59	26,560	0.03
B05	Blood Substitutes and Perfusion Solutions	426	0.02	39,355	0.05

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
С	Cardiovascular System	866,744	30.88	18,108,261	22.35
C01	Cardiac Therapy	10,734	0.38	127,254	0.16
C02	Antihypertensives	25,140	0.90	698,150	0.86
C03	Diuretics	42,329	1.51	177,837	0.22
C04	Peripheral Vasodilators	671	0.02	13,795	0.02
C05	Vasoprotectives	165	0.01	1,081	0.00
C07	Beta Blocking Agents	91,752	3.27	570,666	0.70
C 08	Calcium Channel Blockers	82,002	2.92	874,550	1.08
C09	Agents Acting on the Renin-Angiotensin System	299,751	10.68	4,951,373	6.11
CI0	Lipid Modifying Agents	314,200	11.19	10,693,555	13.20
D	Dermatologicals	4,444	0.15	60,189	0.08
D01	Antifungals for Dermatological Use	1,488	0.05	12,937	0.02
D02	Emollients and Protectives	873	0.03	7,227	0.01
D03	Preparations for Treatment of Wounds and Ulcers	18	0.00	539	0.00
D04	Antipruritics, incl. Antihistamines, Anesthetics, etc.	54	0.00	1,744	0.00
D05	Antipsoriatics	196	0.01	14,886	0.02
D 06	Antibiotics and Chemotherapeutics for Dermatological Use	260	0.01	2,151	0.00
D07	Corticosteroids, Dermatological Preparations	860	0.03	4,504	0.01
D 08	Antiseptics and Disinfectants	366	0.01	2,414	0.00
DI0	Anti-Acne Preparations	114	0.00	1,222	0.00
DII	Other Dermatological Preparations	215	0.01	12,565	0.02
G	Genito Urinary System and Sex Hormones	30,789	1.09	963,298	1.19
G01	Gynecological Anti-infectives and Antiseptics	98	0.00	20,931	0.03
G02	Other Gynecologicals	48	0.00	2,456	0.00
G 03	Sex Hormones and Modulators of the Genital System	1,754	0.06	35,939	0.04
G 04	Urologicals	28,889	1.03	903,972	1.12

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Н	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	28,153	1.00	436,460	0.54
HOI	Pituitary, Hypothalamic Hormones and Analogues	2,141	0.08	147,313	0.18
H02	Corticosteroids for Systemic Use	3,159	0.11	42,065	0.05
H03	Thyroid Therapy	15,424	0.55	36,430	0.05
H04	Pancreatic Hormones	7,422	0.26	210,310	0.26
H05	Calcium Homeostasis	7	0.00	342	0.00
J	Anti-infectives for Systemic Use	15,590	0.56	1,038,065	1.29
JOI	Antibacterials for Systemic Use	14,706	0.52	993,263	1.23
J02	Antimycotics for Systemic Use	538	0.02	26,003	0.03
J04	Antimycobacterials	141	0.01	4,463	0.01
J05	Antivirals for Systemic Use	198	0.01	14,289	0.02
J07	Vaccines	7	0.00	47	0.00
L	Antineoplastic and Immunomodulating Agents	1,447	0.05	66,143	0.09
LOI	Antineoplastic Agents	443	0.02	48,123	0.06
L02	Endocrine Therapy	45	0.00	5,222	0.01
L04	Immunosuppressive Agents	959	0.03	12,798	0.02

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
М	Musculo-Skeletal System	15,974	0.58	253,131	0.31
MOI	Anti-inflammatory and Antirheumatic Products	4,115	0.15	47,151	0.06
M02	Topical Products for Joint and Muscular Pain	473	0.02	3,349	0.00
M03	Muscle Relaxants	5,567	0.20	108,454	0.13
M04	Antigout Preparations	3,031	0.11	15,794	0.02
M05	Drugs for treatment of Bone Diseases	2,259	0.08	73,264	0.09
M09	Other Drugs for Disorders of the Musculo-Skeletal System	529	0.02	5,119	0.01
N	Nervous System	295,458	10.52	12,828,413	15.83
N0I	Anesthetics	290	0.01	22,944	0.03
N02	Analgesics	7,415	0.26	86,019	0.11
N03	Anti-epileptics	221,851	7.90	8,617,443	10.63
N04	Antiparkinson Drugs	30,136	1.07	3,026,431	3.73
N05	Psycholeptics	18,806	0.67	460,206	0.57
N06	Psychoanaleptics	15,274	0.55	517,106	0.64
N07	Other Nervous System Drugs	1,686	0.06	98,264	0.12
P	Antiparasitic Products, Insecticides and Repellents	136	0.00	1,989	0.00
POI	Antiprotozoals	126	0.00	1,923	0.00
P02	Anthelmintics	3	0.00	11	0.00
P03	Ectoparasiticides, incl. Scabicides, Insecticides and Repellents	7	0.00	55	0.00

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	13,262	0.47	356,716	0.45
R0 I	Nasal Preparations	1,277	0.05	13,388	0.02
R02	Throat Preparations	33	0.00	92	0.00
R03	Drugs for Obstructive Airway Diseases	9,039	0.32	256,120	0.32
R05	Cough and Cold Preparations	1,457	0.05	72,856	0.09
R06	Antihistamines for Systemic Use	1,456	0.05	14,260	0.02
S	Sensory Organs	7,353	0.26	114,981	0.14
SOI	Ophthalmologicals	7,193	0.26	114,233	0.14
S02	Otologicals	51	0.00	491	0.00
S 03	Ophthalmological and Otological Preparations	109	0.00	257	0.00
٧	Various	495,300	17.64	23,025,841	28.41
V03	Other Therapeutic Products	241	0.01	37,818	0.05
V 04	Diagnostic Products	283,818	10.11	12,830,232	15.83
V 06	Clinical Nutritional Products	35,453	1.26	4,888,354	6.03
V 07	All Other Non-Therapeutic Products	175,788	6.26	5,269,437	6.50
	Needles/Syringes/Lancets/Swabs	157,753	5.62	3,921,282	4.84
	Urinary Requisites	5,572	0.20	710,594	0.88
	Nutritional/Ancillary Devices	2,483	0.09	303,496	0.37
	Dressings	1,775	0.06	105,105	0.13
	Ostomy Requisites	1,192	0.04	100,580	0.12
	Miscellaneous	7,013	0.25	128,380	0.16
	TOTAL	2,807,757	100.00%	€81,030,040	100.00%

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	1,547	0.40	718,013	0.23
A07A	Intestinal Anti-infectives	270	0.07	51,166	0.02
AIICC	Vitamin D and Analogues	1,087	0.28	192,205	0.06
A16AX	Other Alimentary Tract and Metabolism Products	190	0.05	474,642	0.15
В	Blood and Blood Forming Organs	32,646	8.32	18,411,943	6.01
BOI	Antithrombotic Agents	202	0.05	990,905	0.32
В03	Anti-anemic Preparations	32,444	8.27	17,421,038	5.69
С	Cardiovascular System	5,084	1.30	9,094,324	2.97
C02	Antihypertensives	5,084	1.30	9,094,324	2.97
D	Dermatologicals	4	0.00	1,955	0.00
D03A	Cicatrizants	4	0.00	1,955	0.00
G	Genito Urinary System and Sex Hormones	14,789	3.77	9,750,383	3.18
G03GA	Gonadotropins	14,789	3.77	9,750,383	3.18

Note: Based on the data available from claims submitted, the ingredient costs shown is the gross cost before discount.

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
Н	Systemic Hormonal Preparations, Excl.Sex Hormones and Insulins	35,143	8.96	21,092,676	6.89
HOI	Pituitary and Hypothalamic Hormones and Analogues	15,931	4.06	12,986,559	4.24
H05	Calcium Homeostasis	19,212	4.90	8,106,117	2.65
J	Anti-infectives for Systemic Use	14,141	3.61	16,776,173	5.48
JOI	Antibacterials for Systemic Use	2,906	0.74	6,120,506	2.00
J02	Antimycotics for Systemic Use	1,151	0.29	2,757,254	0.90
J05	Antivirals for Systemic Use	6,178	1.58	3,826,095	1.25
J06	Immune Sera and Immunoglobulins	3,906	1.00	4,072,318	1.33
L	Antineoplastic and Immunomodulating Agents	280,487	71.50	224,563,615	73.31
LOI	Antineoplastic Agents	18,562	4.73	25,533,168	8.33
L02	Endocrine Therapy	58,177	14.83	16,066,531	5.25
L03	Immunostimulants	47,889	12.21	53,993,491	17.63
L04	Immunosuppressive Agents	155,859	39.73	128,970,425	42.10

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
M	Musculo-Skeletal System	959	0.24	260,366	0.09
M05	Drugs for treatment of Bone Diseases	959	0.24	260,366	0.09
N	Nervous System	2,160	0.55	735,539	0.24
N07XX	Other Nervous System Drugs	2,160	0.55	735,539	0.24
R	Respiratory System	4,359	1.11	4,072,793	1.33
R05CB	Mucolytics (Inhaled)	4,359	1.11	4,072,793	1.33
V	Various	930	0.24	829,257	0.27
V03AC	Iron Chelating Agents	930	0.24	829,257	0.27
	TOTAL	392,249	100%	€306,307,037	100%

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 21 GMS: Average Payment to Doctors in Panel Ranges

						Avera	ge Panel R	anges	in 2010					
Health Service Executive	0-10	0	101-2	.50	251-5	00	501-1,	000	1,001-1	,500	1,501-2	2,000	2,001 a	
	€		€		€		€		€		€		€	
East Coast Area	15,672	(72)	73,958	(31)	143,325	(45)	217,503	(64)	333,373	(14)	_		_	
South Western Area	18,365	(57)	61,301	(21)	111,421	(28)	200,327	(94)	292,354	(56)	392,519	(26)	546,324	(1)
Northern Area	18,186	(52)	60,712	(19)	112,269	(35)	207,850	(65)	314,096	(45)	346,504	(24)	537,374	(2)
Midland	16,215	(17)	104,141	(2)	111,775	(13)	230,483	(41)	346,098	(35)	411,480	(18)	530,869	(5)
Mid-Western	19,140	(31)	43,608	(7)	122,768	(32)	227,816	(71)	304,862	(43)	459,871	(13)	444,102	(6)
North Eastern	5,702	(18)	34,240	(8)	119,851	(7)	190,327	(58)	289,720	(58)	362,763	(22)	494,427	(7)
North Western	40,099	(9)	71,187	(6)	138,792	(17)	207,229	(50)	329,541	(39)	385,105	(14)	518,496	(4)
South Eastern	4,674	(21)	61,655	(8)	122,454	(21)	217,205	(110)	323,419	(60)	393,430	(22)	484,486	(2)
Southern	16,395	(68)	61,372	(52)	118,306	(67)	223,383	(151)	358,432	(69)	436,933	(14)	573,963	(4)
Western	12,812	(27)	56,464	(18)	126,168	(38)	233,405	(94)	325,548	(55)	466,261	(19)	607,731	(5)
NATIONAL 2010	€16,162	(372)	€61,913	(172)	€123,338	(303)	€216,604	(798)	€320,873	(474)	€400,641	(172)	€521,585	(36)
NATIONAL 2009	€15,285	(413)	€66,456	(169)	€133,757	(341)	€237,477	(846)	€348,688	(428)	€451,852	(120)	€531,336	(18)

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.

⁽ii) The number of Doctors in each range is shown in brackets.

⁽iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.

⁽iv) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 21.1 GMS: Number of Doctors in Payment Ranges

Health Service Executive		p to),000		,001-),000		,001-),000		,001- 0,000		0,001- 0,000		0,001- 0,000		0,001- 0,000),001- 0,000	l),001- 0,000		0,001- 0,000		0,001- 0,000		0,001 Over
East Coast Area	25	(24)	19	(15)	22	(19)	13	(20)	20	(19)	13	(16)	16	(11)	19	(21)	19	(17)	13	(18)	I	(2)	I	(1)
South Western Area	27	(21)	13	(21)	23	(16)	10	(13)	21	(25)	28	(18)	23	(22)	25	(17)	20	(20)	45	(47)	Ш	(20)	6	(5)
Northern Area	20	(21)	15	(11)	17	(21)	17	(14)	16	(11)	16	(17)	15	(15)	15	(18)	18	(22)	49	(40)	9	(13)	4	(6)
Midland	13	(9)	2	(3)	6	(5)	3	(8)	9	(4)	8	(5)	9	(6)	8	(13)	15	(12)	34	(35)	12	(13)	4	(4)
Mid-Western	23	(17)	6	(7)	8	(6)	10	(11)	17	(15)	12	(16)	18	(16)	24	(22)	16	(18)	39	(37)	11	(17)	4	(4)
North Eastern	10	(9)	5	(3)	4	(8)	Ш	(5)	10	(14)	14	(10)	20	(18)	13	(16)	14	(17)	45	(47)	16	(13)	2	(2)
North Western	4	(5)	4	(4)	6	(5)	6	(8)	8	(11)	13	(7)	14	(11)	14	(13)	10	(13)	37	(31)	14	(23)	6	(7)
South Eastern	6	(9)	6	(4)	8	(8)	10	(12)	П	(10)	25	(19)	20	(28)	34	(30)	20	(19)	65	(66)	21	(15)	7	(10)
Southern	34	(33)	36	(30)	41	(30)	22	(24)	28	(22)	33	(27)	30	(28)	43	(38)	24	(35)	63	(63)	28	(33)	8	(9)
Western	15	(20)	18	(8)	15	(14)	15	(17)	17	(15)	16	(15)	16	(19)	27	(24)	16	(21)	56	(53)	19	(24)	9	(9)
NATIONAL	177	(168)	124	(106)	150	(132)	117	(132)	157	(146)	178	(150)	181	(174)	222	(212)	172	(194)	446	(437)	142	(173)	51	(57)

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.

⁽ii) Above table relates to the payments listed in Table 3.

⁽iii) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges

Health Service Executive		o to),000	1	,001-),000		,001-),000		,001- ,000		,001- 0,000),001-),000),001-),000),001- 0,000),001- 0,000		0,001- 0,000),001- 0,000),001- 0,000	_	0,001 over
East Coast Area	7	(6)	3	(5)	15	(12)	19	(16)	14	(15)	15	(20)	15	(8)	12	(15)	11	(7)	7	(5)	6	(7)	2	(6)	6	(10)
South Western Area	2	(5)	13	(13)	12	(20)	15	(15)	18	(22)	17	(17)	20	(17)	15	(15)	13	(8)	15	(18)	13	(7)	5	(7)	29	(36)
Northern Area	4	(6)	5	(9)	14	(17)	14	(17)	16	(16)	15	(13)	18	(15)	19	(18)	9	(12)	9	(8)	7	(6)	5	(7)	35	(38)
Midland		_	4	(1)	2	(4)	5	(5)	7	(7)	6	(7)	7	(4)	10	(6)	10	(12)	9	(6)	4	(9)	11	(4)	21	(27)
Mid-Western	I	(2)	5	(5)	5	(12)	14	(9)	6	(5)	12	(12)	П	(14)	15	(14)	14	(11)	14	(10)	П	(10)	10	(13)	20	(25)
North Eastern	I	(3)	8	(8)	4	(11)	8	(11)	13	(7)	П	(15)	22	(14)	14	(13)	14	(14)	10	(11)	8	(8)	6	(4)	23	(26)
North Western	ı	(-)	I	(5)	5	(4)	4	(3)	8	(6)	10	(11)	10	(8)	9	(6)	7	(9)	8	(6)	7	(9)	_	(2)	22	(21)
South Eastern	2	(2)	2	(2)	3	(8)	6	(7)	8	(4)	П	(18)	14	(17)	18	(15)	17	(10)	10	(15)	19	(11)	П	(16)	41	(45)
Southern	2	(4)	7	(10)	9	(11)	16	(16)	16	(19)	23	(22)	27	(20)	27	(27)	26	(15)	19	(29)	Ш	(8)	13	(10)	34	(46)
Western	I	(2)	4	(4)	8	(13)	12	(10)	12	(12)	14	(12)	10	(15)	19	(12)	15	(13)	14	(7)	5	(9)	9	(11)	36	(38)
NATIONAL	21	(30)	52	(62)	77	(112)	113	(109)	118	(113)	134	(147)	154	(132)	158	(141)	136	(111)	115	(115)	91	(84)	72	(80)	267	(312)

Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.

Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims

Health Service Executive	*Number of Persons Covered	Unique Number of Claimants	Number of Items	Cost per Item €	Gross Cost €	Net Cost per Claimant €	Paid by HSE €
Eastern Areas	525,606	183,305	4,525,100	30.88	139,723,559	406.31	74,477,827
Midland	99,784	32,567	700,339	29.16	20,421,823	320.74	10,445,520
Mid-Western	164,541	41,486	849,815	29.87	25,385,689	305.16	12,659,796
North Eastern	139,757	44,413	932,729	29.81	27,801,281	320.74	14,245,063
North Western	58,727	18,022	370,775	30.37	11,261,716	313.93	5,657,576
South Eastern	143,700	50,330	1,131,497	29.14	32,974,239	325.75	16,394,868
Southern	260,032	80,012	1,704,690	30.54	52,068,667	326.60	26,131,558
Western	164,901	44,415	855,501	30.84	26,381,795	302.21	13,422,864
NATIONAL 2010	1,557,048	494,550	11,070,446	€30.35	€336,018,769	€350.69	€173,435,072
NATIONAL 2009	1,587,448	663,127	13,372,525	€33.78	€451,707,314	€391.97	€259,928,189

Note: * As at 31st December 2010.

Table 23.1 DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges

Health Service Executive		o to 0,000		,001-),000	1	,001-),000	l	,001-),000		,001- 0,000																
East Coast Area	43	(14)	37	(34)	33	(21)	11	(23)	4	(15)	4	(8)	I	(6)	_	(3)	I	(6)		_	_	(2)	_	(1)		_
South Western Area	59	(27)	62	(47)	28	(37)	23	(25)	9	(13)	4	(15)	_	(16)	I	(10)	I	(3)	_	(1)	_	(2)	_	(1)	I	(3)
Northern Area	59	(29)	47	(42)	29	(33)	18	(11)	10	(23)	3	(16)	2	(5)	2	(5)	2	(6)	_	(5)	_	(1)	_	(1)	_	(5)
Midland	32	(11)	42	(25)	13	(23)	6	(13)	3	(4)	_	(8)	_	(4)	_	(2)	_	(2)		_	-	_		_		_
Mid-Western	66	(24)	54	(47)	12	(36)	4	(19)	2	(7)	_	(4)	_	(2)	_	(2)	_	(1)		_	-	_		_		_
North Eastern	63	(30)	47	(45)	18	(26)	13	(13)	I	(10)	_	(9)	_	(7)	_	(5)		_		_	-	_		_		_
North Western	63	(33)	22	(30)	5	(18)	ı	(3)	_	(4)	_	(1)		_	_	(1)		_		_	-	_		_		_
South Eastern	72	(35)	64	(42)	18	(42)	6	(24)	I	(15)	I	(5)	_	(5)	_	(1)		_		_	-	_	_	(1)		_
Southern	83	(28)	90	(66)	38	(58)	13	(40)	5	(17)	2	(11)	_	(7)	_	(3)	_	(3)	_	(3)	-	_		_	_	(1)
Western	82	(44)	57	(43)	18	(33)	3	(18)	I	(11)	_	(6)	_	(3)		_		_			-	_		_		_
NATIONAL	622	(275)	522	(421)	212	(327)	98	(189)	36	(119)	14	(83)	3	(55)	3	(32)	4	(21)	-	(9)	_	(5)	_	(4)	ı	(9)

Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.

(ii) The above figures do not include the monthly co-payment of €120 paid by an individual or family to the Pharmacist.

Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims

Health Service Executive	*Number of Eligible Persons	Unique Number of Claimants	Number of Items	Cost per Item €	Total Cost €	Cost per Claimant €
Eastern Areas	66,911	27,904	1,177,531	47.14	55,503,977	1,989.10
Midland	8,056	4,197	179,196	42.29	7,578,007	1,805.58
Mid-Western	9,025	4,650	183,652	40.87	7,505,324	1,614.05
North Eastern	10,967	6,090	262,108	44.17	11,577,379	1,901.05
North Western	7,489	4,163	171,856	44.02	7,564,925	1,817.18
South Eastern	14,355	7,094	310,575	41.83	12,992,635	1,831.50
Southern	10,180	8,227	332,569	46.61	15,501,349	1,884.20
Western	7,943	5,167	190,270	45.71	8,698,183	1,683.41
NATIONAL 2010	134,926	67,492	2,807,757	€45.20	€126,921,779	€1,880.55
NATIONAL 2009	127,636	65,731	2,855,361	€48.95	€139,759,172	€2,126.23

Note: * As at 31st December 2010.

Table 24.1 LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges

Health Service Executive	Up €10,		€10, €20,		€20, €30,	I	€30, €40,		€40, €50,		€50,0 €60,0		€60, and	
East Coast Area	20	(12)	39	(28)	28	(31)	9	(17)	15	(12)	11	(10)	11	(23)
South Western Area	18	(19)	50	(40)	48	(47)	25	(23)	12	(17)	15	(20)	19	(34)
Northern Area	23	(23)	47	(36)	28	(29)	21	(29)	27	(16)	12	(20)	12	(29)
Midland	21	(15)	29	(27)	23	(15)	11	(15)	5	(9)	4	(5)	3	(6)
Mid-Western	51	(42)	58	(46)	18	(37)	6	(7)	3	(5)	2	(2)	0	(3)
North Eastern	34	(31)	43	(33)	25	(32)	16	(12)	17	(15)	3	(5)	4	(17)
North Western	23	(18)	23	(16)	17	(19)	14	(11)	8	(7)	3	(11)	3	(8)
South Eastern	45	(40)	45	(33)	39	(35)	23	(34)	5	(13)	3	(9)	2	(6)
Southern	60	(51)	93	(77)	46	(54)	21	(31)	8	(10)	2	(10)	0	(4)
Western	63	(52)	56	(50)	28	(25)	9	(22)	I	(5)	I	(2)	I	(2)
NATIONAL	358	(303)	483	(386)	300	(324)	155	(201)	101	(109)	56	(94)	55	(132)

Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.

Table 25 EEA: Number and Cost of Pharmacists Claims

Health Service Executive	Number of Items	Cost per Item €	Total Cost €
East Coast Area	3,227	19.48	62,869
South Western Area	5,759	20.41	117,566
Northern Area	3,574	19.75	70,599
Midland	4,776	21.47	102,548
Mid-Western	9,398	19.72	185,344
North Eastern	5,221	22.40	116,941
North Western	10,689	20.28	216,811
South Eastern	9,605	19.86	190,734
Southern	19,669	19.55	384,585
Western	14,527	20.41	296,449
NATIONAL 2010	86,445	€20.18	€1,744,446
NATIONAL 2009	85,520	€22.89	€1,957,613

Table 26 DTS: Number of Treatments

Health Service Executive	Above the Line	Below the Line	Total
Eastern Areas	348,006	21,867	369,873
Midland	78,461	7,004	85,465
Mid-Western	116,353	9,965	126,318
North Eastern	120,419	9,197	129,616
North Western	85,765	5,713	91,478
South Eastern	173,387	16,961	190,348
Southern	226,653	17,529	244,182
Western	155,296	16,110	171,406
NATIONAL 2010	1,304,340	104,346	1,408,686
NATIONAL 2009	1,439,431	145,167	1,584,598

Table 26.1 DTS: Number of Dentists in Payment Ranges

Health Service Executive		o to ,000		,001-),000		,001- ,000		,001- ,000		,001- ,000	l .	,001-),000		,001-),000	l .	,001-),000		,001-),000		,001- 0,000		0,001- 0,000	l	0,001- 0,000		0,001 over
Eastern Areas	37	(14)	35	(17)	35	(23)	26	(16)	28	(21)	33	(10)	20	(20)	19	(7)	17	(14)	10	(12)	11	(19)	5	(10)	37	(51)
Midland	3	(6)	2	(-)	3	(2)	3	(-)	3	(3)	3	(1)	3	(3)	6	(-)	5	(3)	4	(4)	I	(2)	3	(6)	14	(19)
Mid-Western	15	(8)	9	(6)	6	(8)	15	(8)	4	(6)	10	(10)	7	(3)	3	(7)	5	(7)	5	(4)	6	(6)	2	(2)	15	(18)
North Eastern	3	(-)	6	(3)	5	(3)	4	(-)	5	(6)	6	(3)	8	(4)	6	(7)	4	(10)	2	(5)	I	(1)	2	(3)	18	(21)
North Western	2	(4)	I	(2)	2	(1)	_	(1)		_	4	(1)	ı	(3)	3	(1)	4	(2)	2	(2)	I	(1)	ı	(-)	16	(17)
South Eastern	8	(6)	6	(1)	7	(1)	10	(4)	14	(3)	7	(9)	10	(5)	12	(8)	9	(2)	6	(5)	4	(5)	5	(3)	28	(36)
Southern	33	(18)	28	(21)	35	(30)	28	(24)	19	(17)	24	(15)	18	(19)	15	(17)	П	(17)	21	(10)	6	(13)	4	(7)	13	(26)
Western	19	(22)	5	(7)	П	(3)	15	(7)	П	(4)	7	(8)	10	(3)	12	(6)	5	(8)	10	(4)	8	(5)	5	(4)	21	(41)
NATIONAL	120	(78)	92	(57)	104	(71)	101	(60)	84	(60)	94	(57)	77	(60)	76	(53)	60	(63)	60	(46)	38	(52)	27	(35)	162	(229)

Note: Dentists who entered or left the Scheme during the year are not included in the above table.

Table 27 HSE-COS: Number of Treatments and Cost of Claims

Health Service Executive	Number of Treatments	Cost of Claims €
Eastern Areas	167,293	6,872,946
Midland	42,544	1,757,890
Mid-Western	61,252	2,375,310
North Eastern	52,344	2,004,039
North Western	46,967	1,753,750
South Eastern	93,790	3,612,768
Southern	100,234	3,968,192
Western	73,426	2,833,107
NATIONAL 2010	637,850	€25,178,002
NATIONAL 2009	564,606	€22,184,541

Note: Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €75,870; Optical services for Teenagers €230,715; Optical services for Children €1,401,894.

Table 27.1 HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges

Health Service Executive	-	o to),000	1	,001-),000		,001- ,000		,001- ,000		,001- ,000		,001- ,000	l .	,001-),000		,001-),000		,001- ,000	1	-	l	-	1	0,001- 0,000	1	0,001 over
Eastern Areas	56	(52)	29	(29)	19	(17)	10	(12)	9	(6)	6	(3)	2	(7)	4	(-)	I	(1)	_	(1)	I	(2)	3	(-)	7	(7)
Midland	12	(9)	6	(5)	4	(2)	2	(2)	5	(7)	2	(1)	I	(2)	I	(1)	I	(-)		_		_	_	(1)	2	(1)
Mid-Western	П	(11)	5	(6)	7	(6)	I	(2)	3	(2)	_	(1)	_	(2)	2	(-)	I	(1)		_		_		_	3	(3)
North Eastern	23	(22)	12	(12)	9	(4)	2	(3)	I	(2)	3	(2)		_	I	(-)	_	(2)	I	(-)	2	(-)		_		_
North Western	5	(6)	6	(4)	4	(5)	3	(1)	2	(5)	6	(3)	2	(1)		_	_	(1)	ı	(-)		_		_	I	(1)
South Eastern	18	(13)	9	(12)	9	(5)	2	(3)	3	(4)	4	(2)	ı	(3)	5	(2)	ı	(3)	2	(2)	ı	(-)	_	(1)	5	(4)
Southern	10	(11)	10	(16)	15	(11)	7	(3)	6	(7)	5	(5)	2	(-)	3	(2)	ı	(-)		_	_	(1)		_	4	(3)
Western	10	(11)	6	(10)	16	(15)	П	(9)	6	(4)		_	ı	(-)		_		_		_	_	(1)		_	2	(1)
NATIONAL	145	(135)	83	(94)	83	(65)	38	(35)	35	(37)	26	(17)	9	(15)	16	(5)	5	(8)	4	(3)	4	(4)	3	(2)	24	(20)

Note: Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.

Table 28 GMS: Investment in General Practice Development

Health Service Executive	2010 €	2009 €
Eastern Areas	833,626	1,285,694
Midland	69,921	71,214
Mid-Western	205,723	191,193
North Eastern	128,681	110,980
*North Western	_	_
South Eastern	331,563	209,684
Southern	159,198	247,531
Western	310,168	767,437
NATIONAL	€2,038,880	€2,883,733

Note: The above are payments from the Indicative Drug Target Savings.

^{*} No funds available to draw down in 2010.

